CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL-2019 1Clinical Study Protocol
Sponsor:
GlaxoSmithKline Biologicals SA
Rue de l‚ÄôInstitut 89,
1330, Rixensart, Belgium
Primary Study vaccine and 
number!GlaxoSmithKline (GSK) Vaccines Institute for 
Global Health (GVGH) Shigella sonnei GMMA 
vaccine (GVGH S. sonnei 1790GAHB vaccine), 
property of GSK Biologicals.
Other Study products !GAHB-Placebo (control and diluent in the bedside
mixing).
!Shigella sonnei 53G (challenge strain developed 
by the Walter Reed Army Institute of Research [WRAIR], Silver Spring, Maryland, USA)referred to as the challenge agent.
eTrack study number and 
Abbreviated Title205626 (S SONNEI MONO GMMA SBVGH-003
[H03_03TP])
Investigational New Drug 
(IND) numberIND18163
Date of protocol Final: 12 December 2017
Date of protocol amendment Amendment 1 Final: 08 February 2018
Amendment 2 Final: 22 June 2019Amendment 3 Final: 07 September 2019Amendment 4 Final: 19 February 2019Amendment 5 Final: 15 April 2019Amendment 6 Final: 23 July 2019
Title Efficacy, safety and immunogenicity of GVGH 
Shigella sonnei vaccine (1790GAHB) in a human 
challenge study of healthy non-immune adults.
Detailed Title A phase IIb, randomized, placebo-controlled, single 
center, observer-blind, human-challenge study to evaluate the efficacy, safety and immunogenicity of 2 vaccinations with GVGH Shigella sonnei vaccine 
(1790GAHB) administered by intramuscular route in healthy non-immune adult population.
Coordinating authors , , Scientific Writers
(XPE Pharma & Science for GSK Biologicals)

CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b1 23-JUL-2019PPD PPD_5HGDFWHG3URWRFRO$PHQGPHQW$SU_70) _
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL-2019 2eTrack study number and 
Abbreviated Title205626 (S SONNEI MONO GMMA SBVGH-003 
[H03_03TP])
Investigational New Drug 
(IND) numberIND18163
Detailed Title A phase IIb, randomized, placebo-controlled, single 
center, observer-blind, human-challenge study to evaluate the efficacy, safety and immunogenicity of 2 vaccinations with GVGH Shigella sonnei vaccine 
(1790GAHB) administered by intramuscular route in healthy non-immune adult population.
Contributing authors ! , GVGH Head of 
Clinical Development and Regulatory Affairs 
! , Project Physician
! , , 
Biostatisticians
! , GVGH Clinical Research 
Associate
! , GVGH Head of Clinical 
Operations
! , Clinical Laboratory Sciences 
Read-out Team Leader
! , , , 
Clinical Laboratory Sciences Study Managers
! , , GVGH 
Serology Representatives (Scientific Technical Leaders)
! , , Safety 
Physician, Safety Evaluation and Risk Management team
! , Safety Scientist, Safety 
Evaluation and Risk Management team
! , Oversight Data Manager
! , GVGH Head of Regulatory 
Affairs
! , Global Patent Affairs Manager
GSK Biologicals‚Äô Protocol DS for Legacy Novartis programs v 1.0
¬©2017-2019 GlaxoSmithKline group of companies or its licensor.

CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b2 23-JUL-2019PPD
PPD
PPD PPD
PPD
PPD
PPD
PPD PPD PPD
PPD PPD
PPD PPD
PPD
PPD
PPD
PPD_5HGDFWHG3URWRFRO$PHQGPHQW$SU_70) _
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 3Protocol Amendment 6 Sponsor Signator y Approval
eTrack study number and 
Abbreviated Title205626 (S SONNEI MONO GMMA SBVGH- 003
[H03_03TP])
Investigational New Drug 
(IND) numberIND18163
Date of protocol am endment Amendment 6 Final :23 July  2019
Detailed Title A phase IIb, randomized, placebo -controlled, single 
center, observer -blind, human
-challenge study  to 
evaluate the efficacy , safety  and immunogenicity  of 2 
vaccinations with GVGH Shigella sonnei vaccine 
(1790GAHB) administered by  intramuscular route in 
healthy  non- immune adult population
Sponsor signatory Audino Pietro Mario Podda,
GVGH Head of Clinical Development and 
Regulatory  Affairs
Signature
Date
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b3 23-JUL-2019- ----------------Checksum----------------!Ver.!Created On -  - 
5889c076f178fb77b7f8644dc83edbbe4030715b 2.0 7/26/2019 10:04:04 AM -  - 
----------------------------------------------------------------------------For internal use only205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 4Protocol A mendment 6Rationale
Amendment number: Amendment 6
Rationale/background for changes:
ÔÇ∑To add a n additional interim analy sis for immunogenicity  data, which will allow a
faster interpretation of study  results and planning of subsequent follow- up studies.
ÔÇ∑To correct an error in the definitions of dy sentery  and more severe shigellosis
,and
align the sedefinitions to other CHIM studies; oral temperature ‚â• 38.0¬∞C (fever ) is
added to the defini tions.
ÔÇ∑To correct an error in the primary  completion date of the study .
ÔÇ∑To clarify the different applicable case definition sof dy sentery in the study .
ÔÇ∑To provide clarification in the study  design b y showing the inpatient stay in the
study  desig n figure as per the Schedule of Activities table .
ÔÇ∑To specify  the allowed time interval window for the blood draw that occurs during
the inpatient stay .
ÔÇ∑To specify the assay  used for the Œ±4Œ≤7 plasmablast anal ysis asmeasuring both
positive and negative cell s by ELISA ,and not using flow cy tometry .
ÔÇ∑To change the assay  used for HLA -B27 testing from PCR to qualitative flow
cytometry .
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b4 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 5Protocol Amendment 6Investigator Agreement
I agree:
ÔÇ∑To conduct the stud y in compliance with this protocol, an y future protocol 
amendments or protocol administrative changes, with the terms of the clinical trial 
agreement and with an y other study  conduct procedures and/or stud y conduct 
documents provided b y GlaxoSmithKline (GSK) Biologicals.
ÔÇ∑To assume responsibility for the proper conduct of the study  at this site.
ÔÇ∑That I am aware of, and will comply  with, ‚ÄòGood Clinical Practice‚Äô (GCP) and all 
applicable regulatory requirements.
ÔÇ∑To ensure that all persons assisting me with the study  are adequatel y informed about 
the GSK Biologicals‚Äô study  vaccine/ placebo and challenge agent and other study -
related duties and functions as described in the protocol and that bedside mixing at 
the study  site will be performed according to GSK Biologicals instructions only  by 
trained site staff with appr opriate qualification required by  local regulations.
ÔÇ∑To acquire the reference ranges for laboratory  tests performed locall y and, if required 
by local regulations, obtain the laboratory ‚Äôs current certification or Quality  
Assurance procedure manual.
ÔÇ∑To ensur e that no clinical samples (including serum samples) are retained onsite or 
elsewhere without the approval of GSK Biologicals and the express written informed 
consent of the subject.
ÔÇ∑To perform no other biological assay s on the clinical samples except those described 
in the protocol or its amendment(s).
ÔÇ∑To co -operate with a representative of GSK Biologicals in the monitoring process of 
the study  and in resolution of queries about the data.
ÔÇ∑That I have been informed that certain regulatory  authorities re quire the sponsor to 
obtain and supply , as necessary , details about the investigator‚Äôs ownership interest in 
the sponsor or the investigational vaccine , and more generall y about his/her financial 
ties with the sponsor. GSK Biologicals will use and disclose the information solely  
for the purpose of comply ing with regulatory  requirements.
Hence I:
ÔÇ∑Agree to suppl y GSK Biologicals with an y necessary  information regarding 
ownership interest and financial ties (including those of my spouse and dependent 
children) .
ÔÇ∑Agree to promptl y update this information if an y relevant changes occur during the 
course of the stud y and for one year following completion of the study.
ÔÇ∑Agree that GSK Biologicals may  disclose any  information it has about such 
ownership interests and f inancial ties to regulatory authorities.
ÔÇ∑Agree to provide GSK Biologicals with an updated Curriculum Vitae and other 
documents required b y regulatory  agencies for this study .
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b5 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 6eTrack study number and 
Abbreviated Title205626 (S SONNEI MONO GMMA SBVGH- 003
[H03_03TP])
IND number IND18163
Date of protocol amendment Amendment 6 Final :23 July  2019
Detailed Title A phase IIb, randomized, placebo -controlled, single 
center, observer -blind, human- challenge study  to 
evaluate the efficacy , safety  and immunogenicity  of 2 
vaccinations with GVGH Shigella sonnei vaccine 
(1790GAHB) administered by  intramuscular route in 
healthy  non- immune adult population
Investigator name
Signature
Date
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b6 23-JUL-2019- ----------------Checksum----------------!Ver.!Created On -  - 
5889c076f178fb77b7f8644dc83edbbe4030715b 2.0 7/26/2019 10:04:04 AM -  - 
----------------------------------------------------------------------------For internal use only205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 7Sponsor Information
1.Sponsor
GlaxoSmithKline Biologicals
Rue de l‚ÄôInstitut 89,
1330 Rixensart, Belgium
2.Sponsor Medical Expert for the Study
Refer to the local study  contact information document.
3.Sponsor Study Monitor
Refer to the local study  contact information document.
4.Sponsor Study Contact for Reporting of a Serious Adverse Event
GSK Biologicals Central Back -up Study  Contact for Reporting SAEs: refer to protocol 
Section 9.4.2.
5.GSK Biologicals‚Äô Central Safety Physician On -Call Contact information for 
Emergency Unblinding
GSK Biologicals Central Safety  Physician and Back -up Phone contact: refer to
protocol Section 9.8.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b7 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 8SYNOPSIS
Detailed Title A phase IIb, randomized, placebo -controlled, single center, 
observer -blind, human- challenge study  to evaluate the 
efficacy , safety and immunogenicity  of 2 vaccinations with 
GVGH Shigella sonnei vaccine (1790GAHB) administered by  
intramuscular route in heal thy non- immune adult population .
Indication The targeted indication of the vaccine is the prevention of 
moderate to severe diarrheal disease caused b y Shigella 
sonnei (S. sonnei ).
Rationale for the 
study and study 
designÔÇ∑Rationale for the study
GSK Vaccines Institute for Global Health (GVGH) has 
developed a vaccine against S. sonnei (1790GAHB vaccine) 
using the new Generalized Modules for Membrane Antigens 
(GMMA) platform technology .
The study  vaccine could be the stepping stone for the 
development of a multivalent broadl y protective Shigella 
vaccine for vaccination of impoverished communities where 
shigellosis is endemic. However, a standalone monovalent 
vaccine against S. sonnei could be used to protect travelers
against diarrheal shigellosis, as the vast majority  of travelers‚Äô
shigellosis is caused b y S. sonnei , and even to protect infants 
in endemic regions where shigellosis is primaril y caused b y 
S.sonnei .
The 1790GAHB vaccine has been tested in two Phase I dose 
escalation studies in Europe to assess its safet y and 
immunogenicit y via three routes of administration: 
intramuscular (IM), intranasal (IN) and intradermal (ID). The 
results from the first study (dose escalation with IM 
vaccination) have shown that the vaccine has an acceptable 
safet y profile and is well -tolerated up to a dose of 100 ¬µg. 
Additionally , the serologic assessment showed that one dose 
of ÔÇ≥1.5/25 ¬µg OAg/protein of 1790GAHB vaccine elicits 
serum immunoglobulin G (IgG) anti -S sonnei
lipopoly saccharide (L PS) levels ‚â• 121 enzy me-linked 
immunosorbent assay  (ELISA) units/mL  (EU/mL) (i.e., 
median antibody  titerin a panel of 87 Israeli convalescent 
subjects after natural infection by  S. sonnei ). The results from 
the sec ond study  (dose escalation with ID, IN and IM 
vaccination) showed that 1790GAHB vaccine is well -
tolerated also when administered by  the ID and IN routes of 
vaccination. However, immunogenicit y data have shown that 
1790GAHB vaccine administered by  the ID and IN routes is 
not as immunogenic as 1790GAHB vaccine administered by 
the IM route.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b8 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 9Therefore, it has been decided to proceed with the clinical 
development program of this vaccine onl y using the IM 
vaccination route. In terms of dosage, the regimen teste d in 
Phase I studies (three doses given onemonth apart) did not 
show an y significant benefit from the third dose in terms of 
immunogenicit y, therefore a two dose schedule was selected 
for next studies. A Phase IIa stud y, conducted in endemic 
regions of Af rica (i.e., Keny a), has just been completed and 
confirmed the acceptable safet y profile and immunogenicity 
of 1790GAHB vaccine .
Performing a vaccine -human challenge study  may give the 
opportunity  to establish evidence of clinical protection 
induced b y the candidate S. sonnei vaccine (1790GAHB 
vaccine) at an earl y development stage.
ÔÇ∑Rationale for the study design
A human challenge m odel of S. sonnei disease for vaccine 
testing was established in Thailand [ Bodhidatta , 2012] and 
showed an attack rate (AR) of 75% in non -immune adult 
volunteers receiving a challenge dose of 1680 colony  forming 
units (CFU) of S. sonnei strain 53G. Clinica l and laboratory  
endpoints of infection and disease, namel y diarrhea , 
dysentery , fever and shedding of S. sonnei in stools were used 
to calculate the AR and thus to establish the optimal infective 
dose. In a subsequent study  though [ Pitisuttithum , 2016], t he 
AR in the control group, using this model, was much less than 
previously  published.
Given this variability , before starting a vaccine -challenge 
study , the proposed human challenge model of S. sonnei to be 
used has been appropriately  developed and the ch allenge dose 
and AR reliabl y established by the Cincinnati Children‚Äôs 
Hospital Medical Center (CCHMC) (Ohio, United States of 
America). The current GSK vaccine -human challenge study  
will be conducted at CCHMC and will use the developed 
challenge model. Volunteers will be treated after development 
of sy mptoms of shigellosis.
ÔÇ∑Rationale for the use of placebo
As currently  there is no widely  available vaccine against 
shigellosis, the efficacy  and safet y of the 1790GAHB vaccine 
will be evaluated against a placebo. The placebo is used to 
better describe the safet y profile of the S. sonnei vaccine as 
well as its ef ficacy  in terms of clinical protection against 
shigellosis caused b y S. sonnei .
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b9 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 10Objective s Primary
ÔÇ∑To demonstrate the efficacy  of two vaccinations with 
25¬µg of 1790GAHB vaccine in health y adults compared 
to placebo (reduction of shigellosis according to the 
protocol primary  case definition, i.e. Shedding of S. 
sonnei 53G accompanied by  moderate or severe di arrhea, 
OR shedding with an oral temperature of ÔÇ≥38.5
¬∞C after 
challenge with S. sonnei strain 53G ).
Criterion:
Vaccine efficacy (VE) of 1790GAHB vaccine will be 
shown if the lower limit (LL) of the 90% confidence 
interval (CI) of VE will be above zero .
Secondary
Efficacy
ÔÇ∑To determine the efficacy of the 1790GAHB vaccine 
compared to placebo against :
ÔÄ≠Shigellosis as defined b y the Controlled Human 
Infection Model (CHIM) expert working group on 
case definition.*
ÔÄ≠Shigellosis, as defined b y: severe diarrhea OR 
moderate diarrhea with fever or with one or more 
moderate constitutional/enteric s ymptoms OR 
dysentery [[ ‚â•2 loose stools with gross blood 
(hem occult positive) in 24 hours] AND [ ‚â•1 
reportable constitutional/enteric s ymptom]] .
ÔÄ≠More severe shigellosis, a sdefined b y: severe or
moderate diarrhea with fever or with one or more 
severe constitutional/enteric sy mptoms OR dy sentery  
[[‚â•2 loose stools wit h gross blood (hemoccult 
positive) in 24 hours] AND [ oral temperature 
‚â• 
38.0¬∞C OR ‚â•1 severe constitutional/enteric 
symptom] ]. (Amended: 23 July 2019)
ÔÄ≠Shedding of S. sonnei strain 53G.
ÔÄ≠Severe diarrhea .
ÔÄ≠More severe diarrhea .
ÔÄ≠Dysentery .
ÔÄ≠Weight of all grade 3 -5 
stools .
ÔÄ≠Totalnumber of all grade 3-5 stools.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b10 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 11ÔÄ≠Confirmed S. sonnei 53G shedding AND moderate 
or severe diarrhea OR d ysentery  OR presence of oral 
temperature ÔÇ≥38.5¬∞C OR presence of one or more 
severe intestinal s ymptoms (abdominal pain, 
cramping, nausea, vomiting , gas,and anorexia ).
ÔÄ≠Disease not fulfilling the protocol primary  case 
definition for shigellosis
associated or not with mild 
to moderate s ymptoms including: passing loose stool 
(not meeting the protocol definition of moderate or 
severe diarrhea), abdominal pain, abdominal cramps, 
gas, anorexia, nausea, headache, my algia, malaise,
arthralgia, fever, vomiting and IV fluid 
administration
.
ÔÄ≠Time to onset of shigellosis according to theprimary  
case definition after challenge.
*According to the working group, the participant must fulfil 
any one of the three following possible endpoints to qualify  as 
having reached the CHIM case definition for this objective:
1.
Severe diarrhea defined as [ ÔÇ≥6 loose stools in 24 hours] 
OR [ ÀÉ800 grams loose stools in 24 hours] 
2.Moderate diarrhea defined as [4 -5 loose stools in 24 
hours OR 400- 800 grams loose stools in 24 hours] AN D 
[oral temperature 
ÔÇ≥38.0oC OR ÔÇ≥1 moderate 
constitutional/enteric symptom OR ÔÇ≥2 episodes of 
vomiting in 24 hours] 
3.Dysentery  defined as [ ÔÇ≥2 loose stools with gross blood 
(hemoccult positive) in 24 hours] AND [oral temperature 
ÔÇ≥38.0oC OR ÔÇ≥1 moderate constitutional/enteric symptom 
OR ÔÇ≥ 2 episodes of vomiting in 24 hours].
Safety
ÔÇ∑To assess the safet y and reactogenicity of the 1790GAHB 
vaccine in terms of solicited adverse events, unsolicited 
adverse events, serious adverse events (SAEs), adverse 
events of special interest (A ESI) and laboratory  
parameters.
ÔÇ∑To assess safety  after challenge in terms of SAEs, 
unsolicited adverse events, AESI ,and laboratory  
parameters.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b11 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 12Immunogenicity
ÔÇ∑To evaluate the IgG ELISA immunogenicity  profile of 
the 1790GAHB vaccine at 7 day s and 28 day s after the 
first and second vaccination (IgG ELISA coated with 
OAg containing L PS).
ÔÇ∑To evaluate the immunogenicity  profile of the 
1790GAHB vaccine at pre- challenge and at 7 and 28 day s 
after challenge (IgG ELISA coated with OAg containing 
LPS).
ÔÇ∑Number and percentage of seroresponders for anti- S. 
sonnei LPS at 28 day s after first and second vaccination.
ÔÇ∑To assess anti-S.sonnei LPS concentration ‚â• 121 EU/ml 
at 28 day s after first and second vaccination. 
Tertiary
The following tertiary objectives, which are part of the study  
exploratory  objectives may  be evaluated in addition to the 
primary  and secondary  objectives and will complement 
assessment of the vaccine immunogenicit y profile:
ÔÇ∑Evaluate S. sonnei specific secretory  immunoglobulin A
(sIgA)in stool at Day  1 and 7 day s after first and second 
vaccina tionand 7 day s after challenge (Day  64).
ÔÇ∑Evaluate S. Sonnei LPS IgG -specific Œ±4Œ≤7+/ -
plasmablast response at Day  1 and 7 day s after first and 
second vaccinat ion and 7 day s after challenge (Day  64).
(Amended: 23 July 2019)
ÔÇ∑Evaluate serum bactericidal activity  against S. sonnei at 
Day 1 and 28 day s after first and second vaccination.
ÔÇ∑Evaluate correlation between serum anti -S. sonnei LPS 
IgG level, serum bactericidal activity  titer, shigellosis, 
shedding, mild, moderate ,severe or more severe diarrhea , 
and dysentery  after challenge.
ÔÇ∑Evaluate gl ycosylation of fragment cry stallisable (Fc) 
portion of IgG antibodies at Day  1 and 28 day s after 
second vaccination and association with clinical 
protectio n and/or serological endpoints.
ÔÇ∑Evaluate inflammatory response from stools collected 
before challenge at Visit 5 
(Day  57)and dail y, post 
challenge, during inpatient stay  (Day  57 to Day  64).
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b12 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 13ÔÇ∑Evaluat e gene expression signatures at Day  1 and 7 day s 
after first and second vaccination and 7 day s after 
challenge (Day  64).
ÔÇ∑Investigate gut microbiome at Day  1 and 28 day s after 
second vaccination and its potential association with 
protection and immune respo nse.
Study design ÔÇ∑Experimental design : Phase IIb, observer -blind, 
randomized, placebo -controlled, mono -centric study  with 
two parallel groups.
ÔÇ∑Duration of the study :
ÔÄ≠Epoch 001: Starting at Screening Visit (Day  -45 to 
Day -1) and ending before Visit 1 (Day 1).
ÔÄ≠Epoch 002: Starting the day  of randomization and 
first vaccination (Visit 1) and ending before the 
receipt of the challenge agent, 28 day s after second 
vaccination (Visit 5) .
ÔÄ≠Epoch 003: Starting with the receipt of the challenge 
agent at 28 day s after second vaccination (Visit 5) 
and ending 6 months after challenge (Visit 8).
ÔÇ∑Primary completion date (PCD): Visit 5(Day 6 4).
(Amended: 23 July 2019)
ÔÇ∑End of Study (EoS): Last testing results released of 
samples collected for primary  and secondary  objective s at 
Visit 8.
ÔÇ∑Study groups:
Synopsis Table 1 Study  groups and epochs foreseen in the study
Study 
groupsNumber of 
subjectsAge (Min -Max)Epochs
Epoch 001 Epoch 002 Epoch 003
Screening 1stand 2ndvaccination Challenge
S. sonnei 36 18 years ‚Äì50 years x x x
Placebo 36 18 years ‚Äì50 years x x x
Synopsis Table 2 Study  groups and treatment foreseen in the study
Treatment nameVaccine/placebo/
challenge agent nameStudy Groups
S. sonnei Placebo
S. sonnei 1790GAHB x
Placebo GAHB -Placebo x
Challenge S. sonnei 53G strain x x
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b13 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 14ÔÇ∑Control: Placebo control with GAHB -Placebo with the 
same composition as the vaccine except the active 
ingredient. GAHB- Placebo will also be used as diluent 
for bed sidemixing of the vaccine.
ÔÇ∑Vaccination schedule: Subjects will receive 2 doses of 
either the stud y vaccine or placebo 28 day s apart. At 28 
days after the second dose, all subjects will receive the 
challenge dose.
ÔÇ∑Treatment allocation: Following the screening period 
before the first vaccination (Day  -45 to Day  -1), 
subjects will be randomized in a 1:1 r atio to receive 
either the stud y vaccine or the placebo.
ÔÇ∑Blinding: The study  will be observer -blind.
Synopsis Table 3 Blinding of study  epochs
Study Epochs Blinding
Screening (Epoch 001) N/A
1stand 2ndvaccination (Epoch 002) observer -blind
Challenge (Epoch 003) observer -blind
ÔÇ∑Sampling schedule:
ÔÄ≠5 mL  for hematology : Screening Visit, Visit 2, 
Visit 3, Visit 4, Visit 5 and Visit 8. 
Additionally , hematology  is repeated weekl y 
until resolution if neutropenia occurs.
ÔÄ≠5 mL  for biochemical analy sis: Screening 
Visit.
ÔÄ≠10 mL  for hepatitis B, hepatitis C and HI V: 
Screening Visit.
ÔÄ≠10 mL  for HLA -B27 testing: Screening Visit.
ÔÄ≠5 mL  for local anti S. sonnei LPS IgG 
Screening -ELISA: Screening Visit.
ÔÄ≠Urine sampl e for urinal ysis: Screening Visit 
and Visit 5.
ÔÄ≠Urine sample for pregnancy  test for women of 
childbearing potential: Screening Visit, Visit 1, 
Visit 3, Visit 5 and Visit 8.
ÔÄ≠20 mL  for immunological tests (antibody  
response) at Visit 1, Visit 2, Visit 3, Visi t 4, 
Visit 5, 7 day s after Visit 5 (Day  64), Visit 6,
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b14 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 15ÔÄ≠For serum bactericidal activity  tests at Visit 1, 
Visit 3 and Visit 5
ÔÄ≠And for Fc gl ycosylation test on leftover serum 
samples collected at Visit 1 and Visit 5.
ÔÄ≠50mL of peripheral venous blood for Œ±4Œ≤7+/ -
plasmablast analysis by ELISA and RNA 
extraction from peripheral blood mononuclear 
cells ( PBMC )for gene expression profiling : 
Visit 1, Visit 2, Visit 4 and 7 day s after Visit 5 
(Day  64). (Amended: 23 July 2019)
ÔÄ≠Stool sample for inflammatory  response b efore 
challenge at Visit 5 (Day 57) and dail y, post 
challenge, during inpatient stay  (Day  57 to Day  
64).
ÔÄ≠Stool sample: for microbiome testing at Visit 1 
and Visit 5, for S. sonnei specific sIgA at Visit 
1, Visit 2, Visit 4 and 7 days after challenge 
(Day  64) and stool anal ysis, culture and qPCR 
daily  during inpatient stay  (from Visit 5 to 7 
days after challenge [Day  57 to Day  64] or 
prolonged until 2 consecutive negative stool 
samples if subject still shedding).
ÔÇ∑Type of study : self -contained.
ÔÇ∑Data collection : Standardized electronic Case 
Report Form (eCRF).
ÔÇ∑Safety monitoring:
An Independent Data Monitoring Committee 
(IDMC) will be established to monitor the safet y of 
subjects throughout the study . The IDMC will 
review unblinded data, to assess safet y signals and 
make recommendations to the Sponsor concerning 
continuation, termination, or other modifications of 
the study  based on the observed adverse effects. 
The membership and roles of the IDMC will be 
outlined in the I DMC charter.
The safet y review team (SRT) will monitor the 
safet y of subjects throughout the study. The SRT 
will review blinded data, assess safet y signals and 
make recommendations to the IDMC and to the 
Sponsor concerning continuation, termination, or 
other modifications of the study  based on the 
observed adverse effects.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b15 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 16A dedicated Safet y Management Plan will be 
prepared to ensure appropriate safety  reporting 
responsibilities and roles are defined.
Case definitions Stools will be graded as follows: Grade 1: firm formed; 
Grade 2: soft formed; Grade 3: viscous opaque liquid or 
semi -liquid which assumes the shape of the bowl; Grade 
4: watery  opaque liquid; Grade 5: clear watery  or 
mucoid liquid.
Diarrhea
For the purpose of this study , diarrhea is defined as:
ÔÇ∑Moderate diarrhea: 4 to 5 loose or watery  (Grade 3 
to 5) stools or 400 to 800 grams of Grade 3 to 5 
stools within 24 hours.
ÔÇ∑Severe diarrhea: 6 or more loose or watery  (Grade 3 
to 5) stools or > 800 grams of Grades 3 to 5 stools 
within 24 hours or required medical intervention. In
case of severe diarrhea, medical intervention is 
defined as intravenous (IV) fluids administration or 
anticipation of antibiotic treatment before the 5 th
day after challenge.
ÔÇ∑More severe diarrhea: 10 or more loose or watery
(Grade 3 to 5) stools or ÔÇ≥1000 grams of Grade 3 to 
5 stools within 24 hours .
Dysentery (Amended: 23July 2019)
For the purpose of the endpoint ‚ÄúRate of shigellosis as 
defined by the CHIM expert working group occurring 
within a period starting with challenge visit and 
lasting until the end of the inpatient stay, in all 
subjects‚Äù, dysentery is defined as follows:
ÔÇ∑At least 2 loose stools with gross blood (hemoccult 
positive) in 24 hours AND [oral temperature 
‚â•38.0oC OR ‚â•1 moderate constitutional/enteric 
symptom OR ‚â•2 episodes of vomiting in 24 hours]. 
In this case constitutional/enteric symptom are the 
following: nause a, abdominal pain, abdominal 
cramping, myalgia, arthralgia, malaise.
For the purpose of the endpoint ‚ÄúRate of shigellosis, 
as defined by: severe diarrhea OR moderate diarrhea 
with fever or with one or more moderate 
constitutional/enteric symptoms OR dysent ery‚Äù, 
dysentery is defined as follows:
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b16 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 17ÔÇ∑At least 2 loose stools with gross blood (hemoccult 
positive) in 24 hours AND [‚â•1 reportable 
constitutional/enteric symptom]. In this case 
constitutional/enteric symptom are the following: 
headache, fatigue, arthralgia, malaise, myalgia, 
chills, nausea, abdominal cramping, abdominal 
pain, gas, anorexia, vomiting.
For the purpose of the endpoint ‚ÄúRate of more severe 
shigellosis as defined by: severe or moderate diarrhea 
with fever or with one or more severe 
constitution al/enteric symptom OR dysentery [[ ‚â•2 
loose stools with gross blood (hemoccult positive) in 24 
hours] AND [ oral temperature ‚â•38.0oC OR ‚â•1 severe 
constitutional/enteric symptom]]. ‚Äù, dysentery is 
defined as follows:
ÔÇ∑At least 2 loose stools with gross blood (h emoccult 
positive) in 24 hours] AND [oral temperature 
‚â•38.0oC OR ‚â•1 severe constitutional/enteric 
symptom]. In this case constitutional/enteric 
symptom are the following: headache, fatigue, 
arthralgia, malaise, myalgia, chills, nausea, 
abdominal cramping, abdominal pain, gas, 
anorexia, vomiting.
For the purpose of the endpoints ‚ÄúDysentery‚Äù and 
‚ÄúConfirmed S. sonnei 53G shedding AND moderate or 
severe diarrhea OR dysentery OR presence of oral 
temperature ‚â• 38.5¬∞C OR presence of one or more 
severe intestinal symptoms (abdominal pain, 
cramping, nausea, vomiting, gas, and anorexia)‚Äù, 
dysentery is defined as follows:
A Grade 3, 4, or 5 stool with gross blood on at least 2 
occasions within 24 hours and presence of 
constitutional/enteric symptoms. In this case, 
cons titutional/enteric symptoms consist of headache, 
fatigue, arthralgia, malaise, myalgia, chills, nausea, 
abdominal cramping, abdominal pain, gas, anorexia, 
vomiting, and fever
.
[Amended: 23July 2019)
Shigellosis
For the primary  and secondary  objectives in the 
challenge phase of the study , the protocol primary case 
definition for shigellosis is:
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b17 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 18ÔÇ∑Shedding of S. sonnei 53G accompanied by  
moderate or severe diarrhea OR shedding with an 
oral temperature of ÔÇ≥38.5¬∞C . 
For the secondary  objectives in the challenge phase of 
the study , 2 definitions of shigellosis areused:
1.CHIM working group case definition for shigellosis 
as defined b y any one of the three following 
possible endpoints:
ÔÄ≠Severe diarrhea defined as [ ÔÇ≥6 loose stools in 
24 hours] OR [ ÀÉ800 grams loose s tools in 24 
hours]
ÔÄ≠Moderate diarrhea defined as [4 -5 loose stools 
in 24 hours OR 400- 800 grams loose stools in 
24 hours] AND [oral temperature ÔÇ≥38.0oC OR 
ÔÇ≥1 moderate constitutional/enteric s ymptom 
OR ÔÇ≥ 2 episodes of vomiting in 24 hours]  
ÔÄ≠Dysentery  defined as [ÔÇ≥2 loose stools with 
gross blood (hemoccult positive) in 24 hours] 
AND [oral temperature ÔÇ≥38.0¬∞C OR 
ÔÇ≥1 
moderate constitutional/enteric s ymptom OR 
ÔÇ≥2 episodes of vomiting in 24 hours].
2.Shigellosis as defined b y any one of the three 
following possible endpoints:
ÔÄ≠Severe diarrhea defined as [ ‚â•6 loose stools in 
24 hours OR ÀÉ800 grams loose stools in 24 
hours]
ÔÄ≠Moderate diarrhea defined as [4 -5 loose stools 
in 24 hours OR 400- 800 grams loose stools in 
24 hours] AND [oral temperature ‚â•38.0oC OR 
‚â•1 moderate constitutional/enteric s ymptom].
ÔÄ≠Dysentery  defined as [ ‚â•2 loose stools with 
gross blood (hemoccult positive) in 24 hours] 
AND [ ‚â•1 reportable constitutional/enteric 
symptom].
For the secondary  objectives in the challenge phase of 
the study , more severe shige llosis is defined by  any one 
of the two following possible endpoints:
ÔÄ≠Moderate OR severe diarrhea [ ‚â•4 loose stools 
in 24 hours OR ‚â•400 grams loose stools in 24 
hours] AND [oral temperature ‚â•38.0oC OR ‚â•1 
severe constitutional/enteric sy mptom] .
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b18 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 19ÔÄ≠Dysentery  defined as [ ‚â•2 loose stools with 
gross blood (hemoccult positive) in 24 hours] 
AND [ oral temperature ‚â•38.0oC OR ‚â•1 severe 
constitutional/enteric symptom] .(Amended: 23
July 2019)
Number of subjects Target enrolment is approximately  72 subjects (36 per 
treatment group).
Endpoints Primary
Efficacy
VE will be evaluated with:
ÔÇ∑Rate of shigellosis (fulfilling the protocol primary 
case definition) occurring within a period starting 
with the challenge visit and lasting up to the end of 
the inpatient stay , in all subjects.
Secondary
Efficacy
VE, in subjects receiving the 1790GAHB vaccine vs. 
placebo, will be also measured during inpatient stay  
(Day  57 to Day  64)against:
ÔÇ∑Rate of shigellosis as defined by the CHIM 
working group case definition for shigellosis ) 
occurring within a period starting with challenge 
visit and lasting until the end of the inpatient stay , 
in all subjects. (Amended: 23July 2019)
ÔÇ∑Rate of shigellosis, as defined by : severe diarrhea 
OR moderate diarrhea with fever or with one or 
more moderate constitutional/ enteric s ymptom OR 
dysentery [[‚â•2 loose stools with gross blood 
(hemoccult positive) in 24 hours] AND [ ‚â•1 
reportable constitutional/enteric s ymptom] ].
ÔÇ∑Rate of more severe shigellosis as defined b y: 
severe ormoderate diarrhea with fever or with one 
or more severe constitutional/enteric s ymptom OR 
dysentery  [[‚â•2 loose stools with gross blood 
(hemoccult positive) in 24 hours] AND [ oral 
temperature ‚â• 38.0¬∞C OR ‚â•1 severe 
constitutional/enteric symptom] ].(Amended: 23
July 2019)
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b19 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 20ÔÇ∑Shedding of S. sonnei strain 53G. 
Shedding of S. sonnei strain 53G is defined as 
positivity of at least one stool sample either by 
culture or qPCR or both.
ÔÇ∑Severe diarrhea.
ÔÇ∑More severe diarrhea.
ÔÇ∑Dysentery .
ÔÇ∑Weight of all grade 3 -5 stools .
ÔÇ∑Total number of all grade 3-5 stools.
ÔÇ∑Confirmed S. sonnei 53G shedding AND moderate 
or severe diarrhea OR dysentery  OR presence of 
oral temperature ÔÇ≥38.5¬∞C OR presence of one or 
more severe intestinal symptoms (abdominal pain, 
cramping, nausea, vomiting, gas, and anorexia)
ÔÇ∑Disease not fulfilling the protocol primary  case 
definition for shigellosis associated or not with mild 
to moderate s ymptoms inclu ding: passing loose 
stool (not meeting the protocol definition of 
moderate or severe diarrhea), abdominal pain, 
abdominal cramps, gas, anorexia, nausea, headache, 
myalgia, malaise, arthralgia, fever, vomiting and IV 
fluid administration.
ÔÇ∑Time to onset of shigellosis after challenge, 
according to the protocol primary  case definition.
Safety
Solicited adverse events
ÔÇ∑Occurrence of each solicited local and s ystemic 
adverse event within 7 day s after each vaccination .
Unsolicited adverse events
ÔÇ∑Occurrence of unsolicited AEs within 28 day s after 
vaccination and after challenge , according to 
Medical Dictionary  for Regulatory  Activities 
(MedDRA) classification.
Serious adverse events
ÔÇ∑Occurrence of all SAEs and related SAEs from Day
1 to study  end.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b20 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 21Adverse events of special interest
ÔÇ∑Occurrence of AESI (i.e., sy mptomatic 
neutropenia) from Day  1 to study  end.
Laboratory  parameters
ÔÇ∑Out of laboratory  reference range and/or clinically 
significant value (according to local ranges) for 
hematology  at 7 days after first and second 
vaccination and at last study visit (Visit 8).
Immunogenicity
The measures of immunogenicity , against the L PS of 
S.sonnei , will include:
ÔÇ∑IgG geometric mean concentrations (GMCs) pre -
vaccination (Day  1), 7 and 28 day s after first and 
second vaccination by antibody  concentration at 
baseline (i.e., above vs. below the assay  detection 
limit), as determined by  anti- S.sonnei LPS IgG 
ELISA.
ÔÇ∑IgG GMC pre -challenge (Day  57), 7 and 28 day s 
after challenge (Day  64 and Day  85) as determined 
by anti-S. sonnei LPS IgG ELI SA.
ÔÇ∑Number and percentage of subjects achieving a post 
vaccination anti -S. Sonnei LPS concentration ‚â• 121 
EU/ml at 28 day s after first and second vaccination.
ÔÇ∑Number and percentage of seroresponders
*for anti-
S. sonnei LPS at 28 day s after first and second 
vaccination.
*Seroresponse is aimed to define a significant 
increase in anti S. sonnei LPS IgG concentration in 
post-vaccination samples and relies on the 
definition alread y used in a previous phase II study 
in Keny an population. For the purpose of this study  
seroresponse is defined as:
ÔÄ≠If the baseline value is greater than 50 EU/mL  
then an increase of at least 50% in the post -
vaccination sample as compared to baseline.
ÔÄ≠If the baseline value is less o r equal to 
50EU/mL  then an increase of at least 
25EU/mL  in the post -vaccination sample as 
compared to baseline.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b21 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 22Note: Threshold values/increases given in the definition 
of seroresponse might be subject to change during the 
course of the stud y (e.g., in c ase of optimization 
/qualification/validation of the anti S. sonnei LPSIgG
ELISA).
Tertiary
ÔÇ∑Specific anti -S. sonnei LPS sIgA antibod y 
concentration in stool samples at Day  1, 7 day s 
after first and second vaccination and 7 day s after 
challenge (Day  64).
ÔÇ∑Frequency  of S. sonnei LPS specific IgG Œ±4Œ≤7+ /-
antibody  secreting cells per 10^6 PBMC 
plasmablast at Day  1 and 7 day s after first and 
second vaccination and 7 day s after challenge 
(Day 8, Day  36 and Day  64). (Amended: 23July
2019)
ÔÇ∑Glycosylation profiles of IgG antibodies at Day  1 
and 28 day s after second vaccination (Visit 5; Day 
57).
ÔÇ∑Number and percentage of subjects that show 
correlation between serum anti- S. sonnei LPS IgG 
concentration, serum bactericidal activit y titer, 
shigellosis, shedding, moderat etosevere diarrhea 
(MSD) , dysentery  and mild diarrhea after 
challenge.
ÔÇ∑Concentration of stool markers of intestinal 
inflammation (e.g. calprotectin and 
myeloperoxidase) before oral challenge with S. 
sonnei, 53G at Visit 5 (Day  57) and dail y during the 
inpatient stay  after challenge administration (Day  
57 to Day  64).
ÔÇ∑The number of differential expressed genes 7 days 
after first and second vaccination and 7 day s after 
challenge b y comparing the relative abundance of 
mRNA sequences compared to Day  1 (pre -
vaccination baseline).
ÔÇ∑Diversity  and frequency  of microbiome components
(taxa and/or genes according to technology ) at 
Day 1 prior to vaccination and 28 day s after second 
vaccination (Visit 5; Day 57) .
Exploratory  anal ysis for hy potheses generation will 
include the evaluation of the association of the 
microbiome components w ith efficacy  and 
immunogenicit y described above.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b22 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 23TABLE OF CONTENTS
PAGE
SPONSOR INFORMATION ............................................................................................ 7
SYNOPSIS ...................................................................................................................... 8
LIST OF ABBREVIATION S (AMENDED: 23 JULY 2019) .............................................. 31
GLOSSARY OF TERMS ............................................................................................... 34
TRADEMARKS ............................................................................................................. 39
1.INTRODUCTION .................................................................................................... 40
1.1. Background ................................................................................................ 40
1.2. Rationale for the study and study design .................................................... 40
1.2.1. Rationale for the study ................................................................ .40
1.2.2. Rationale for the study design ...................................................... 41
1.2.3. Rationale for the use of placebo .................................................. 41
1.3. Benefit:Risk assessment ............................................................................. 42
1.3.1. Risk assessment .......................................................................... 42
1.3.2. Benefit assessment ..................................................................... 44
1.3.3. Overall benefit: Risk conclusion ................................................... 44
2.OBJECTIVES ......................................................................................................... 45
2.1. Primary objective ........................................................................................ 45
2.2. Secondary objectives .................................................................................. 45
2.3. Tertiary objectives ....................................................................................... 47
3. STUDY DESIGN OVERVIE W................................................................................ 47
3.1. Vaccination Phase ...................................................................................... 48
3.2. Challenge Phase ........................................................................................ 49
4.CASE DEFINITIONS .............................................................................................. 54
4.1. Diarrhea ...................................................................................................... 54
4.2. Dysentery (Amended: 23 July 2019) ........................................................... 55
4.3. Shigellosis .................................................................................................. 56
5.STUDY COHORT ................................................................................................... 57
5.1. Number of subjects/center .......................................................................... 57
5.2. Inclusion criteria .......................................................................................... 57
5.3. Exclusion criteria ......................................................................................... 58
6.CONDUCT OF THE STUDY .................................................................................. 60
6.1. Regulatory and ethical considerations, including the informed 
consent process .......................................................................................... 60
6.2. Subject identification and randomization ..................................................... 61
6.2.1. Subject identification .................................................................... 61
6.2.2. Randomization of treatment ......................................................... 61
6.2.2.1. Randomization of supplies .......................................... 61
6.2.2.2. Treatment allocation to the subject ............................. 61
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b23 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 246.2.2.2.1. Study group and treatment 
number allocation ................................... 61
6.2.3. Allocation of subjects to assay subsets ........................................ 62
6.3. Method of blinding ...................................................................................... 62
6.4. General study aspects ................................................................................ 63
6.4.1. Independent data monitoring committee ...................................... 63
6.5. Outline of study procedures ........................................................................ 64
6.6. Detailed description of study procedures .................................................... 67
6.6.1. Informed consent ......................................................................... 67
6.6.2. Check inclusion and exclusion criteria ......................................... 67
6.6.3. Collect demographic data ............................................................ 67
6.6.4. Medical history ............................................................................. 68
6.6.5. Physical examination / history directed physical 
examination ................................................................................. 68
6.6.6. Pregnancy test ............................................................................. 68
6.6.7. Check contraindications to vaccination ........................................ 68
6.6.8. Assess pre -vaccination body temperature ................................... 69
6.6.9. Study group and treatment number allocation .............................. 69
6.6.10. Sampling ...................................................................................... 69
6.6.10.1. Blood sampling for safety or immune response 
assessments .............................................................. 69
6.6.10.2. Urine sampling ........................................................... 69
6.6.10.3. Stool sampling ............................................................ 69
6.6.11. Study vaccine/placebo administration .......................................... 70
6.6.12. Challenge administration and inpatient stay ................................ .70
6.6.13. Check and record concomitant medication/vaccination and 
intercurrent medical conditions .................................................... 70
6.6.14. Recording of AEs, SAEs, pregnancies and AESIs ....................... 70
6.6.14.1. Subject Diary .............................................................. 71
6.6.14.2. Post-vaccination reminders ........................................ 71
6.6.14.2.1. Subject Diary reminder calls ................... 71
6.6.15. Study conclusion .......................................................................... 71
6.7. Biological sample handling and analysis ..................................................... 72
6.7.1. Use of specified study materials .................................................. 73
6.7.2. Biological samples ....................................................................... 73
6.7.3. Laboratory assays ....................................................................... 73
6.7.4. Biological samples evaluation ...................................................... 77
6.7.4.1. Immunological read -outs ............................................ 77
6.7.4.2. Hematology/blood chemistry ...................................... 78
6.7.5. Immunological correlates of protection ......................................... 78
7.STUDY VACCINE/PRODUCTS AN D ADMINISTRATION ...................................... 79
7.1. Description of study vaccine/placebo and challenge agent ......................... 79
7.2. Storage and handling of study vaccine/placebo and challenge agent ......... 79
7.3. Dosage and administration of study vaccine/placebo and challenge 
agent .......................................................................................................... 80
7.3.1. Vaccine/placebo preparation ........................................................ 80
7.3.2. Preparation of challenge agent .................................................... 80
7.3.3. Vaccine/placebo dosage and administration ................................ 80
7.3.4. Challenge agent dosage and administration ................................ 81
7.4. Replacement of unusable vaccine/placebo doses and challenge 
agent .......................................................................................................... 82
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b24 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 257.5. Contraindications to subsequent vaccination or challenge .......................... 82
7.6. Concomitant medications/products and concomitant vaccinations .............. 83
7.6.1. Recording of concomitant medications/products and 
concomitant vaccinations ............................................................. 83
7.6.2. Concomitant medications/products/vaccines that may lead 
to the elimination of a subject from per-protocol analyses ............ 83
7.7. Intercurrent medical conditions that may lead to elimination of a 
subject from per -protocol analyses ............................................................. 84
8.HEALTH ECONOMICS .......................................................................................... 84
9.SAFETY ................................................................................................................. 85
9.1. Safety definitions ........................................................................................ 85
9.1.1. Definition of an adverse event ...................................................... 85
9.1.2. Definition of a serious adverse event ........................................... 86
9.1.3. Solicited adverse events .............................................................. 87
9.1.3.1. Solicited local Adverse events .................................... 87
9.1.3.2. Solicited systemic Adverse events .............................. 87
9.1.3.3. Solicited events after challenge phase ........................ 88
9.1.4. Unsolicited Adverse Events ......................................................... 88
9.1.5. Clinical laboratory parameters and other abnormal 
assessments qualifying as adverse events or serious 
adverse events ............................................................................ 89
9.1.6. Adverse events of special interest ................................................ 89
9.2. Events or outcomes not qualifying as adverse events or serious 
adverse events ........................................................................................... 91
9.2.1. Pregnancy ................................................................................... 91
9.3. Detecting and rec ording adverse events, serious adverse events 
and pregnancies ......................................................................................... 92
9.3.1. Time period for detecting and recording adverse events, 
serious adverse events and pregnancies ..................................... 92
9.3.2. Post-study adverse events and serious adverse events ............... 94
9.3.3. Evaluation of adverse events and serious adverse events ........... 94
9.3.3.1. Active questioning to detect adverse events 
and serious adverse events ........................................ 94
9.3.3.2. Assessment of adverse events ................................... 94
9.3.3.2.1. Assessment of intensity .......................... 94
9.3.3.2.2. Assessment of causality ......................... 97
9.3.3.3. Assessment of outcomes ............................................ 98
9.3.3.4. Medically attended visits ............................................. 98
9.4. Reporting of serious adverse events, pregnancies, and other events ......... 98
9.4.1. Prompt reporting of serious adverse events, pregnancies, 
and other events to GSK Biologicals ............................................ 98
9.4.2. Contact information for reporting serious adverse events, 
pregnancies and AESIs ............................................................... 99
9.4.3. Completion and transmission of SAE reports to GSK 
Biologicals ................................................................................... 99
9.4.3.1. Back -up system in case the electronic 
reporting system does not work .................................. 99
9.4.4. Completion and transmission of pregnancy reports to GSK 
Biologicals ................................................................................. 100
9.4.5. Reporting of AESIs to GSK Biologicals ...................................... 100
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b25 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 269.4.6. Updating of SAE, pregnancy, and AESI informat ion after 
removal of write access to the subject‚Äôs eCRF ........................... 101
9.4.7. Regulatory reporting requirements for serious adverse 
events ........................................................................................ 101
9.5. Follow -up of adverse events, serious adverse events, and 
pregnancies .............................................................................................. 101
9.5.1. Follow -up of adverse events and serious adverse events .......... 101
9.5.1.1. Follow -up during the study ........................................ 101
9.5.1.2. Follow -up after the subject is discharged from 
the study ................................................................... 102
9.5.2. Follow -up of pregnancies ........................................................... 102
9.6. Treatment of adverse events .................................................................... 102
9.7. Unblinding ................................................................................................ .102
9.8. Emergency unblinding .............................................................................. 103
9.9. Subject card .............................................................................................. 103
9.10. Holding rule and safety monitoring ............................................................ 104
9.10.1. Holding rule ............................................................................... 104
9.10.2. Safety monitoring ....................................................................... 104
10.SUBJECT COMPLETION AND WITH DRAW AL................................................... 104
10.1. Subject completion ................................................................................... 104
10.2. Subject withdrawal .................................................................................... 104
10.2.1. Subject withdrawal from the study ............................................. 104
10.2.2. Subject withdrawal from study vaccine/placebo or 
challenge agent ......................................................................... 105
11.STATISTICAL METHODS .................................................................................... 106
11.1. Primary endpoint ....................................................................................... 106
11.2. Secondary endpoints ................................................................................ 106
11.3. Tertiary endpoints ..................................................................................... 108
11.4. Determination of sample size .................................................................... 109
11.5. Analysis sets ............................................................................................. 109
11.5.1. All Enrolled Set .......................................................................... 109
11.5.2. All Exposed Set ......................................................................... 109
11.5.3. Safety set ................................................................................... 109
11.5.3.1. Solicited Safety Set (solicited local and 
systemic adverse events an d other solicited 
adverse events) ........................................................ 109
11.5.3.2. Unsolicited Safety Set (unsolicited adverse 
events) ..................................................................... 110
11.5.3.3. Overall safety set ...................................................... 110
11.5.4. Full analysis set (FAS) efficacy/Immunogenicity set ................... 110
11.5.4.1. Full analysis set efficacy ........................................... 110
11.5.4.2. Full analysis set Immunogenicity .............................. 110
11.5.5. Per-protocol (PP) set for efficacy/Immunogenicity set ................ 110
11.5.6. Other analysis sets .................................................................... 111
11.5.7. Sub-groups ................................................................................ 111
11.6. Derived and transformed data ................................................................... 111
11.7. Analysis of demographics ......................................................................... 112
11.8. Analysis of efficacy ................................................................................... 112
11.9. Analysis of immunogenicity ....................................................................... 112
11.10. Analysis of safety ...................................................................................... 113
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b26 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 2711.11. Interpretation of analyses .......................................................................... 114
11.12. Conduct of analyses ................................................................................. 114
11.12.1. Sequence of analyses ................................................................ 114
11.12.2. Statistical considerations for interim analyses ............................ 114
12.ADMINISTRATIVE MATTERS ............................................................................. 115
12.1. Electronic case report form instructions .................................................... 115
12.2. Subject Diary ............................................................................................ 115
12.3. Study monitoring by GSK biologicals ........................................................ 116
12.4. Record retention ....................................................................................... 117
12.5. Quality assurance ..................................................................................... 117
12.6. Posting of information on publicly available clinical trial regi sters and 
publication policy ...................................................................................... 117
12.7. Provision of study results to investigators ................................................. 118
12.8. Data sharing ............................................................................................. 118
12.9. Pharmacogenomics .................................................................................. 118
13.COUNTRY SPECIFIC REQUIREMEN TS............................................................. 118
14.REFERENCES ..................................................................................................... 119
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b27 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 28LIST OF TA BLES
PAGE
Table 1 Study groups and epochs foreseen in the study ..................................... 52
Table 2 Study groups and treatment foreseen in the study ................................ .52
Table 3 Blinding of study epochs ........................................................................ 53
Table 4 List of study procedures ......................................................................... 64
Table 5 Intervals between study visits (Amended: 23 July 2019) ........................ 67
Table 6 Biological samples ................................................................................. 73
Table 7 Immunity (Antibody determination) ......................................................... 74
Table 8 Cell-Mediated Immunity ( CMI) (Amended: 23 July 2019) ....................... 74
Table 9 Excretion of Challenge agent ................................................................ .74
Table 10 Hematology, Serum Chemistry, Virology, HLA -B27 test, Urine 
and Stool tests (Amended: 23 July 2019) ............................................... 75
Table 11 Immunological read -outs........................................................................ 77
Table 12 Hematology/Blood Chemistry read- outs................................................. 78
Table 13 Study vaccine/placebo and challenge agent ........................................... 79
Table 14 Dosage and administration ..................................................................... 81
Table 15 Solicited local adverse events ................................................................ 87
Table 16 Solicited systemic adverse events .......................................................... 87
Table 17 List of potential AESI to be followed during the study ............................. 89
Table 18 Evaluation of symptomatic neutropenia .................................................. 90
Table 19 Reporting periods for collecting safety information ................................ .93
Table 20 Intensity scales for solicited symptoms ................................................... 95
Table 21 Timeframes for submitting serious adverse event, pregnancy and 
other events reports to GSK Biologicals ................................................. 99
Table 22 GSK Biologicals‚Äô laboratories ............................................................... 122
Table 23 Outsourced laboratories ....................................................................... 122
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b28 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 29LIST OF FIGURES
PAGE
Figure 1 Study design (Amended: 23 July 2019) .................................................. 51
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b29 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 30LIST OF A PPENDICES
PAGE
Appendix A LABORATORY ASSAYS ..................................................................... 120
Appendix B CLINICAL LABORATORIES ................................................................ 122
Appendix C AMENDMENTS AND ADMINISTRATIVE CHANGES TO THE 
PROTOCOL ......................................................................................... 123
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b30 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 31LIST OF A BBREVIATIONS (Amend ed: 23July 2019)
AE: Adverse Event
AESI: Adverse Event of Special Interest
AR: Attack Rate
CCHMC: Cincinnati Children‚Äôs Hospital Medical Center (USA)
CDC: Centers for Disease Control and Prevention
CFU: Colony  Forming Units
CHIM: Controlled Human Infection Model
CI: Confidence Interval
CMI: Cell-Mediated Immunity
DNA: Deox yribonucleic acid
eCRF: electronic Case Report Form
ELISA: Enzy me-linked immunosorbent assay
EoS: End of Study
EU: ELISA unit
FAS: Full Anal ysis Set
Fc: Fragment crystallisable
FDA: Food and Drug Administration, United States of America
GCP: Good Clinical Practice
GMC: Geometric Mean Concentration
GMMA: Generalized Modules for Membrane Antigens
GMR: Geometric Mean Ratio
GSK: GlaxoSmithKline
GVGH: GSK Vaccines Institute for Global Health
HCG: Human Chorionic Gonadotropin
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b31 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 32HIV: Human Immunodeficiency  Virus
HLA: Human Leukocy te Antigen
IB: Investigator Brochure
ICF: Informed Consent Form
ICH: International Council for Harmonisation
ID: Intradermal
IDMC: Independent Data Monitoring Committee
IEC: Independent Ethics Committee
IgG: Immunoglobulin G
IM: Intramuscular
IMP: Investigational Medicinal Product
IN: Intranasal
IRB: Institutional Review Board
LL: Lower Limit
LPS: Lipopol ysaccharide
LSLV: Last Subject Last Visit
MACDP: Metropolitan Atlanta Congenital Defects Program
MedDRA: Medical Dictionary  for Regulatory  Activities
MSD: Moderate to Severe Diarrhea
OAg: O antigen
PBMC: Peripheral Blood Mononuclear Cells
PCD: Primary  Completion Date
PPS: Per-Protocol Set
qPCR: quantitative Poly merase Chain Reaction
S. sonnei: Shigella sonnei
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b32 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 33SAE: Serious Adverse Event
SBA : Serum Bactericidal Assay
SBIR: Source DataBase for Internet Randomization
SDB: Source Document Verification
sIgA: Secretory  Immunoglobulin A
SPM: Study  Procedures Manual
TMP -SMX: Trimethoprim -sulfamethoxazole
TSA: Trypticase soy  agar
VE: Vaccine Efficacy
WRAIR: Walter Reed Arm y Institute of Research
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b33 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 34GLOSSA RY OF TERMS
Adequate contraception: Adequate contraception is defined as a contraceptive 
method with failure rate of less than 1% per y ear when 
used consistently  and correctl y and when applicable, in 
accordance with the product label for example:
ÔÇ∑Abstinence from penile-vaginal intercourse, when 
this is their preferred and usual lifesty le,
ÔÇ∑Combined estrogen and progesterone oral 
contraceptives,
ÔÇ∑Injectable progestogen,
ÔÇ∑implants of etonogestrel or levonorgestrel,
ÔÇ∑Contraceptive vaginal ring,
ÔÇ∑Percutaneous contraceptive patches,
ÔÇ∑Intrauterine device or intra uterine s ystem,
ÔÇ∑Male partner sterilization prior to the female 
subject‚Äôs entry  into the study , and this male is the 
sole partner for that subject,
The information on the male sterility  can come from 
the site personnel‚Äôs review of the subject‚Äôs medical 
records; or interview with the subject on her medical 
history .
ÔÇ∑Male condom combined with a vaginal spermicide 
(foam, gel, film, cream or suppository ),and/or 
progesterone alone oral contraceptive.
Adequate contraception does not apply  to subjects of 
childbeari ngpotential with same sex partners, or for 
subjects who are and will continue to be abstinent from 
penile -vaginal intercourse on a long term and persistent 
basis, when this is their preferred and usual lifest yle.
Adverse event: Any untoward medical occurrence in a patient or clinical 
investigation subject, temporally associated with the use 
of a medicinal product, whether or not considered re lated 
to the medicinal product.
An adverse event (AE) can therefore be an y unfavorable
and unintended sign (in cluding an abnormal laboratory  
finding), s ymptom, or disease (new or exacerbated) 
temporally  associated with the use of a medicinal product. 
For marketed medicinal products, this also includes 
failure to produce expected benefits (i.e. lack of efficacy ), 
abuse or misuse.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b34 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 35Adverse Event of Special 
Interest: Adverse events of special interest (AESIs): are predefined 
(serious or non-serious) adverse events of scientific and 
medical concern specific to the product or program, for 
which ongoing monitoring and rapid communication by  
the investigator to the sponsor can be appropriate, 
because such an event might warrant further investigation 
in order to characterize and understand it.
Blinding: A procedure in which one or more parties to the trial are 
kept unawa re of the treatment assignment in order to 
reduce the risk of biased study outcomes. The level of 
blinding is maintained throughout the conduct of the trial, 
and only  when the data are cleaned to an acceptable level 
of quality  will appropriate personnel be unblinded or 
when required in case of a serious adverse event. In an 
observer -blind study , the subject and the site and sponsor 
personnel involved in the clinical evaluation of the 
subjects are blinded while other stud y personnel may be 
aware of the treat ment assignment (see Section 6.2.3 for 
detail s on observer -blinded studies).
Eligible: Qualified for enrolment into the study  based upon strict 
adherence to inclusion/exclusion criteria.
End of Study :
(Synony m of End of Trial)For studies without collection of human biologicals 
samples or imaging data EoS is the last subject last visit 
(LSLV).
For studies with collection of Human Biologicals 
Samples or imaging data, EoS is defined as the date of the 
last testing/reading released of the Human Biological 
Samples or imaging data, related to primary  and 
secondary  endpoints. EoS must be achieved no later than 
8 months after L SLV.
Epoch: An epoch is a set of consecutive timepoints or a single 
timepoint from a single protocol. Epochs are defined to 
support a main purpose which is either to draw 
conclusions on subject participation or to draw a 
complete conclusion to define or precise the targeted 
label 
of the product. Supporting means that data collected 
at the timepoints included in an epoch must be sufficient 
to fulfil the purpose of the epoch.
Typical examples of epochs are screening, primary  
vaccinations, boosters, yearl y immunogenicity follow -
ups, a nd surveillance periods for efficacy  or safet y.
eTrack: GSK‚Äôs tracking tool for clinical trials.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b35 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 36Immunological correlate 
of protection:The defined immune response above which there is a high 
likelihood of protection in the absence of an y host factors 
that might increase susceptibility  to the infectious agent.
Investigational vaccine :
(Synony m of 
Investigational Medicinal 
Product)A pharmaceutical form of an active ingredient being 
tested in a clinical trial, including a product with a 
marketing authorization when used in a way different 
from the approved form, or when used for an unapproved 
indication, or when used to gain further inf ormation about 
an approved use.
Menarche: Menarche is the onset of menses for the first time in a 
young female and is preceded by  several changes 
associated with pubert y including breast development and 
pubic hair growth. Menarche usuall y occurs within 1-2 
years of breast development, thelarche. However, a y oung 
female can become pregnant before her first menses. 
Thus, a conservative definition of non- childbearing 
potential in a pre -menarcheal female is a y oung female 
who has not y et entered puberty  as evidenced by  lack of 
breast development (palpable glandular breast tissue).
Menopause: Menopause is the age associated with complete cessation 
of menstrual cy cles, menses, and implies the loss of 
reproductive potential by ovarian failure. A practical 
definition accepts menopa use after 1 year without menses 
with an appropriate clinical profile at the appropriate age 
e.g. > 45 years.
Pharmacogenomics: The International Co uncil forHarmoni sation (ICH) E15 
Guidance for Industry  defines pharmacogenomics as 
Study  of variation of DN A and RNA characteristics as 
related to drug or treatment response. Pharmacogenetics, 
which is a subset of pharmacogenomics, is ‚Äúthe study  of 
variations in DNA sequence as related to drug response.‚Äù 
Pharmacogenomic biomarkers include germline (host) 
DNA an d RNA as well as somatic changes (e.g., 
mutations) that occur in cells or tissues. 
Pharmacogenomic biomarkers are not limited to human 
samples but include samples from viruses and infectious 
agents as well as animal samples. The term 
pharmacogenomic experi ment includes both the 
generation of new genetic or genomic (DNA and/or 
RNA) data with subsequent anal ysis as well as the 
analysis of existing genetic or genomic data to understand 
drug or treatment response (pharmacokinetics, safety , 
efficacy  or effective ness, mode of action). Proteomic and 
metabolomic biomarker research are not 
pharmacogenomics.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b36 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 37Primary completion 
date:The date that the final subject was examined or received 
an intervention for the purpose of final collection of data 
for all primary  outcome s, whether the clinical trial was 
concluded according to the pre -specified protocol or was 
terminated.
Protocol amendment: The International Co uncil forHarmoni sation (ICH) 
defines a protocol amendment as: ‚ÄòA written description 
of a change(s) to or formal clarification of a protocol.‚Äô 
GSK Biologicals further details this to include a change 
to an approved protocol that affects the safet y of subjects, 
scope of the inve stigation, study  design, or scientific 
integrit y of the stud y.
Randomization : Process of random attribution of treatment /schedule to 
subjects in order to reduce bias of selection.
Self-contained study: Study  with objectives not linked to the data of anot her 
study .
Site Monitor: An individual assigned by the sponsor who is responsible 
for assuring proper conduct of clinical studies at one or 
more investigational sites.
Solicited adverse event: AEs to be recorded as endpoints in the clinical study . The 
presence/occurrence/intensity  of these events is actively  
solicited from the subject or an observer during a 
specified post -vaccination follow -up period.
Study vaccine/product : Any investigational vaccine/product being tested and/or 
any authorized use of a vaccine/ product /placebo as a 
reference or administered concomitantly , in a clinical trial 
that evaluates the use of an investigational 
vaccine/product.
Subject: Term used throughout the protocol to denote an 
individual who has been contacted in order to participate 
or participates in the clinical study , either as a recipient of 
the vaccine or as a control.
Subject number: A unique number identify ing a subject, assigned to each 
subject consenting to participate in the study .
Subset :
(Synony m of Immuno-
subset)Selection of blood samples among all blood sample 
collected at give n time point(s) for testing b y specific 
assay .
Treatment: Term used throughout the clinical study  to denote a set of 
investigational product(s) or marketed product(s) or 
placebo intended to be administered to a subject.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b37 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 38Treatment number: Aunique number identify ing a treatment to a subject, 
according to treatment allocation.
Unsolicited adverse 
event:Any AE reported in addition to those solicited during the 
clinical study . Also any ‚Äòsolicited‚Äô sy mptom with onset 
outside the specified period of follow -up for solicited 
symptoms will be reported as an unsolicited adverse 
event.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b38 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 39TRADEM ARKS
The following trademarks are used in the present protocol.
Note: I n the body  of the protocol (including the sy nopsis), the names of the 
vaccines/products and/or medications will be written without the superscript sy mbol ‚Ñ¢ 
or ¬Æ and in italics.
Trademarks not owned by the G SK
group of companiesGeneric description
Alhydrogel (Brenntag Nordic A/S [Brenntag 
Biosector A/S])Aluminium Hydroxide, Hydrated, for 
Adsorption (Alhydrogel 2% - Ph.Eur.)
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b39 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 401. INTRODUCTION
1.1. Background
Shigellosis is a major public health problem around the world; it is one of the leading 
causes of diarrheal disease in low and middle income countries and is estimated to cause 
an all age mortalit y of 164 300 deaths every  year [GBD , 2015]. The majority  of these 
cases occur in children less than 5 y ears of age living in middle and low income 
countries. Currentl y, there are no vaccines licensed for use in these populations (except 
for China) and available interventions are under threat from the increasing rates of 
antibiotic resistance of Shigella sonnei (S. sonnei )around the world. Natural infection 
generates a seroty pe specific protective immune response against the O antigen (OAg) of 
the bacterial lipopoly saccharide (LPS) . Previousl y, S.sonnei 
and Shigella flexneri type 2a 
were selected for a prototype OAg conjugate vaccine that produced a protective efficacy  
of 70% in children three y ears of age and older. However, there was no noted efficacy  in 
children younger than three years of age, thus necessitating new approaches to vaccine 
development. Additionally, it is likely  that a multivalent OAg vaccine will be required in 
order to achieve broad protection against the 4 -6 seroty pes causing the largest burden of 
disease in young children liv ing in sub- Saharan Africa and South Asia.
Please refer to the current I nvestigator Brochure for information regarding the pre -
clinical and clinical studies with the 
1790GAHB vaccine andthe epidemiological 
information .
1.2. Rationale for the study  and study  design
1.2.1. Rationale for the study
GlaxoSmithKline (GSK) Vaccines Institute for Global Health (GVGH) has developed a 
vaccine against S. sonnei (1790GAHB vaccine) using the new Generalized Modules for 
Membrane Antigens (GMMA) platform technology  that in future could be also used to 
develop vaccines against other gram negative pathogens. 
The study  vaccine could be the stepping stone for the development of a multivalent 
broadly  protective Shigella vaccine for vaccination of impoverished communities where 
shigellosis is endemic. However, a standalone monovalent vaccine against S. sonnei
could be used to protect travelers against diarrheal shigellosis, as the vast majority  of 
travelers‚Äô shigellosis is caused by  
S. sonnei , and even to protect infants in endemic 
regions where shigellosis is primarily  caused b y S. sonnei .
The 1790GAHB vaccine has been tested in two Phase I dose escalation studies in Europe 
to assess its safet y and immunogenicit y via three routes of administr ation: intramuscular 
(IM), intranasal (IN) and intradermal (ID). The results from the first study  (dose 
escalation with IM vaccination) have shown that the vaccine has an acceptable safety  
profile and is well- tolerated up to a dose of 100 ¬µg. Additionally ,the serologic 
assessment showed that one dose of ‚â• 1.5/25 ¬µg OAg/protein of 1790GAHB vaccine 
elicits serum immunoglobulin G (IgG) anti
-S sonnei LPS levels ‚â• 121 enzyme -linked 
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b40 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 41immunosorbent assay  (ELISA) units/mL (EU/mL ) (i.e., median antibody  titer in a panel 
of 87 Israeli convalescent subjects after natural infection by  
S. sonnei ). The results from 
the second stud y (dose escalation with ID, IN and IM vaccination) showed that 
1790GAHB vaccine is well- tolerated also when administered by  the ID and IN routes of 
vaccination. However, immunogenicity data have shown that 1790GAHB 
vaccine 
administered b y the ID and IN routes is not as immunogenic as 1790GAHB vaccine
administered b y the IM route. Therefore, it has been decided to proceed with the clinical 
developm ent program of this vaccine onl y using the IM vaccination route. In terms of 
dosage, the regimen tested in Phase I  studies (three doses given onemonth apart) did not 
show an y significant benefit from the third dose in terms of immunogenicity, therefore a 
two dose schedule was selected for next studies.
A Phase IIa study , conducted in endemic regions of Africa (i.e., Keny a), has just been 
completed and confirmed the acceptable safet y profile and immunogenicity of 
1790GAHB vaccine .
Performing a vaccine -human challenge study  may give the opportunity  to establish 
evidence of clinical protection induced b y the candidate S. sonnei vaccine (1790GAHB 
vaccine) at an earl y development stage.
1.2.2. Rationale for the study  design
A human challenge m odel of S. sonnei disease for vaccine testing was established in 
Thailand [Bodhidatta , 2012 ]and showed an attack rate (AR) of 75% in non -immune 
adult volunteers receiving a challenge dose of 1680 colony  forming units (CFU) of S. 
sonnei strain 53G. Clinical and laboratory  endpoints of infection and disease, namel y 
diarrhea , dysentery , fever and shedding of S. sonnei in stools were used to calculate t he 
AR and thus to establish the optimal infective dose. In a subsequent study  though 
[Pitisuttithum , 2016] , the AR in the control group, using this model, was much less than 
previously  published.
Given this variability , before starting a vaccine -challenge study , the proposed human 
challenge model of S. sonnei to be used has been appropriatel y developed and the 
challenge dose and AR reliably  established by the Cincinnati Children‚Äôs Hospital 
Medical Cent er(CCHMC) (Ohio, United States of America). The current GSK vaccine -
human challenge stud y will be conducted at CCHMC and will use the developed 
challenge model. Volunteers will be treated after development of s ymptoms of 
shigellosis.
1.2.3. Rationale for the use of placebo
As currently  there is no widely  available vaccine against shigellosis, the efficacy  and 
safet y of the 1790GAHB vaccine will be evaluated against a placebo. The placebo is used 
to bet ter describe the safety  profile of the S. sonnei vaccine as well as its efficacy  in terms 
of clinical protection against shigellosis caused b y S. sonnei .
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b41 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 421.3. Benefit: Risk a ssessment
Please refer to the current I nvestigator Brochure for the summary  of potential risks and 
benefits of the 1790GAHB vaccine .
The following section outlines the risk assessment and mitigation strateg y for this study  
protocol:
1.3.1. Risk assessment
Important Potential/Identified 
RiskData/Rationale for Risk Mitigation Strategy
Investigational vaccine: 1790GAHB vaccine
Symptomatic Neutropenia Eight cases ofGrade 2 or Grade 3 
neutropenia were reported from 
Phase 1 clinical trials 
(asymptomatic).
All cases occurred in the first 20 
days after administration of first 
vaccine dose , and reversed after 
discontinuation.
Literature review of reports of 
neutropenia in association with 
vaccination indicates factors noted 
to be associated with neutropenia 
(including ethnicity, and low 
baseline counts) with the majority 
of cases detected wit hin 2 weeks 
of the vaccination. None of the 
reported cases was clinically 
symptomatic.
Five cases of asymptomatic 
neutropenia (Grade 1 and 2) have 
been reported at Day 7 after 
receipt of the first dose in 5 
subjects.
One of the 5 subjects had an 
additional Grade1 neutropenia 
episode at Day 28, and another 
one had two additional episodes, 
one of which was Grade 3 (940 
cells/mL) at 7 days after the 
second dose and the second was
Grade 2 (1,410 cells/mL) at 28 
days after second vaccination. All 
cases were resolved before last 
study visit.Exclusion criteria for this clinical study
include :
ÔÇ∑ Subjects with a low baseline 
neutrophil count below 1800 
cells/¬µL (LLN).
ÔÇ∑ Previous history of Benign Ethnic 
Neutropenia, or drug related 
Neutropenia.
ÔÇ∑ Concomitant treatment with 
neutropenic agents.
Monitoring for this clinical study to 
include:
ÔÇ∑ Baseline neutrophil counts .
ÔÇ∑ Full blood counts with differential 
measured at 7 days post each 
scheduled vaccination .
ÔÇ∑ Assessment of clinical impact of 
neutropenia .
Subjects will be clos ely monitored 
during the entire study and have 
hematology repeated every 7 days 
when neutropenia is identified until 
resolution. If a case of neutropenia does 
not resolve based on most recent 
available laboratory results, before the 
second vaccination, or challenge agent 
administration, the subject will not be re -
vaccinated or administered the 
challenge agent .
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b42 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 43Important Potential/Identified 
RiskData/Rationale for Risk Mitigation Strategy
Study Procedures
Risks related to blood sample 
collectionWhen blood samples are taken 
from a vein, there is a risk of 
bruising at the site. There is a rare 
possibility of bleeding, fainting and 
infection or of nerve injury 
soreness.Safe sampling procedures will be 
applied by appropriately trained and 
qualified staff to minimize distress and 
sampling errors.
The potential risk of feeling faint, or 
experiencing mild local pain, bruising, 
irritation or redness at the site where 
blood was taken, is mentioned in the 
informed consent form. The amount of 
blood to be taken for sampling will not 
be harmful to the subject‚Äôs health.
Risk related to rectal sw abs Rectal swabs may cause 
discomfort for patients and in case 
of special conditions (e.g. 
hemorrhoids , and rectal polyps) 
bleeding might happen.Rectal swabs are only collected when it 
is not possible to obtain a stool sample. 
Study staff will instruct the subjects on 
how to do the rectal swab .
Other (c hallenge phase)
Severe and invasive diarrhea after 
challengeIllness caused by Shigella ranges 
from mild (watery diarrhea being 
the main symptom) to severe 
illness (fever and abdominal 
cramping with frequent small 
volume blood streaked stools 
containing mucus) , dehydration 
and even shock.
Perianal soreness, which is a skin 
irritation on your buttocks as a 
result of diarrhea, is possible .Administration of an effective antibiotic 
will significantly red uce, or eliminate, 
symptoms within 24 hours of initiation. 
In addition, all challenged subjects will 
receive an effective antibiotic on the 5th
day after challenge or earlier as 
required and intensive care unit is 
available to provide appropriate care in 
case of emergency.
If perianal soreness occurs, it can be 
treated with topical lotion .
Risk of bacteremia after challenge Bacteremia can occur with any 
invasive bacterial infection not 
appropriately contained with 
adequate antibacterial therapy .The S. sonnei 53G challenge strain used 
in the challenge phase is known to be 
susceptible to multiple antimicrobial 
agents including Trimethoprim -
Sulfamethoxazole ( TMP -SMX )and 
quinolones which will be used in this 
study. To ensure there is no spread of 
shigella in the environment, subject will 
be discharged only following two 
negative Shigella cultures in stools.
Reiter‚Äôs syndrome A post -dysenteric reactive arthritis, 
with ocular and/or urethral 
inflammation, which has an onset 
typically 1 to 3 weeks after the 
onset of diarrhea , has been 
reported to occur in patients with 
shigellosis.Data suggest that the risk of reactive 
arthritis following shigellosis may be 
higher in persons carrying the human 
leukocyte antigen (HLA) -B27, thus the 
exclusion of subjects with a positive 
HLA-B27 test at screening.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b43 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 44Important Potential/Identified 
RiskData/Rationale for Risk Mitigation Strategy
Other (challenge phase)
Risk related to antibacterial 
therapyThere are documented side effects 
with the use of antibiotics.However ,ciprofloxacin, the antibiotic 
given to all subjects on the 5thday after 
challenge, is generally well -tolerated. 
The most frequently reported drug 
related events for all indications of 
ciprofloxacin therapy have been 
nausea, diarrhea , abnormal liver 
function tests, vomiting, and rash which 
are all mild to moderate in most cases.
The most common symptoms that 
happen after taking TMP -SMX are 
nausea, vomiting, loss of appetite, skin 
rash and itching.
All subjects will be monitored closely 
and given adequate care when the need 
arises.
1.3.2. Benefit assessment
There may  not be a direct medical benefit to the subject as a result of taking part in this 
study . However, the study  vaccine may  provide protection against S. sonnei bacteria as 
well as the administered challenge agent .
The subject, b y participating in th is study  may  help provide data about the tolerability  of 
the experimental vaccine and about its ability  to stimulate the immune sy stem to produce 
antibodies against S. sonnei and provide clinical protection.
1.3.3. Overall benefit: Risk conclusion
Based on the clinical experience with 1790GAHB vaccine, tested in clinical studies, it is 
expected that 1790GAHB vaccine will also have an acceptable safet y profile in future 
clinical studies and will be associated with clinically  acceptable local and sy stemic 
reactions. In previous studies, the vaccine has shown good immunogenicity. If 
immunogenicit y will correlate to clinical protection in this proposed study, the vaccine 
will help protect the subjects who received it from shigellosis caused b y S. sonnei .
However, a similar benefit is not anticipated for subjects who will receive placebo. 
Overall, all subjects may  help in the characterization of the vaccines‚Äô immunogenicity  
and ability  to provide protection. Administration of the challenge agent causes dis comfort 
and illness that ranges from mild (watery  diarrhea being the main sy mptom) to severe 
(fever and abdominal cramping with frequent small volume blood streaked stools 
containing mucus) diarrhea. However ,the S. sonnei 53G challenge strain used in the 
challenge phase is known to be susceptible to multiple antimicrobial agents including 
TMP- SMX and quinolones which will be used in this study  and will be given to all 
challenged subjects 5 day s after administration of the challenge agent (day 62) or earlie r 
if medically  needed. Additionally , should an y allergic reaction occur after challenge 
administration, an intensive care unit with medications is available at the study  site in 
order to treat the possible anaph ylactic/allergic reactions.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b44 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 452. OBJECTIVES
2.1. Primar y objective
ÔÇ∑To demonstrate the efficacy  of two vaccinations with 25 ¬µg of 1790GAHB vaccine 
in healthy  adults compared to placebo (reduction of shigellosis according to the 
protocol primary  case definition, i.e. Shedding of S. sonnei 53G accompanied by  
moderate or severe diarrhea, OR shedding with an oral temperature of ‚â•38.5¬∞C after 
challenge with S. sonnei strain 53G ).
Criterion:
Vaccine efficacy (VE) of 1790GAHB vaccine will be shown if the lower limit (LL) of 
the 90% confidence interval (CI) of V E will be above zero.
Refer to S ection 4for the protocol primary  case definition of
shigellosis and to Section 
11.1 for the definition of the primary  endpoint.
2.2. Secondary  objective s
Efficacy
ÔÇ∑To determine the efficacy of the 1790GAHB vaccine compared to placebo against :
ÔÄ≠Shigellosis as defined b y the CHI M expert working group on case definition .* 
ÔÄ≠Shigellosis, as defined b y: severe diarrhea OR moderate diarrhea with fever or 
with one or more moderate constitutional/enteric symptoms OR dy sentery [[ ‚â•2 
loose stools with gross blood (hemoccult positive) in 24 hours] AND [ ‚â•1 
reportable constitutional/enteric s ymptom]] .
ÔÄ≠More severe shigellosis , as defined b y: severe or moderate diarrhea with fever or 
with one or more severe constitutional/enteric symptoms OR dy sentery  [[‚â•2 
loose stools with gross blood (hemoccult positive) in 24 hours] AND [ oral 
temperature ‚â•38.0oCOR‚â•1 severe constitutional/enteric s ymptom] ]
.
(Amended: 23July 2019)
ÔÄ≠Shedding of S. sonnei strain 53G.
ÔÄ≠Severe diarrhea.
ÔÄ≠More severe diarrhea.
ÔÄ≠Dysentery .
ÔÄ≠Weight o f allgrade 3 -5 stools .
ÔÄ≠Total n umber of all grade 3-5 
stools.
ÔÄ≠Confirmed S. sonnei 53G shedding AND moderate or severe diarrhea OR 
dysentery  OR presence of oral temperature ‚â• 38.5¬∞C OR presence of one or 
more severe intestinal symptoms (abdominal pain, cramping, nausea, vomiting , 
gas,and anorexia ).
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b45 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 46ÔÄ≠Disease not fulfilling the protocol primary  case definition for shigellosis 
associated or not with mild to moderate s ymptoms including: passing loose stool 
(not meeting the protocol definition of moderate or severe diarrhea), abdominal 
pain, abdominal cramps, gas, anorexia, nausea, headache, myalgia, malaise, 
arthralgia, fever, vomiting and IV fluid administration.
ÔÄ≠Time to onset of shigellosis after challenge, according to the primary  case 
definition.
*According to the working group, the participant must fulfil any  one of the three 
following possible endpoints to qualify  as having reached the CHIM case definition for 
this objective:
1. Severe diarrhea defined as [ ÔÇ≥6 loose stools in 24 hours] OR [ ÀÉ800 grams loose stools 
in 24 hours ]
2. Moderate diarrhea defined as [4- 5 loose stools in 24 hours OR 400-800 grams loose 
stools in 24 hours ]AND [oral temperature ÔÇ≥38.0oC OR ÔÇ≥ 1 moderate 
constitutional/enteric symptom OR ÔÇ≥2 episodes of vomiting in 24 hours]
3.Dysentery  defined as [ÔÇ≥2 loose stools with gross blood (hemoccult positive) in 24 
hours ]AND [oral temperature ÔÇ≥38.0oC OR ÔÇ≥1 moderate constitutional/enteric 
symptom OR ÔÇ≥ 2 episodes of vomiting in 24 hours].
Safety
ÔÇ∑To assess the safet y and reactogenicity of the 1790GAHB vaccine in terms of 
solicited adverse events, unsolicited adverse events , serious adve rse events (SAEs), 
adverse events of special interest (AESI) and laboratory  parameters.
ÔÇ∑To assess safety  after challenge in terms of SAEs, unsolicited adverse events , AESI , 
and laboratory  parameters.
Immunogenicity
ÔÇ∑To evaluate the IgG ELISA immunogenicity  profile of the 1790GAHB vaccine at 7 
days and 28 day s after the first and second vaccination (IgG ELISA coated with OAg 
containing LPS) .
ÔÇ∑To evaluate the immunogenicity  profile of the 1790GAHB vaccine at pre -challenge 
and at 7 and 28 day s after challenge (IgG ELISA coated with OAg containing LPS) .
ÔÇ∑Number and percentage of seroresponders for anti- S. sonnei L PS at 28 days after 
first and second vaccination.
ÔÇ∑To assess anti -S.sonnei LPS concentration 
‚â• 121 EU/ml at 28 day s after first and 
second vaccination.
Refer to Section 11.2 for the defin ition of the secondary  endpoint s.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b46 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 472.3. Tertiary  objective s
The following tertiary  objectives which are part of the study  exploratory  objectives may 
be evaluated in addition to the primary  and secondary  objectives and will complement 
assessment of the vaccine immunogenicit y profile:
ÔÇ∑Evaluate S. sonnei specific secretory  immunoglobulin A (sIgA)in stool at Day  1 and 
7 day s after first and second vaccination and 7 day s after challenge (Day  64).
ÔÇ∑Evaluate S. Sonnei LPS IgG -specific Œ±4Œ≤7+/ -plasmablast response at Day  1 and 7 
days after first and second vaccination and 7 day s after challenge (Day  64).
(Amended: 23July 2019)
ÔÇ∑Evaluate serum bactericidal activity  against S. sonnei at Day  1 and 28 day s after first 
and second vaccination .
ÔÇ∑Evaluate correlation between serum anti -S. sonnei LPS IgG level, serum bactericidal 
activity  titer, shigellosis , shedding, mild, moderate ,severe or more severe diarrhea , 
and dysentery  after challenge .
ÔÇ∑Evaluate gl ycosylation of fragment cry stallisable (Fc) portion of IgG antibodies at 
Day 1 and 28 day s after second vaccination and association with clinical protection 
and/or serological endpoints.
ÔÇ∑Evaluate inflammatory  response from stools collected bef ore challenge at Visit 5 
(Day  57) and dail y, post challenge, during inpatient stay (Day 57 to Day 64) .
ÔÇ∑Evaluate gene expression signatures at Day  1 and 7 day s after first and second 
vaccination and 7 day s after challenge (Day  64).
ÔÇ∑Investigate gut micro biome at Day  1 and 28 day s after second vaccination and its 
potential association with protection and immune response.
These last two tertiary  objective sinvolve pharmacogenomics testing. Refer to the 
glossary  of terms for the definition of Pharmacogenomics.
Refer to Section 11.3 for the defi nition of the tertiary  endpoint s and to S ection 11.12.1 for 
the reportin g of tertiary  endpoint results.
3. STUDY DESIGN OVERVIEW
This study  will evaluate the efficacy , safet y and immunogenicit y of the 1790GAHB 
vaccine administered via IM route to adults (18 -50 years of age at enrolment). The 
objectives will be assessed through the conduct of the study  in two phases: a vaccination 
ph
ase with 1790GAHB vaccine or placebo followed by  a challenge phase with S. sonnei 
strain 53G.
The total of 72 subjects will be divided in 4 cohorts of 18 subjects each (for logistical 
reasons due to bed capacity  at the stud y site). The vaccination and chal lenge will be done 
in overlapping cohort s and randomization will ensure there is the same number of 
vaccines and controls in each cohort. However, if for an y reason, a cohort 
does not reach 
the planned 18 subjects, additional subjects can be added in the n extcohorts. The 
maximum number of subjects must not be more than 20 (maximum number of beds in the 
clinic) in each cohort.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b47 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 483.1. Vaccination Phase
During the screening period befo re the first vaccination (Day  -45to Day  -1), subjects 
providing informed consent will have their medical history  recorded and be scre ened for 
general health status.
Female subjects with child bearing potential must use acceptable birth control measures 
(defined as hormonal [e.g., oral, injection, transdermal patch, implant, cervical ring], 
barrier [e.g., condom with spermicide or diaphragm with spermicide], intrauterine device, 
or be in a monogamous relationship with a partner who has been vasectomized for 6 
months or more prior to the sub ject‚Äôs stud y entr y) during the entire stud y participati on.
Refer to the glossary  of terms for the definition of adequate contraception.
At the end of the screening, subjects will be evaluated for eligibility . Onl y subjects who 
meet all inclusion criteria and none of the exclusion criteria will be eligible for 
enrolment. Following informed consent and confirmation of eligibility  according to the 
inclusion and exclusion criteria, subjects will be randomized in a 1:1 ratio to receive 
either the stud y vaccine or the placebo. Subjects will receive two vaccinations, 28 days 
apart.
Subjects will be observed at the site for at least 30 minutes after each vaccination. All 
subjects will have their vital signs (temperature, heart rate, sitting blood pressure )taken
before vaccination and at the end of the observation period to ensure they  are stable 
before they  go home. Subjects will be provided with a diary  card and will be trained on 
how to fill it in. Subjects will be reminded before they  go home of the importance of 
filling the diary  card and a phone call will be performed by  the site staff to the subjects at 
2 and 6 day s following each vaccination t o remind them that the diary  card should be 
completed (no update on the status of the subject‚Äôs health will be solicited during these 
phone calls, as they  are not intended for safet y data collection) and of the clinical visit at 
7 day s after each vaccinati
on. The diary  card will be used to collect all solicited and 
unsolicited AEs, and medications for the first 7 day s after each vaccination starting 6 
hours after the administration of the vaccine /placebo . At 7 day s following each 
vaccination and until 28 days after vaccination, only  unsolicited AEs, solicited adverse 
reactions that continue at the 7thday, and related medications will be collected during 
visits at the study  site. Any  AE reported in the diary  card bey ond the 7thday will be 
followed up accordingl y and the frequency  of the follow -up will depend on its nature.
Prior to each vaccination, subjects will be assessed through their medical history  since the 
last visit and phy sical examination to check if continued participation in the study  is in 
their best interest and that there are no contraindications for vaccination (e.g. fever or 
acute illness on the day  of vaccination). Subjects will also be evaluated for continued 
eligibility  with regard to the inclusion and exclusion criteria. Vaccination wi ll only  take 
place after the subjects‚Äô medical history , clinical examination and evaluation of inclusion 
and exclusion criteria confirm his/her continuous eligibility . Investigator judgment will 
also apply  to evaluate subjects‚Äô continued eligibility  in the study . Subjects will be 
encouraged to visit the study  clinic or call the study  staff if they  have fever or are unwell 
between planned visits. This, depending on the nature, may  prompt an unscheduled visit 
by a stud y physician. Any  Grade 3 or more reaction after vaccination may  also prompt a 
review b y a stud y physician at the study  clinic.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b48 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 493.2. Challenge Phase
Four weeks after completion of the two -dose vaccination schedule (approximately  28 
days after Visit 3) subjects will be admitted the day before the challe nge date (Day  56) 
and will stay  for 9days in the inpatient unit. Biological sample collection could start for 
logistical reason at Day  56 (the day  of admission before challenge). The day of challenge 
(Visit 5; Day  57), they  will be administered a 1500 CFU challenge dose of S. sonnei 53G. 
Before receiving the challenge, all inclusion and exclusion criteria and hematology will 
be assessed .
When assessing inclusion and exclusion criteria, the investigator will also inquire about
antibiotic treatment during the week prior to the challenge date. Any  subject who had a 
course of antibiotic the week prior to challenge, will not receive the challenge agent.
Subjects will fast for 90 minutes prior to receiving the S. sonnei 53G challenge inoculum 
and an additional 90 minutes after challenge. All subjects in the same cohort will be 
challenged in the same day  using the same inoculum, which will ensure the consistency  
of the dose used. Approximately  5 minutes before drinking the challenge suspension, the 
subject will d
rink a 120 mL  solution of sodium bicarbonate to neutralize gastric acidit y. 
A subject with fever or signs of acute illness will not receive the challenge agent and an y 
subject who vomits following ingestion of the challenge agent will not be re -dosed. A 
note will be made in the subject source documents regarding the apparent amount of the 
vomitus (small, moderate or large). The subject will still continue in the study  and 
undergo all study -related procedures
. Care will be taken to ensure that a minimum 
amou
nt of time, not to exceed 2 hours, is spent between the reconstitution of the 
challenge inoculum and the oral administration o f the inoculum to the subject.
Two mL  of the inoculum will be retained for pre- and post -challenge quantification of the 
dose. Ali quots of the retained inoculum will be streaked onto try pticase soy agar (TSA) 
plates and after incubation, average number of colonies on the TSA plates will be 
counted and CFU/mL  will be calculated. Study  staff will take all necessary precaution 
needed fo r handling of S. sonnei 53G and adhere to the CCHMC policy  and procedures.
During thefirst 8 days in the inpatient unit (Day  57 to Day  64) following challenge,
subjects will be monitored daily  for AEs, gastrointestinal or other s ystemic signs and 
symptoms. Subjects will be assessed for vital signs (including sitting blood pressure, 
temperature and pulse rate) according to local standards for inpatient care. Stoo l analy sis 
will be carried out daily  during the inpatient stay . All stools will be collected and visually  
assessed for consistency, blood or mucus. Stools that are loose or watery  (grades 3- 5) will 
be weighed, and if there is visible blood, a 
Hemoccult test will be performed to confirm 
presence of occult blood. Up to two stools with blood present b y visual inspection in a 24 
hour period will be tested by  Hemoccult . Study  staff will record the information in the 
subject‚Äôs source document. I f a subject is una ble to produce a stool by  midnight, a rectal 
swab will be obtained (up to 2 adequatel y collected swabs per day ). Study  staff will 
record the information in the subject‚Äôs source document. The first stool sample collected 
during a 24 hour period on the day  after challenge agent administration (from 00:01 to 
24:00) will be anal yzedby culture and quantitative poly merase chain reaction (qPCR) 
specific for S. sonnei 53G. The day  before discharge (Day  64), two stool samples will be 
collected to confirm that the s ubject is no longer shedding. Instructions for appropriate 
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b49 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 50collection, transportation and storage of stool samples will be provided to the 
investigators. For diarrhea episodes to be considered as separate episodes, there should be 
at least a 6 -hour interva l between them (refer to Section 4for details on stool grading) .
On the 5thday after challenge (Day  62), subjects will receive as first -line treatment
500mg of ciprofloxacin twice dail y for 3 days. Subjects with contraindic ation to 
ciprofloxacin may  receive as second -line treatment trimethoprim- sulfamethoxazole 
(160 mg/800 mg twice daily ), amoxicillin (500 mg three times dail y)for 5 day s, orany 
antibiotic that is deemed suitable according to local guidelines and the invest igator‚Äôs 
assessment can be used.
Subjects may  be treated with antibiotics before the 5thdayafter challenge (Day  62)if:
ÔÇ∑They  have diarrhea (any severit y stool Grade 3 or higher) andtwo or more of the 
following s ymptoms: severe abdominal pain/cramps, severe nausea, severe 
headache, severe m yalgia, severe arthralgia, gross blood in ÔÇ≥ 2 stools, any fever 
(ÔÇ≥38.0¬∫C measured orally), or an y vomiting.
ÔÇ∑They  experience unexpectedly  severe e vents such as hy potension (disproportionate 
to volume loss), renal d ysfunction, or altered mental state (e.g. somnolence) at the 
discretion of the investigators.
ÔÇ∑A study  physician determines earl y treatment is warranted for other reasons.
A subject receivi ng early antibiotic treatment will still remain on the unit until the 
planned day  of discharge (the 9thdayof inpatient stay : Day  65). On thatday, if a subject 
isclinically  well and ha shad at least 2 negative stool cultures, collected at least 6 hours 
apart, for S. sonnei , s/he will be discharged. A subject that, on the planned day  of 
discharge, still ha dS. sonnei isolated from the Day 64 stools will be asked to remain in 
the unit unti l s/he is no longer shedding. A subject still shedding 48 hours after initiation 
of ciprofloxacin will be switched to a Septra DS (1 tablet twice a day for five day s). If a 
subject is still positive 48 hours after the second -line antibiotic is administered
, a culture 
and antibiotic sensitivity  test will be obtained and therapy  initiated based on sensitivity
results. If a subject has two consecutive negative stool samples and is eligible to be 
discharged from the inpatient stay  but did not finish his treatme nt course, s/he can be 
given the remaining doses to complete at home.
Following discharge, subjects will return at 28 days (Visit 6), 56 days (Visit 7) and 6 
months (Visit 8) after challenge for outpatient clinical assessment. During these visits, 
clinical assessment will be done to assess their general health status and find out about 
the occurrence of AESI, any  AE and SAE. 
Subjects will be advised at the time of their discharge to contact the stud y staff/doctor if 
they feel unwell. The subjects will be f ollowed up until 6 months after the challenge. At 
the last study  visit, at 6 months after challenge, the subject will be reviewed for the 
occurrence of an y AESI and the site staff will ensure all AEs are resolved.
Through the entire stud y, all subjects wil l be advised to report to the stud y facility 
whenever they  are sick. Standard patient care, according to local guidelines will be 
provided for all illnesses in both the outpatient and inpatient facilities. Additional 
investigations may  be conducted if the investigator considers them necessary  to better 
evaluate the subject‚Äôs condition. An overview of the study  design is given in Figure 1.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b50 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6Final
23-JUL -2019 51Figure 1 Study design (Amended: 23July 2019)
*Refer to Section 3.2for details of procedures during the inpatient stay (Amended: 23 July 2019)
Scr: Screening
N: Number of subjects
B: Blood sampling
S:Stool sampling
U: Urine sampling
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b51 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6Final
23-JUL -2019 52Protocol waivers or exemptions are not allowed unless necessary  for the management of 
immediate safet y concerns. Therefore, adherence to th e study  design requirements, 
including those specified in the outline of study  procedures (Section 6.4.1), are essential 
and required for stud y conduct.
ÔÇ∑Experimental design: Phase IIB, observer- blind, randomized, 
placebo control , 
mono -centric study  with two parallel groups (S. sonnei group and placebo group).
ÔÇ∑Duration of the study : Each subject will be followed up for approximately 6 months 
after challenge with the pathogenic S. sonnei strain 53G, with a total study  duration 
of approximately  32 weeks (i.e., 8 months) for each study  subjec t.
ÔÄ≠Epoch 001: S tarting at Screening Visit (Day  
-45to Day  -1) and ending before 
Visit 1 (Day  1).
ÔÄ≠Epoch 002: Starting the day  of randomization and first vaccination (Visit 1) and 
ending before the receipt of the challenge agent, 28 day s after second 
vaccination (Visit 5).
ÔÄ≠Epoch 003: Starting with the receipt of the challenge agent at 28 day s after 
second vaccination (Visit 5) and ending 6 months after challenge (Visit 8).
ÔÇ∑Primary completion 
date (PCD): End of inpatient stay (Visit 5, Day 64).
(Amended: 23July 2019)
Refer to glossary  of terms for the definition of PCD.
ÔÇ∑End of Study (EoS): Last testing results released of samples collected for primary  
and secondary  objectives at Visit 8.
Refer to glossary  of terms for the definition of EoS.
ÔÇ∑Study groups:
Table 1 Study  groups and epochs foreseen in the study
Study 
groupsNumber of 
subjectsAge (Min -Max)Epochs
Epoch 001 Epoch 002 Epoch 003
Screening 1stand 2ndvaccination Challenge
S. sonnei 36 18years ‚Äì50years x x x
Placebo 36 18years ‚Äì50years x x x
Table 2 Study  groups and treatment foreseen in the study
Treatment nameVaccine/ placebo/
challenge agent nameStudy Groups
S. sonnei Placebo
S. sonnei 1790GAHB x
Placebo GAHB -Placebo x
Challenge S. sonnei 53G strain x x
ÔÇ∑Control: Placebo control with GAHB -Placebo with the same composition as the 
vaccine except the active ingredient. GAHB -Placebo will also be used as diluent for 
bedsidemixing of the vaccine.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b52 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6Final
23-JUL -2019 53ÔÇ∑Vaccination schedule : Subjects will receive 2 doses of either the stud y vaccine or 
placebo 28 day s apart. At 28 day s after the second dose, all subjects will receive the 
challenge dose.
ÔÇ∑Treatment allocation : Following the screening period before the first vaccination 
(Day  -45to Day  -1), subjects will be randomized in a 1:1 ratio to receive either the 
study  vaccine or the placebo.
ÔÇ∑Blinding : The study  will be observer- blind .
Table 3 Blinding of study  epochs
Study Epochs Blinding
Screening ( Epoch 001 ) N/A
1stand 2ndvaccination ( Epoch 002 ) observer -blind
Challenge ( Epoch 003 ) observer -blind
ÔÇ∑Sampling schedule:
ÔÄ≠5 mL  for hematology : Screening Visit, Visit 2, Visit 3, Visit 4, Visit 5 and 
Visit 8. Additionally , hematology is repeated weekly  until resolution if 
neutropenia occur s.
ÔÄ≠5 mL  for biochemical analy sis: Screening Visit .
ÔÄ≠10 mL  for hepatitis B, hepatitis C and HI V: Screening Visit .
ÔÄ≠10 mL  for HLA -B27 testing: Screening Visit .
ÔÄ≠5 mL  for local anti 
S. sonnei LPS IgGScreening -ELISA : Screening Visit .
ÔÄ≠Urine sample for urinal ysis: Screening Visit and Visit 5
.
ÔÄ≠Urine sample for pregnancy  test for women of childbearing potential: Screening 
Visit, Visit 1, Visit 3, Visit 5 and Visit 8.
ÔÄ≠20 mL  for immunological tests (antibody respons e) at Visit 1, Visit 2, Visit 3, 
Visit 4, Visit 5, 7 day s after Visit 5 (Day  64), Visit 6,
ÔÄ≠Forserum bactericidal activity tests at Visit 1, Visit 3 and Visit 5
ÔÄ≠And for Fc glycosylation test on leftover serum samples collected at Visit 1 and 
Visit 5.
ÔÄ≠50mL of peripheral venous blood for Œ±4Œ≤7 +/-plasmablast analysis by ELISA
and RNA extraction from PBMCs for gene expression profiling: Visit 1, Visit 2, 
Visit 4 and 7 day s after Visit 5 (Day  64).(Amended: 23July 2019)
ÔÄ≠Stool sample for inflammatory  response before challenge 
at Visit 5(Day  57)and 
daily , post challenge, during inpatient stay  (Day  57 to Day  64).
ÔÄ≠Stool sample: for microbiome testing at Visit 1 and Visit 5, for S. sonnei specific
sIgA at Visit 1, Visit 2, Visit 4 and 7 days after challenge (Day  64) and stool 
analysis, culture and qPCR daily  during inpatient stay  (from Visit 5 to 7 days 
after challenge [Day  57 to Day  64]or prolonged until 2 consecutive negative 
stool samples if subject still shedding ).
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b53 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6Final
23-JUL -2019 54ÔÇ∑Type of study : self-contained .
ÔÇ∑Data collection : Standardized electronic Case Report Form ( eCRF ).
ÔÇ∑Safety monitoring: An Independent Data Monitoring Committee (IDMC) will be 
established to monitor the safet y of subjects throughout the stud y. The ID MC will 
review unblinded data, to assess saf ety signals and make recommendations to the 
Sponsor concerning continuation, termination, or other modifications of the study  
based on the observed adverse effects. The membership and roles of the IDMC will 
be outlined in the IDMC charter.
The safet y revie w team (SRT) will monitor the safety  of subjects throughout the 
study . The SRT will review blinded data, assess safet y signals and make 
recommendations to the IDMC and Sponsor concerning continuation, termination, or 
other modifications of the study  based on the observed adverse effects.
A dedicated Safet y Management Plan will be prepared to ensure appropriate safet y 
reporting responsibilities and roles are defined.
Refer to S ection 9.10 for detailed description of holding rule and safet y monitoring.
4. CASEDEFINITIONS
Stools will be graded as follows:
ÔÇ∑Grade 1: firm formed;
ÔÇ∑Grade 2: soft formed;
ÔÇ∑Grade 3: viscous opaque liquid o r semi -liquid which assumes the shape of the bowl;
ÔÇ∑Grade 4: wa tery opaque liquid;
ÔÇ∑Grade 5: clear watery  or mucoid liquid.
4.1. Diarrhea
For the purpose of this study , diarrhea is defined as:
ÔÇ∑Moderate diarrhea : 4 to 5 loose or watery  (Grade 3 to 5 ) stools or 400 to 800 grams 
of Grade 3 to 5 stools within 24 hours.
ÔÇ∑Severe diarrhea : 6 or more loose or watery  (Grade 3 to 5 )stools or > 800 grams of 
Grades 3 to 5 stools within 24 hours or required medical intervention. In case of 
severe diarrhea, medical intervention is defined as intravenous (IV) fluids 
administration or anticipation of antibiotic treatment before the 5th day  after 
challenge.
ÔÇ∑More severe diarrhea: 10 or more loose or watery  (Grade 3 to 5) stools or ÔÇ≥1000 
grams of Grade 3 to 5 stools within 24 hours .
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b54 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6Final
23-JUL -2019 554.2. Dysentery (Amended: 23July 2019)
For the purpose of the endpoint ‚Äú Rate of s higellosis as defined by the CHIM expert 
working group occurring within a period starting with challenge visit and lasting until 
the end of the inpatient stay, in all subjects‚Äù, dysentery is defined as follows:
ÔÇ∑At least 2 loose stools with gross blood (hemoccult positive) in 24 hours AND [oral 
temperature ‚â•38.0oC OR ‚â•1 moderate constitutional/enteric symptom OR ‚â•2 
episodes of vomiting in 24 hours]. In this case constitutional/enteric symptom are 
the following: nausea, abdominal pain, abdominal cramping, myalgia, arthralgia, 
malaise .
For the purpose of the endpoin t ‚ÄúRate of s higellosis, as defined by: severe diarrhea OR 
moderate diarrhea with fever or with one or more moderate constitutional/enteric 
symptoms OR dysentery‚Äù , dysentery is defined as follows:
ÔÇ∑At least 2 loose stools with gross blood (hemoccult positive ) in 24 hours AND [ ‚â•1 
reportable constitutional/enteric symptom] . In this case constitutional/enteric 
symptom are the following: headache, fatigue, arthralgia, malaise, myalgia, chills, 
nausea, abdominal cramping, abdominal pain, gas, anorexia, vomiting.
For the purpose of the endpoint ‚Äú Rate of m ore severe shigellosis as defined by: severe 
or moderate diarrhea with fever or with one or more severe constitutional/enteric 
symptom OR dysentery [[ ‚â•2 loose stools with gross blood (hemoccult positive) in 24 
hours] AND [ oral temperature ‚â•38.0oC OR ‚â•1 severe constitutional/enteric 
symptom]]. ‚Äù
, dysentery is defined as follows:
ÔÇ∑At least 2 loose stools with gross blood (hemoccult positive) in 24 hours] AND 
[oral temperature ‚â•38.0oC OR ‚â•1 severe constitutional/enteric symptom] . In this 
case constitutional/enteric symptom are the following: headache, fatigue, 
arthralgia, malaise, myalgia, chills, nausea, abdominal cramping, abdominal pain, 
gas, anorexia, vomiting .
For the purpose of the endpoints ‚ÄúDysentery‚Äù and ‚ÄúConfirm ed S. sonnei 53G shedding 
AND moderate or severe diarrhea OR dysentery OR presence of oral temperature ‚â• 
38.5¬∞C OR presence of one or more severe intestinal symptoms (abdominal pain, 
cramping, nausea, vomiting, gas, and anorexia)‚Äù, dysentery is defined as follows:
ÔÇ∑A Grade 3, 4, or 5 stool with gross blood on at least 2 occasions within 24 hours 
and presence of constitutional/enteric symptoms. In this case, 
constitutional/enteric symptoms consist of headache, fatigue, arthralgia, malaise, 
myalgia, chills, na usea, abdominal cramping, abdominal pain, gas, anorexia, 
vomiting, and fever.
(Amended: 23July 2019)
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b55 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6Final
23-JUL -2019 564.3. Shigellosis
For the primary  and secondary  objectives in the challenge phase of the study , the protocol
primary case definition for shigellosis is:
ÔÇ∑Shedding of S. sonnei 53G accompanied by  moderate or severe diarrhea OR 
shedding with an oral temperature of ÔÇ≥38.5
¬∞C).
For the secondary  objectives in the challenge phase of the study , 2 definitions of 
shigellosis are used:
1.CHIM working group case definition for shigellosis as defined by  any oneof the 
three following possible endpoints:
ÔÄ≠Severe diarrhea defined as [ ÔÇ≥6 loose stools in 24 hours] OR [ ÀÉ800 grams loose 
stools in 24 hours]
ÔÄ≠Moderate diarrhea defined as [4 -5 loose stools in 24 hours OR 400 -800 grams 
loose stools in 24 hours] AND [oral temperature ÔÇ≥38.0oC OR ÔÇ≥1 moderate 
constitutional/enteric symptom OR ÔÇ≥2 episodes of vomiting in 24 hours]  
ÔÄ≠Dysentery  defined as [ ÔÇ≥2 loose stool s with gross blood (hemoccult positive) in 
24 hours] AND [oral temperature ÔÇ≥38.0¬∞C OR ÔÇ≥ 1 moderate 
constitutional/enteric symptom OR ÔÇ≥2 episodes of vomiting in 24 hours].
2.Shigellosis as defined b y any one of the three following possible endpoints:
ÔÄ≠Severe d iarrhea defined as [ ‚â•6 loose stools in 24 hours OR ÀÉ800 grams loose 
stools in 24 hours]
ÔÄ≠Moderate diarrhea defined as [4 -5 loose stools in 24 hours OR 400 -800 grams 
loose stools in 24 hours] AND [oral temperature ‚â•38.0oC OR ‚â•1 moderate 
constitutional/enteric symptom].
ÔÄ≠Dysentery  defined as [
‚â•2 loose stools with gross blood (hemoccult positive) in 
24 hours] AND [ ‚â•1 reportable constitutional/enteric symptom].
For the secondary  objectives in the challenge phase of the study , more severe shig ellosis 
is defined b y any one of the two following possible endpoints: 
ÔÄ≠Moderate OR severe diarrhea [ ‚â•4 loose stools in 24 hours OR ‚â•400 grams loose 
stools in 24 hours] AND [oral temperature ‚â•38.0oC OR ‚â•1 severe 
constitutional/enteric symptom].
ÔÄ≠Dysentery  defined as [‚â•2 loose stools with gross blood (hemoccult positive) in 
24 hours] AND [ oral temperature ‚â•38.0oC OR ‚â•1 severe constitutional/enteric 
symptom]. (Amended: 23July 2019)
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b56 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6Final
23-JUL -2019 575. STUDY COHORT
5.1. Number of subjects/ center
Target enrolment is up to 72 eligible s ubjects (36 per treatment group). Refer to Sections 
5.2and 5.3for eligibility criteria and to Section 11.4 for the determination of sample size.
Enrolment will take place in 4 overlapping cohorts of 18 subjects each to accommodate 
for the availability  of beds required for the challen ge phase of the study at the clinical site 
(see also Section 
11.12.1 ). However, if for an y reason, a cohort does not reach the 
planned 18 subjects, additional subjects can be added in the next cohorts. The maximum 
number of subjects must not be more than 20 (maximum number of beds in the clinic) in 
each cohort. The vaccinatio n and challenge will be done per cohort.
5.2. Inclusion criteria
Deviations from inclusion criteria are not allowed because they  can potentially  jeopardize 
the scientific integrit y, regulatory  acceptability of the study  or subject safety . Therefore, 
adherence t o the criteria as specified in the protocol is essential.
All subjects must satisfy  ALL the following criteria at study  entry :
ÔÇ∑Subjects who, in the opinion of the investigator, can and will comply  with the 
requirements of the protocol (e.g. completion of t he diary  cards, return for follow -up 
visits).
ÔÇ∑Written informed consent obtained from the subject prior to perform ing any study  
specific procedure.
ÔÇ∑Individuals who, after the nature of the study  has been explained to them, have 
shown adequate comprehens ion of the study  procedures and knowledge of study .
ÔÇ∑A male or female between, and including, 18 and 50 y ears of age at the time of the 
first vaccination.
ÔÇ∑Health ysubjects as established by  medical history and clinical examination before 
entering into the study .
ÔÇ∑Seronegative for HIV, hepatitis B and C.
ÔÇ∑Female subjects of non -childbearing potential may  be enrolled in the study.
ÔÄ≠Non-childbearing potential is defined as pre- menarche, current bilateral tubal 
ligation or occlusion, hy sterectom y, bilateral ovariectomy or post- menopause. 
Please refer to the glossary  of terms for the definition of menarche and menopause.
ÔÇ∑Female subjects of childbearing potential may  be enrolled in the study , if the subject:
ÔÄ≠Has practiced adequate contraception for 30 day s prior to vacci nation, and
ÔÄ≠Has a negative pregnancy  test on the day  of vaccination, and
ÔÄ≠Hasagreed to continue adequate contraception during the entire study  period.
Please refer to the glossary  of terms for the definition of adequate contraception.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b57 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6Final
23-JUL -2019 585.3. Exclusion criteria
Deviations from exclusion criteria are not allowed because they  can potentially  
jeopardize the scientific integrit y, regulatory acceptability  of the study  or subject safet y. 
Therefore, adherence to the criteria as specified in the protocol is essential.
The following criteria should be checked at the time of study  entry and at each 
vaccination and challenge administration visit. IfANY exclusion criterion applies, the
subject must not be included in the study :
ÔÇ∑Received an investigational or non -registered medicinal product within 30 day s (Day  
-29 to Day  1) prior to informed consent, or planned use during the study  period .
ÔÇ∑Any beha vioral or cognitive impairment or psy chiatric disease that, in the opinion of 
the investigator, may  interfere with the subject's ability  to participate in the study .
ÔÇ∑History  of any  neurological disorders or seizures.
ÔÇ∑Any other clinical condition that, in the opinion of the investigator, might pose 
additional risk to the subject due to participation in the study .
ÔÇ∑HLA -B27 positive test at screening and/or with history
 of reactive arthritis.
ÔÇ∑Clinical conditions representing a contraindication to intramuscular vaccination and 
blood draws .
ÔÇ∑Chronic administration (defined as more than 14 day s in total) of 
immunosuppressants or other immune- modify ing drugs during the period starting six 
months prior to the first vaccine /placebo dose. For corticosteroids, this will mean 
prednisone ÔÇ≥ 20 mg/day , or equivalent. Inhaled except for doses > 800 ÔÅ≠g/day  and 
topical steroids are allowed.
ÔÇ∑Administration of long -acting immune -modify ing drugs at any  time during the study  
period (e.g. infliximab ).Subjects may  be on chronic or as needed medications if, in 
the opinion of the site principal investigator or appropriate sub -investigator, they  
pose no additional risk to subject safet y or assessment of reactogenicit y and 
immunogenicit y and do not indic ate a worsening of medical diagnosis or condition.
ÔÇ∑Known bleeding diathesis or an y condition that may be associated with a prolonged 
bleeding time.
ÔÇ∑Concurrentl y participating in another clinical study, at an y time during the study  
period, in which the subject has been or will be exposed to an investigational or a 
non-investigational vaccine/product (pharmaceutical product or device).
ÔÇ∑History  of having participated in a previous Shigella challenge study .
ÔÇ∑Individuals who have a previously  laboratory  confirmed case of disease caused by  S. 
sonnei or serology  positive for local anti S. sonnei LPS IgG Screening -ELISA at 
screening.
ÔÇ∑History  of any  serious chronic or progressive disease according to judgment of the 
investigator (e.g., neoplasm, insulin dependent diabetes, cardiac, renal or hepatic 
disease).
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b58 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6Final
23-JUL -2019 59ÔÇ∑History  of any  malignancy  or lymphoproliferative disorder.
ÔÇ∑Known to be part of study personnel or being a close family  member to the personnel 
conducting this stud y.
ÔÇ∑History  of anaph ylactic rea ction or allergy  to vaccine /placebo or challenge agent
components or an y other allergies deemed b y the investigator to increase the risk of 
an AE if they  were to participate in the study .
ÔÇ∑Known allergy  to ciprofloxacin or the other antibiotics used for treatment as deemed 
by the investigator.
ÔÇ∑Individuals receiving a course of antibiotics within a week of the challenge will be 
ineligible to receive the challenge strain.
ÔÇ∑History  of gastric acid hyper -secretory  disorders (e.g., Zollinger -Ellison sy ndrome) 
as assessed and judged by  the investigator or any  other significant intestinal disorder.
ÔÇ∑Any confirmed or suspected immunosuppressive or immunodeficient condition, 
based on medical history  and phy sical examination (no labora tory testing required).
ÔÇ∑Family  history  of congenital or hereditary  immunodeficiency .
ÔÇ∑History  of any  reaction or hy persensitivity  likel y to be exacerbated b y any 
component of the vaccine/placebo or challenge agent.
ÔÇ∑Acute disease and/or fever at the time of enrolment .
ÔÄ≠Fever is defined as temperature ÔÇ≥38.0¬∞C / 100.4¬∞F. The preferred location for 
measuring temperature in this study  will be the oral cavity .
ÔÄ≠Subjects with a minor illness (such as mild diarrhea , mild upper respiratory  
infection) withou t fever may , be enrolled at the discretion of the investigator. 
Note: enrolment may  be postponed/delay ed until such transient circumstances have 
terminated.
ÔÇ∑Acute or chronic, clinically  significant pulmonary , cardiovascular, hepatic or renal 
functional abnormalit y, as determined b y physical examination or laboratory  
screening tests. Chronic medical diagnoses or conditions should be stable for the last 
60 day s. This includes no change in chronic prescription medication, dose, or 
frequency  as a result of d eterioration of the chronic medical diagnosis or condition in 
the 60 day s prior to enrolment.
ÔÇ∑A clinically  significant sign or s ymptoms of acute illness, significant anomalies in 
vital signs.
ÔÇ∑Known to handle food as part of work related activities.
ÔÇ∑Hepatomegal y, right upper quadrant abdominal pain or tenderness.
ÔÇ∑Received immunoglobulins or an y blood products within 180 days prior to informed 
consent or planned administration during the study period.
ÔÇ∑Pregnant or lactating female.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b59 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6Final
23-JUL -2019 60ÔÇ∑Female planning to become pregnant or planning to discontinue contraceptive 
precautions.
ÔÇ∑Females with history  of stillbirth, neonatal loss, or previous infant with anomaly , 
except those who have had a planned termination of pregnancy , hysterectomy  or 
bilateral tubal ligation.
ÔÇ∑History  of chronic alcohol consumption and/or drug abuse. Chronic alcohol 
consumption is defined as: a prolonged period of frequent, heavy  alcohol use; the 
inability  to control drinking once it has begun; phy sical dependence manifested by  
withdra wal s ymptoms when the individual stops using alcohol; tolerance, or the need 
to use more and more alcohol to achieve the same effects; a variety  of social and/or 
legal problems arising from alcohol use.
ÔÇ∑Known to have close household or professional conta cts with people with 
immunosuppressive condition.
ÔÇ∑Documented HIV, hepatitis B and C positive subject.
ÔÇ∑Any condition which, in the opinion of the investigator, may  pose an increased and 
unreasonable safety  risk to the subject if they  participated in the study .
ÔÇ∑Subjects with a baseline neutrophil count below 1800 cells/ÔÅ≠L(LLN) OR with 
clinically  significant abnormalities in other laboratory  values (CBC, CMP, UA), 
according to local reference ranges and investigator judgment.
ÔÇ∑Previous history  of Benign Ethnic Neutropenia, or drug related Neutropenia.
ÔÇ∑Concomitant treatment with neutropenic agents.
6. CONDUCT OF THE STUDY
6.1. Regulatory  and ethical considerations, including the 
informed consent process
The study  will be conducted in accordance with all applicable regulatory  requirements.
The study  will be conducted in accordance with the I CH Guideline for GCP , all 
applicable subject privacy requirements and the guiding principles of the Declaration of 
Helsinki. 
GSK will obtain favorable opinion/approva l to conduct the study  from the appropriate 
regulatory  agency , in accordance with applicable regulatory  requirements, prior to a site 
initiating the study  in that country .
Conduct of the study  includes, but is not limited to, the following:
ÔÇ∑Institutional R eview Board (IRB)/Independent Ethics Committee (I EC) review and 
favorable opinion/approval of study  protocol and any  subsequent amendments.
ÔÇ∑Subject informed consent.
ÔÇ∑Investigator reporting requirements as stated in the protocol.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b60 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6Final
23-JUL -2019 61GSK will provide full details of the above procedures to the investigator, either verbally , 
in writing, or both.
Freely  given and written informed consent must be obtained from each subject prior to 
participation in the study . 
GSK Biologicals will prepare a model Informed Consent F orm (ICF) which will embody  
the ICH GCP and GSK Biologicals required elements. While it is strongly  recommended 
that this model I CF is to be followed as closely  as possible, the informed consent 
requirements given in this document are not intended to pre-e mpt any  local regulations 
which require additional information to be disclosed for informed consent to be legall y 
effective. Clinical judgment, local regulations and requirements should guide the final 
structure and content of the local version of the ICF.
The investigator has the final responsibility for the final presentation of the ICF, 
respecting the mandatory requirements of local regulations. The ICF generated b y the 
investigator with the assistance of the sponsor‚Äôs representative must be acceptable t o 
GSK Biologicals and be approved (along with the protocol, and an y other necessary  
documentation) b y the IRB/IEC.
6.2. Subject identification and randomization
6.2.1. Subject identification
Subject identification numbers will be assigned sequentially  to the subjects who have 
consented to participate in the study, according to the range of subject identification 
numbers allocated to the study  center .
6.2.2. Randomization of treatment
6.2.2.1. Randomization of supplies
The randomization of supplies for the Vaccination Phase (1790GAHB vaccine and 
placebo) within blocks will be performed by the study biostatistician or delegate . Entire 
blocks will be shipped to the study  
center .No randomization will be done for the 
challenge phase .
6.2.2.2. Treatment allocati on to the subject
The treatment numbe rs will be allocated b y dose.Throughout the stud y, a single 
treatment number will identify  each dose to be administered to each randomized subject.
6.2.2.2.1. Study group and treatment number allocation
The target will be to enroll approximately  72eligible subjects who will be randomly  
assigned to 
two study  groups in a 1: 1 ratio (approximately  36subjects in each group).
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b61 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6Final
23-JUL -2019 62Subjects will be enrolled in 4 overlapping cohorts of 18 subjects each, for logistical 
reasons at the clinical site, therefore a 1:1 ratio should be maintained at the cohort level.
However, if for an y reason, a cohort does not reach the planned 18 subjects, additional 
subjects can be added in the next cohorts. The maximum number of subjects must not be 
more than 20 (maximum number of beds in the clinic) in each cohort.
Allocation of the subject to a study  group at the investigator site will be performed using 
the Source DataBase for Internet Randomization system (SBIR). The randomization 
algorithm might use a minimization procedure; more details are provided in the Statistical 
Analy sis Plan.
After obtaining the signed and dated ICF from the subject and having checked the
eligibility  of the subject, the site staff in charge of the vaccine/placebo administration will 
access SBIR. Upon providing the subject identification number, the randomization
system will determine the study  group and will provide the treatment number to be used 
for each dose.
A randomization blocking scheme (1:1 ratio) will be used to ensure the balance between 
treatments is maintained, accounting also for the enrolment cohorts: same number of 
vaccine and control recipients in each cohort.
The number of each administered treatment m ust be recorded in the eCRF on the Vaccine 
Administration screen.
When SBI R is not available, please refer to the SBIR user guide or the Study  Procedures 
Manual (SPM) for specific instructions.
6.2.3. Allocation of subjects to assay  subsets
Leftover serum samples collected at Day  1 and 28 day s after second vaccination for the 
antibody  response analy sis will be used for the Fc gl ycosylation test (immunological tests 
mentioned in the tertiary  objectives) that will be performed at Rockefeller University  (see 
Appendix B).
6.3. Method of blinding
Data will be collected in an observer -blind manner. By  observer-
blind, it is meant that 
during the course of the study , the va ccine /placebo recipient and those responsible for the 
evaluation of an y stud y endpoint (e.g. safety, reactogenicity, immunogenicity  and 
efficacy ) will be unaware of which vaccine (stud y vaccine or placebo) was administered. 
To do so, vaccine /placebo prepar ation and administration will be done by  authorized
medical personnel who will not participate in any  of the study  clinical evaluation assay s.
The laboratories in charge of the laboratory  testing will be blinded to the treatment , 
subject and visit number , and codes will be used to link the subject , visit and study
(without any  link to the treatment attributed to the subject) to each sample.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b62 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6Final
23-JUL -2019 636.4. General study  aspects
Supplementary  study  conduct information not mandated to be present in this protocol is 
provided in the accompany ing SPM. The SPM provides the investigator and the site 
personnel with administrative and detailed technical information that does not impact the 
safet y of the subjects.
6.4.1. Independent data monitoring committee
An IDMC will be established by  GSK Biologicals for the purpose of monitoring the 
study  and to provide independent, non- binding advice on safety  and ethics. The IDMC 
will provide recommendations about stopping, continuing or modify ing the study . Refer 
to Section 9.10 for a description of the holding rule and safet y monitoring put in place for 
this study .
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b63 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6Final
23-JUL -2019 646.5. Outline of study  procedures
Table 4 List of study  procedures
Epoch Screening Vaccination Challenge
Type of contactScreening 
visitVisit 1 Phone Call Visit 2 Visit 3 Phone call Visit 4 Visit 5Inpatient 
stayVisit 6 Visit 7 Visit 8
Timepoints (days)Day -45to
Day -1Day 1Day 3 and
Day 7Day 8 Day 29Day 31 and 
Day 35Day 36 Day 57Day 57 to
Day 6 58Day 
85Day 
113Day 237 
(Month 8)
Sampling timepoints Screening Pre-vacc 1Post -
vacc 1Pre-vacc 2Post -
vacc 2Pre-
challenge9Inpatient 
stayPost -challenge
Informed consent ‚óè
Check inclusion/exclusion criteria ‚óè ‚óè ‚óè
Collect demographic data ‚óè
Measure/record height and weight ‚óè
Medical history ‚óè
History directed physical examination O O O O O O
Physical examination ‚óè ‚óè ‚óè ‚óè
Urine pregnancy test1 ‚óè ‚óè ‚óè ‚óè ‚óè
Check contraindications to vaccination O O O
Pre-vaccination /placebo/challenge agent 
administration body temperature‚óè ‚óè ‚óè
Vaccine/placebo/challenge agent administration
Study group and treatment number 
allocation‚óè
Recording of administered treatment 
number‚óè ‚óè
Vaccine /placebo administration ‚óè ‚óè
Challenge with S. sonnei 53G ‚óè
Laboratory assays
Blood sampling for antibody response 
(~20mL)‚óè2, 3 ‚óè ‚óè2 ‚óè ‚óè2, 3 ‚óè4 ‚óè
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b64 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6Final
23-JUL -2019 65Epoch Screening Vaccination Challenge
Type of contactScreening 
visitVisit 1 Phone Call Visit 2 Visit 3 Phone call Visit 4 Visit 5Inpatient 
stayVisit 6 Visit 7 Visit 8
Timepoints (days)Day -45to
Day -1Day 1Day 3 and
Day 7Day 8 Day 29Day 31 and 
Day 35Day 36 Day 57Day 57 to
Day 6 58Day 
85Day 
113Day 237 
(Month 8)
Sampling timepoints Screening Pre-vacc 1Post -
vacc 1Pre-vacc 2Post -
vacc 2Pre-
challenge9Inpatient 
stayPost -challenge
Blood sampling for PBMC isolation 
(Œ±4Œ≤7 +/-plasmablasts response and 
transcriptomics) (~50 mL) (Amended: 23
July 2019)‚óè ‚óè ‚óè ‚óè4
Blood sampling for hematology (5 mL)5 ‚óè ‚óè ‚óè ‚óè ‚óè ‚óè
Blood sampling for biochemical analysis 
(~5 mL)‚óè
Serology for virology : HIV, HBV, HCV 
(~10 mL)‚óè
Blood test for HLA -B27 and local anti S. 
sonnei LPS IgG ( Screening -ELISA) ( ~15 
mL)‚óè
Urine sampling for urinalysis6 ‚óè ‚óè
Stool sample for sIgA ‚óè ‚óè ‚óè ‚óè4
Stool sample for microbiome testing7 ‚óè ‚óè
Stool sample for inflammatory response ‚óè ‚óè
Stool assessment: weight, consistency, 
blood and S. sonnei by culture and qPCR‚óè
Safety assessment
Record any concomitant 
medications/vaccinations‚óè ‚óè ‚óè ‚óè ‚óè ‚óè ‚óè ‚óè ‚óè ‚óè
Distribution of diary cards O O
Return of diary cards ‚óè ‚óè
Diary card transcription by investigator ‚óè ‚óè
Recording of solicited adverse events 
within 7 days post -vaccination‚óè ‚óè
Recording of unsolicited adverse events 
within 28 days post -vaccination‚óè ‚óè ‚óè ‚óè
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b65 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6Final
23-JUL -2019 66Epoch Screening Vaccination Challenge
Type of contactScreening 
visitVisit 1 Phone Call Visit 2 Visit 3 Phone call Visit 4 Visit 5Inpatient 
stayVisit 6 Visit 7 Visit 8
Timepoints (days)Day -45to
Day -1Day 1Day 3 and
Day 7Day 8 Day 29Day 31 and 
Day 35Day 36 Day 57Day 57 to
Day 6 58Day 
85Day 
113Day 237 
(Month 8)
Sampling timepoints Screening Pre-vacc 1Post -
vacc 1Pre-vacc 2Post -
vacc 2Pre-
challenge9Inpatient 
stayPost -challenge
Recording of solicited adverse events 
within 7 days post -challenge‚óè
Recording of unsolicited adverse events 
within 28 days post -challenge‚óè ‚óè
Recording of AESI, SAEs and
pregnancies‚óè ‚óè ‚óè ‚óè ‚óè ‚óè ‚óè ‚óè ‚óè ‚óè
Recording of SAEs related to study 
participation, or to a concurrent GSK 
medication/vaccine‚óè ‚óè ‚óè ‚óè ‚óè ‚óè ‚óè ‚óè ‚óè ‚óè
Study Conclusion ‚óè
V: Visit, D: Day, Vacc : Vaccination; HIV : Human Immunodeficiency Virus , HCV : Hepatitis C Virus , HBV : Hepatitis B Virus , ELISA : Enzyme -linked immunosorbent assay, AESI: 
Adverse Events of Specific Interest , SAEs : Serious Adverse Events .
‚óè is used to indicate a study procedure that requires documentation in the individual eCRF.
Ois used to indicate a study procedure that does not require documentation in the individual eCRF .
1Female subjects will be randomized and study vaccine/placebo or challenge agent may only be administered if the pregnancy test is negative.
2Serum bactericidal a ssay will be performed at these visits in addition to the S. sonnei LPS IgG antibody response.
3Fc glycosylation test on leftover serum samples will be performed at these visits in addition to the S. sonnei LPS IgG antibody response and serum bactericidal a ssay.
4Sampling to be done 7 days after challenge agent administration (i.e. ,Day 64).
5Additionally, hematology is repeated weekly until resolution if neutropenia occurs. On the day of vaccination/ challenge, sampling will be done before vaccination/ challenge.
6Urine dipstick to be done for all subjects and, in case of abnormal results, a urine culture is to be performed (urinalysis) .
7Before vaccination/ challenge (Day 1/Day 57 sample can be collected by the subject at most a week b efore and stored as described in the Investigator Manual and SPM .
8Sampling to be done daily during inpatient stay and if subject is still shedding 7 days post -challenge administration (Day 64) . However, all subjects even if not shedding anymore will 
remain in the inpatient stay until 7 days post -challenge and will be dis charged on Day 65 .
9Samples collection can be performed between Day 56 and Day 57.
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b66 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 67Whenever possible, the investigator should arrange study  visits within the interval 
described in Table 5.
Table 5 Intervals between study visits (Amended: 23July 2019)
Interval Optimal length of interval Allowed interval
Screening visit ÔÇÆVisit 1 -7days -45days ‚Äì -1days
Visit 1 ÔÇÆPhone Call 3days 2days - 6days
Visit 1 ÔÇÆVisit 2 7days 7days -10days
Visit 1 ÔÇÆVisit 3 28days 26days -33days
Visit 3 ÔÇÆPhone call 3days 2days - 6days
Visit 3 ÔÇÆVisit 4 7days 7days -10days
Visit 3 ÔÇÆVisit 5 28days 26days -33days
Visit 5 ÔÇÆInpatient stay 9days 9days -as needed
Visit 5 ÔÇÆVisit 5 post -challenge 
blood draw
(Amended: 23July 2019)7 days
(Amended: 23July 2019)7 days ‚Äì10 days
(Amended: 23July 2019)
Visit 5 ÔÇÆVisit 6 28days 28days -35days
Visit 5 ÔÇÆVisit 7 56days 49days -63days
Visit 5 ÔÇÆVisit 8 180days 166days -194days
6.6. Detailed description of study  procedures
6.6.1. Informed consent
The signed informed consent of the subject must be obtained before stud y participation. 
Refer to Section 6.1for the requirements on how to obtain informed consent.
6.6.2. Check inclusion and exclu sion criteria
Check all inclusion and exclusion criteria as described in Sections 5.2and 5.3before 
enrolment.
Subjects who meet all inclusion criteria and none of the exclusion criteria, with screening 
tests within normal values and women of child bearing potential with negative urine 
pregnancy  test at Screening will be eligible for enrolment .
Continued participation of the subject in the study  will also be checked against inclusion 
and exclusion criteria.
6.6.3. Collect demographic data
Record demographic data such as yearof birth, gender , geographic ancestry and 
anthropometric measurements ( height and weight ) in the subject‚Äôs eCRF.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b67 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 686.6.4. Medical history
Obtain the subject‚Äôs medical history  by interview and/or review of the subject‚Äôs medical 
records and record an y pre-existing conditions or signs and/or s ymptoms present in a 
subject prior to the first study  vaccination in the eCRF.
Relevant medical history can also include an y medica l history  that contributes to the 
understanding of an adverse event that occurs during stud y participation, if it represents 
an exacerbation of an underly ing disease/pre -existing problem.
6.6.5. Physical examination / h istory  directed physical examination
Perform a complete physical examination at Screening , at each vaccination visit and at 
the day  of challenge (Day  57) and a symptom/history  directed phy sical examination of 
the subject at each other visit of the vaccination and challenge phase.
The phy sical examination will be performed b y the investigator and an y outcome 
recorded in the subject source document. Phy sical examination includes assessment of 
oral body  temperature and resting vital signs as appropriate, after at least 10 minutes 
of 
rest.
If the investigator determines that the subject‚Äôs health on the day sof vaccination 
temporaril y precludes vaccination, the visit will be rescheduled within the site planning 
as possible. As challenge is performed per cohort, any subject with fever the day  of 
challenge will not receive the challenge dose.
Treatment of any abnormality observed during this examination has to be performed 
according to loc al medical practice outside this study  or by referral to an appropriate 
health care provider.
6.6.6. Pregnancy  test
Female subjects of childbearing potential are to have a urine pregnancy  test at Screening
visit, prior to study  vaccine /placebo administration (anydose) , prior to c hallenge and at 
last study  visit (Visit 8) . The study  vaccine /placebo and challenge agent may only  be 
administered if the pregnancy  test is negative.
Note: P regnancy  test must be performed even if the subject is menstruating at the time o f 
the study  visit.
6.6.7. Check contraindications to vaccination
Contraindications to vaccination must be checked at Screening visit and at 
the beginning 
of each vaccination visit. Refer to Section 7.5for more details.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b68 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 696.6.8. Assess pre -vaccination body temperature
The oral body  temperature of each subject needs to be measured prior to any  study  
vaccine /placebo or challenge agent administration. If the subject has fever (fever is 
defined as temperature ÔÇ≥38.0¬∞C/100.4¬∞F ) on the day  of vaccination, the visit will be 
rescheduled within the allowed interval (see Table 5).If fever occurs at the day  of 
challenge, the subject will not receive the challenge agent.
6.6.9. Study group and treatment number allocation
Study  group and treatment number allocation will be performed as described in Section 
6.2.2
. The number of each administered treatment must be recorded in the eCRF.
6.6.10. Sampling
Refer to the Module on Bios pecimen Management in the Sponsor‚Äôs SPM for detailed 
instructions for the collection, handling and processing of the samples.
6.6.10.1. Blood sampling for safety  or immune response assessments
Blood samples will be taken during certain study  visits as specified in Section 3and 
Section 6.5. Refer to the SPM for details on samples handling, storage and shipment 
conditions.
ÔÇ∑An overall volume of 400mL will be collected per subject during the entire study  
period (8 months).
6.6.10.2. Urine sampling
ÔÇ∑A urine sample for urinaly sisshould be collected from all subjects at each pre defined
timepoint , as per investigator‚Äôs judgment
.
ÔÇ∑Urine samples for the pregnancy  test will be collected from women of childbearing 
potential at each pre defined timepoint (refer to Section 6.6.6).
6.6.10.3. Stool sampling
For the microbiome analy sis, subjects will take a stool sample at home/at the hospital 
using the sampling material and instructions provided as close as possible to the study
visit (preferably  on the day  of the visit). Immediately  after stool sampling, participants 
will write down date and time of sampling and time since previous defecation and 
determine stool consistency  using the Bris tol Stool Score chart provided.
Aliquots of stool will be collected for fecal sIgA, inflammatory  response , culture and 
qPCR , at each pre defined timepoint (see Table 
4). If , during the inpatient stay ,no stools
are passed on a given day , up to two rectal swabs can be collected for culture and qPCR 
(see also Section 3.2
). The aliquots for fecal sIgAand inflammatory  markers should be 
frozen at -80¬∞C as soon as possible at the clinical site .
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b69 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 70Refer to the SPM for more details on sample collection and storage conditions.
6.6.11. Study v accine/placebo administration
ÔÇ∑After completing all prerequisite procedures prior to vaccination, one dose of study  
vaccine or placebo will be administered IM preferably  in the deltoid of the non -
dominant arm (refer to Section 7for deta iled description of the vaccine/placebo
administration procedure). If the investigator or delegate determines that the 
subject‚Äôs health on the day  of administratio n temporaril
y precludes vaccine/p lacebo
administration, the visit will be rescheduled within the allowed interval for this visit 
(refer to Table 5 ).
ÔÇ∑The subjects will be observed closel y for at least 30 minutes following th e 
administration of the vaccine/placebo, with appropriate medical treatment readil y 
available in case of anaphy laxis.
6.6.12. Challenge administration and inpatient stay
ÔÇ∑After completing all prerequisite procedures prior to challenge, one challenge dose 
of S. sonnei 53G will be administered. If the investigator or delegate determines that 
the subject‚Äôs health on the day  of administration precludes challenge administration, 
the challenge ag ent will not be administrated to the subject.
ÔÇ∑The subjects will be observed closel y for the entire period of the inpatient stay  
(9days, from Day  57 to Day  65) following the administration of the challe nge, with 
appropriate medical treatment readil y availa ble in case of need.
Refer to Section 3.2and SPM for more details related to the preparation and 
administration of the challenge agent and the collection of sample sduring the inpatient 
stay.
6.6.13. Check and record concomitant medication/vaccination and 
intercurrent medical conditions
Concomitant medication/vaccination must be checked and recorded in the eCRF as 
described in Section 7.6.
Intercurrent medical conditions must be checked and recorded in the eCRF as described 
in Section 7.7
.
6.6.14. Recording of A Es, SA Es, pregnancies and AESIs
ÔÇ∑Refer to Section 9.3for procedures for the investigator to record AEs, SAEs, 
pregnancies and AESIs . Refer to Section 9.4for guidelines andhow to report SAE, 
pregnancy  and AESI reports to GSK Biologicals.
ÔÇ∑The subjects will be instructed to contact the investigator immediatel y should they
manifest an y signs or s ymptoms they  perceive as serious. 
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b70 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 716.6.14.1. Subject Di ary
A Paper Diary  (pDiary ), hereafter referred to as Subject Diary ,will be used in this study  
to capture solicited adverse events. The subject should be trained on how and when to 
complete each field of the Subject Diary .
Subject Diary  training should be directed at the individual(s) who will perform the 
measurements of adverse events and who will enter the information into the Subject 
Diary . This individual may  not be the subject, but if a person other than the subject enters 
information into the Subject Diary , this person‚Äôs identity  must be documented in the 
Subject ‚Äôs source records
.Any individual that makes entries into the Subject Diary  must 
receive training on completion of the Subject Diary  at the time of the visit when Subject 
Diary  is dispensed. This training must be documented in the subject‚Äôs source record.
The same individual should complete the Subject Diary  throughout the course of the 
study .
The subject should be trained on how to self- measure local solicited adverse events and 
body  temperature. 
The measurement of solicited local adverse events is to be performed using the ruler 
provided b y the site.
Subjects will be instructed to measure and record the oral body  temperature in the 
evening. Should additional temperature measurements be performed at other times of 
day, subjects will be instructed to record the highest t emperature in the Subject Diary .
6.6.14.2. Post -vaccination reminders
Reminder calls or alerts are not intended to be an interview for collection of safet y data. 
If the subject wishes to describe safet y information, this information should only be 
collected b y a healthcare professional at the site, and the safet y data described must be 
written down in the subject‚Äôs medical chart.
6.6.14.2.1. Subject Diary  reminder calls
Subject Diary  reminder calls will be performed on Day  3, Day  7, Day  31 and Day  35. 
The purpose of this call is to remind the subject about completion of the Subject Diary . 
The call follows the Subject Diary Reminder Telephone Call Script provided to the 
site. 
The subject should be reminded to contact the site via the telephone number provided in 
the informed consent to discuss medical questions.
6.6.15. Study conclusion
The investigator will:
ÔÇ∑Review data collected to ensure accuracy and completeness .
ÔÇ∑Complete the Study  Conclusion screen in the eCRF.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b71 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 726.7. Biological sample handling and analy sis
Please refer to the SPM and I nvestigator Manual for details on biospecimen management 
(handling, storage and shipment).
Samples stored at the clinical site or shipped to exte rnal laboratories will not be labelled 
with information that directly identifies the subject but will be coded with a unique 
sample identifier .Samples anal yzed locall y (e.g., safet y lab samples) would have a label 
with the subject‚Äôs identifiers and medica l record number.
ÔÇ∑Collected samples will be used for protocol- mandated research and purposes related 
to the improvement, development and quality  assurance of the laboratory  tests 
described in this protocol. This may include the management of the quality  of these 
tests, the maintenance or improvement of these tests, the development of new test 
methods, as well as making sure that new tests are comparable to previous methods 
and work reliably .
ÔÇ∑It is also possible that future findings may  make it desirable to use the samples 
acquired in this study  for future research, not described in this protocol. Therefore, 
all subjects will be asked to give a specific consent to allow GSK or a contracted 
partner to use the samples for future research. Future research will be subject to the 
laws and regulations in the respective countries and will only  be performed once an 
independent Ethics Committee or Review Board has approved this research.
Information on further investigations and their rationale can be obtained from GSK 
Biologicals.
Any sample testing will be done in line with the consent of the individual subject .
Refer also to the Investigator Agreement , where it is noted that the investigator cannot 
perform an y other biological assay s except those described in the protocol or its 
amendment(s). 
If additional testing is performed, th e marker priority  ranking given in Section 6.7.4 may 
be changed.
Collected samples will be stored for a maximum of 20 years (counting from when the last 
subject performed the last study  visit), unless local rules, regulations or guidelines require 
different timeframes or different procedures, which will then be in line with the subject 
consent. These extra requirements need to be communicated formall yto and discussed 
and agreed with GSK Biologicals.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b72 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 736.7.1. Use of specified study materials
When materials are provided by  GSK Biologicals, it is MANDATORY that all clinical 
samples (including serum samples) be collected and stored exclusively  using those 
materials in the appropriate manner. The use of other materials could result in the 
exclu sion of the subject from the per -protocol analy sis (See Section 11.5.5 for the 
definition of analysis sets to be analyzed). The investigator must ensure that his/her 
personnel and the laboratory (ies) under his/her supervision comply  with this requirement. 
However, when GSK Biologicals does not provide material fo r collecting and storing 
clinical samples, appropriate materials from the investigator‚Äôs site must be used. Refer to 
the Module on Clinical Trial Supplies in the SPM.
6.7.2. Biological samples
Table 6 Biological samples
Sample type (analysis) (All subjects) Quantity Unit Timepoint
Blood ( hematology ) ~ 5 ml scheduled
Blood (biochemistry) ~ 5 ml scheduled
Blood (hepatitis B, hepatitis C and HIV) ~ 10 ml scheduled
Blood (HLA -B27) ~ 10 ml scheduled
Blood (antiS. sonnei LPS IgG-Screening )* ~ 5 ml scheduled
Blood (antibody response **, SBA and Fc glycosylation) ~ 20 ml scheduled
Blood ( PBMC )for Œ±4Œ≤7+/-plasmablasts response and 
transcriptomics )(Amended: 23July 2019)~ 50 ml scheduled
Urine ( urinalysis ) scheduled
Stool *** (sIgA, microbiome, inflammatory markers, weight, 
consistency and blood assessment, culture and qPCR)scheduled
*For l ocal Screening -ELISA.
**Includes anti S. sonnei LPS IgG -ELISA
***During the challenge phase , if stool samples are unavailable, rectal swabs will be taken for culture and qPCR .
HIV: Human immunodeficiency virus
HLA: Human leukocyte antigen
ELISA: Enzyme -linked immunosorbent assay
IgG: Immunoglobulin G 7
SBA: Serum bactericidal assay
Fc: Fragment crystallisable
sIgA: Secretory immunoglobulin A
qPCR: quantitative polymerase chain reaction
6.7.3. Laboratory  assay s
Please refer to Appendix Afor a detai led description of the assay s performed in the 
study . Please refer to Appendix Bfor the address of the clinical laboratories used for 
sample anal ysis.
The assay s to be performed in the study  are summarized in the Table 7
, Table 8, Table 9
and Table 10:
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b73 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 74Table 7 Immunity  (Antibody  determination)
System Component MethodKit/
ManufacturerUnit2 Cut-off2 Laboratory3
Serum
(screening)Anti-S. sonnei
LPS IgGELISA1 WRAIREndpoint 
titerplate 
dependentCCHMC
Serum
(except 
screening)Anti-S. sonnei
LPS IgGELISA In-house EU/mLplate 
dependentGVGH4or 
GVGH 
designated lab
SerumBactericidal 
antibodiesSBA In-houseDilution 
Factor 
(titer)NAGVGH4or 
GVGH 
designated lab
StoolAnti-S.sonnei
LPS sIgAELISA WRAIR EU/mL 10 CCHMC
Stool Anti-total sIgA ELISA WRAIR mg/mL 0.001 CCHMC 
1 Local Screening -ELISA will be used for this testing.
2Assay cut -off and unit might be subject to change during the course of the study (e.g. in case of requalification, 
revalidation or standardization). In this case, this will be documented in the clinical report.
3Refer to Appendix Bfor the laboratory addresses.
4GVGH laboratory refers to the GVGH -laboratories in Siena , Italy.
ELISA : enzyme -linked immunosorbent assay, NA: n ot applicable, EU: ELISA unit, LPS: lipopolysaccharide, IgA/G: 
immunoglobulin A/G, SBA : serum bactericidal Assa y, WRAIR : Walter Reed Army Institute of Research (US), GVGH : 
GSK Vaccines Institute for Global Health , CCHMC : Cincinnati Children‚Äôs Hospital Medical Cent er; sIgA: secretory 
Immunnoglobulin A
Table 8 Cell-Mediated Immunity (CMI) (Amended: 23July 2019)
System Component Method Unit Laboratory
PBMCŒ±4Œ≤7 positive 
plasmablast
(Amended: 23
July 2019)ELISA
(Amended: 23
July 2019)Anti-S. sonnei 
LPS specific Titer/ 
5x10^6 cells
(Amended: 23
July 2019)WRAIR or GVGH designated lab
PBMC
(Amended: 
23July
2019)Œ±4Œ≤7 negative 
plasmablast
(Amended: 23
July 2019)ELISA
(Amended: 23
July 2019)Anti-S. sonnei 
LPS specific Titer/ 
5x10^6 cells
(Amended: 23
July 2019)WRAIR or GVGH designated lab
(Amended: 23July 2019)
PBMCGene 
expression 
(transcriptomics) 
studyNextGen 
sequencing/ 
microarraySequencing or 
fluorescent 
intensityGVGH* or GVGH designated lab
ELISA : Enzyme -Linked Immunosorbent Assay; PBMC : peripheral blood mononuclear cells ,WRAIR : Walter Reed 
Army Institute of Research (US) ,GVGH: GSK Vaccines Institute for Global Health .
*GVGH laboratory refers to the GVGH- laboratories in Siena, Italy.
Table 9 Excretion of Challenge agent
System Component Family Method Unit Laboratory
Stool S. sonnei 53G culture Not applicable CCHMC
Stool S. sonnei 53G qPCR RFU WRAIR
qPCR : quantitative polymerase chain reaction , RFU : relative fluorescence units, CCHMC : Cincinnati Children‚Äôs 
Hospital Medical Cent er,WRAIR : Walter Reed Army Institute of Research (US) .
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b74 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 75Table 10 Hematology , Serum Chemistry , Virology , HLA -B27 test, Urine and 
Stool tests (Amended: 23July 2019)
System Component Method Laboratory
EDTA Blood Hematology CBC Study site
EDTA blood Chemistry* Renal and liver function test Study site
Clotted Blood Hep B, Hep C and HIV TBD Study site
EDTA Blood HLA-B27Qualitative flow cytometry (Amended: 23
July 2019)Study site
Urine Urinalysis Urine dipstick (urine culture as appropriate) Study site
Urine Urine pregnancy test ÔÅ¢HCG Study site
Stool Microbiome16s ribosomal DNA amplicon sequencing 
and/or shotgun whole genome sequencingGVGH ** or GVGH
designated lab
Stool Inflammatory markers ELISA WRAIR or GVGH 
designated lab
EDTA : Ethylene Diamine Tetra -Acetic Acid , CBC: Complete Blood Count , ELISA : Enzyme- Linked Immunosorbent 
Assay, Hep: Hepatitis, HIV : Human Immunodeficiency Virus ,HLA: Human Leukocyte Antigen , ÔÅ¢HCG : beta-Human 
Chorionic Gonadotropin , GVGH : GSK Vaccines Institute for Global Health , WRAIR: Walter Reed Arm y Institute of 
Research (US ).
*Chemistry performed only at screening unless required for subject management
**GVGH laboratory refers to the GVGH- laboratories in Siena, Italy
Note that hematology data post vaccination/c hallenge will be transferred from the study  
laboratory  performing the testing into the clinical database as soon as possible to ensure 
that all necessary  information are available for IDMC reviews. In addition, results will be 
communicated as soon as possible to the investigators via lab repor ts, hard copies, faxes 
or emails.
Microbiome anal ysis in stool will be done using 16s ribosomal deox yribonucleic acid 
(DNA) amplicon sequencing and/or shotgun whole genome sequencing. These will use 
DNA sequencing to identify  the bacteria and their genes p resent in the sample to explore 
associations to immunogenicity and challenge outcome. Shotgun sequencing might 
generate subject‚Äôs DNA sequence information; however, these sequences are filtered out 
and will not be analyzed. Depending on the results of the microbiome analysis, additional 
follow -up studies might include microbiome gene expression profiling ( ribonucleic acid
sequencing or another method), culture and functional characterization of the bacteria in 
the sample in animal models.
Fecal markers of i ntestinal inflammation will be meas ured as a sensitive predictor for 
inflammatory  activities in the gastrointestinal tract. This analy sis willassess if 
concentrations of inflammatory  markers such as calprotectin and m yeloperoxidase will 
increase after oral challenge with S. sonnei 53G andwill additionally  investigate if the S. 
sonnei 1790GAH Bvaccine canreduce or abrogate the inflammatory  response in the 
intestine after oral challenge .
Gene expression will be studied using high -throughput techno logies (including but not 
limited to RNAseq or microarray s) measuring the relative abundance of RNA molecules 
in PBMCs harvested at several timepoints following vaccination and challenge. 
Computational analy sis will subsequently  identify  pathway s and biolo gical themes 
associated with vaccination and acute disease and transcriptional patterns may  be related 
to metadata including humoral and cellular responses to vaccination.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b75 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 76Additional exploratory  testing on the vaccine and/or on the disease under study  may  be 
performed within the framework of the stud y if deemed necessary  for accurate 
interpretation of the data or should such assay(s) become available at GSK. These assay s 
may not be represented in the objectives/endpoints of the study  protocol.
Sera will be archived at GSK laboratory  
or its designated lab for future research on 
immunogenicit y of the Shigella vaccine. Stud y-related future research may include 
additional evaluation of immunogenicit y on S. sonnei (i.e.,IgM, sIgA against the OAg or 
IgG against other antigens of S. sonnei , sIgA from stimulated ly mphocy tes supernatant , 
FACS /CyTOF Phenoty ping (C ytokine stimulation ).Non-study  related future research 
may include serology  on other Shigella serot ypes and other bacteria causing infectious 
diseases in developing countries (e.g. ,Salmonella typhi , Salmonella paratyphi , non-
typhoidal Salmonella, meningitis) to inform development of other vaccines relevant to 
the populations in developing countries.
The GSK Biologicals‚Äô clinical laboratories have es tablished a Quality  System supported 
by procedures. The activities of GSK Biologicals‚Äô clinical laboratories are audited 
regularl y for quality assessment by  an internal (sponsor -dependent) but laboratory -
independent Qualit y Department.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b76 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 776.7.4. Biological samples e valuation
6.7.4.1. Immunological read -outs
Table 11 Immunological read -outs
Sampling timepoint
Sub-cohort nameNo. 
subjectsComponentComponents 
priority rankType of contact 
and timepointSampling 
timepoint
Screening Visit ScreeningAll screened 
subjectsNAAnti HIV* 1
HBsAg* 1
Anti HCV* 1
Serum a nti-S.sonnei LPS IgG * 1
HLA-B27 1
Visit 1 (Day1) Pre-VaccAll subjects enrolled 72Serum anti -S. sonnei LPS IgG 1
Serum anti -S. sonnei
bactericidal antibodies2
Serum for Fc Glycosylation 3
Œ±4Œ≤7 plasmablast 2
Transcriptomics 2
All subjects enrolled 72 sIgA in stool NA
Visit 2 (Day 8) Post Vacc 1 All subjects enrolled 72Serum anti -S. sonnei LPS IgG 1
sIgA in stool NA
Œ±4Œ≤7 plasmablast 2
Transcriptomics 2
Visit 3 (Day 29) Post Vacc 1 All subjects enrolled 72Serum anti -S. sonnei LPS IgG 1
Serum anti -S. sonnei
bactericidal antibodies2
Visit 4 (36) Post Vacc 2 All subjects enrolled 72Serum anti -S. sonnei LPS IgG 1
Œ±4Œ≤7 plasmablast 2
Transcriptomics 2
sIgA in stool NA
Visit 5 (Day 57) Pre-challenge All subjects enrolled 72Serum anti -S. sonnei LPS IgG 1
Serum anti -S. sonnei
bactericidal antibodies2
Serum for Fc Glycosylation 3
Inpatient Stay 
(Day 64)Inpatient Stay All subjects enrolled 72Serum anti -S. sonnei LPS IgG 1
sIgA in stool NA
Œ±4Œ≤7 plasmablast 2
Transcriptomics 2
Visit 6 (Day 85)Post-
challengeAll subjects enrolled 72 Serum anti -S. sonnei LPS IgG NA
Note: Anti -S.sonnei LPS IgG will be determined by local Screening -ELISA at screening and by GVGH ELISA for the 
rest of the timepoints.
*This testing is performed at screening and the results might potentially impact the subject medical care.
Vacc : Vaccination, Fc: Fragment crystallisable, LPS: Lipopolysaccharide, IgG: Immunoglobulin G, Œ±4Œ≤7 : Gut -homing 
integrin, sIgA : Secretory specific Immunoglobulin A, IgG: Immunoglobulin G, HIV: Human Immunodeficiency Virus ; 
HBsAg : Hepatitis B surface Antigen; H CV: Hepatitis C Virus , NA: Not Applicable
In case of insufficient blood sample volume to perform assay s, the samples will be 
analyzedaccording to priority  ranking provided in Table 11.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b77 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 786.7.4.2. Hematology /blood chemistry
Table 12 Hematology /Blood Chemistry  read -outs
Blood sampling timepoint No. 
subjectsComponent*Type of contact and timepoint Sampling timepoint
Screening Pre-Vacc 1 NAHematology
Chemistry
Visit 2 (Day 8) Post-Vacc 1 72 Hematology
Visit 3 (Day 29) Pre-Vacc 2 72 Hematology
Visit 4 (Day 36) Post-Vacc 2 72 Hematology
Visit 5 (Day 57) Pre-challenge 72 Hematology
Visit 8 (Day 237) Post-challenge 72 Hematology
*Hematology is repeated at 7 and 28 days after each vaccination and repeated weekly until resolution if neutropenia
occur s.
Vacc : Vaccination, NA: Not applicable
6.7.5. Immunological correlates of protection
No generally  accepted immunological correlate of protection has been demonstrated so 
far for Shigellosis and consequently  for the candidate vaccine. However, in GVGH Phase 
I clinical protocols a high seroresponse was defined as a post- vaccination level of 
ÔÇ≥121serum IgG E U/mL against the S. sonnei OAg containing LPS used as coating 
antigen in GVGH ELISA. This concentration corresponds to a titer of 1:800 in the 
ELISA method published by  Cohen [ Cohen, 1989] and is the median antibody  
concentration of a set of 87 Israeli convalescent subjects previously  exposed to S. sonnei . 
The value of 121 E U/mL in the GVGH ELISA (anti-S. sonnei LPS IgG -ELIS A)has been 
determined b y calibration against the Cohen ELISA (i.e., the GVGH standard serum was 
tested in Cohen‚Äôs lab using the Cohen‚Äôs methodology ) [Gerke , 2015].
The availability  of this threshold has allowed GVGH to correlate the immunogenicity  
data induced b y 1790GAHB vaccine with antibody  levels after natural exposure in 
humans, which are associated with clinical protection from subsequent infections with the 
same Shigella serot ype [ Cohen
, 1991; Ferreccio, 1991]. To confirm the proof of concept 
outcome of GVGH Phase I studies (post -immunization median antibody  titer in vaccinees 
ÔÇ≥121 EU/mL ), as part of the objectives of this study , any potential correlation between 
antibody  response (ELISA and SBA) after vaccination and likelihood of infection will be 
evaluated. Additionall y, potential correlation between antibod y response by  ELISA and 
serum bactericidal activity  will be explored. Further correlat ion can be established post -
challenge.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b78 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 797. STUDY VACCINE/PRODUCTS A ND ADM INISTRA TION
7.1. Description of study  vaccine /placebo and challenge agent
The 1790GAHB candidate vaccine has been developed by GVGH, propert y of GSK 
Biologicals.
The S. sonnei 53G challenge strain was developed by  Walter Reed Arm y Institute of 
Research (WRAI R), Silver Spring, Mary land, USA.
The Quality  Control Standards and Requirements for the candidate vaccine/ placebo and 
challenge agent are described in separate Qualit y Assurance documents (e.g. ,release 
certificate/ certificate of compliance ) and required approvals will be obtained before use .
The vaccine /placebo and challenge agent arelabelled and packed according to applicable 
regulatory  requirements.
Table 13 Study  vaccine/placebo and challenge agent
Treatment 
name*Vaccine /
placebo 
and 
challenge 
agent nameFormulation PresentationVolume to be 
administeredNumbe
r of 
doses
S. sonnei *Shigella 
sonnei 
1790GAHB200 ÔÅ≠g 1790- GMMA 
protein adsorbed to 
0.7mg aluminum3+/mLWhite opalescent s terile 
suspension for injection0.5 m Lafter 1:4 
dilution with 
GVGH Placebo2
Placebo *GAHB -
PlaceboAluminum hydroxide 
(wet gel suspension 
Alhydrogel 2.0%) 0.7 
mg aluminum3+/mL of 
constituted vaccineWhite opalescent sterile 
suspension for injection0.5 mL 2
S. sonnei 
53G 
challenge 
strain **S. sonnei 
53G
ChallengeS. sonnei strain 53G1 mL of the inoculum 
(CFU TBD) will be 
added to 30 mL of 
sterile normal saline 
0.9% for administration1500 CFU 1
*The supply is managed by GVGH with the support of a local Contract Manufacturing Organization .
**S. sonnei 53G strain will be used for the challenge.
7.2. Storage and handling of study  vaccine/placebo and 
challenge agent
The study  vaccine/p lacebo and challenge agent must be stored at the respective label 
storage temperature conditions in a safe and locked place. Access to the storage space 
should be limited to authorized study  personnel. The storage conditions will be assessed 
during pre -study  activities under the responsibility of the sponsor study  contact. The 
storage temperature should be continuously  monitored with calibrated (if not validated) 
temperature monitoring device(s) and recorded. Refer to the Module on Clinical Trial 
Supplies in the SPM for more de tails on storage of the study  vaccine/placebo and 
challenge agent .
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b79 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 80Temperature excursions must be reported in degree Celsius.
Any temperature excursion outside the range of +2 to +8ÔÇ∞C (for +2 to +8¬∞C label storage 
condition) impacting 1790GAHB vaccine and placebo or -80¬∞C ÔÇ±10¬∞C for the challenge 
agent must be reported to GSK using the appropriate temperature excursion form. The 
impacted IMPs must not be used and must be stored in quarantine at label temperature 
conditions until usage approval has been obtained from the sponsor .
Refer to the Module on Clinical Trial Supplies in the SPM for details and instructions on 
the temperature excursion reporting and usage decision process, packaging and 
accountability  of the study  vaccine/placebo and challenge age nt.
7.3. Dosage and administration of study  vaccine/ placebo and 
challenge agent
7.3.1. Vaccine /placebo preparation
Bedside mixing and vaccine/ placebo administration at the study  site will be performed 
according to the Sponsor instructions by  trained site staff. The site staff responsible for 
these activities will be personnel who are qualified according to applicable laws and 
regulations and will not be involve din the clinical assessment of the subjects . The 
Sponsor, or its authorized delegate , will provide specific procedures and training for these 
activities.
7.3.2. Preparation of challenge agent
Preparation and administration of the challenge agent at the study  site will be performed 
according to stud y site instructions by trained site staff. The site staff responsible for 
these activities will be personnel who are qualified according to applicabl e laws and 
regulations. S.sonnei 53G is classified as a BSL -2 category  organism. Personnel will take 
appropriate precautions for working with BSL -2 organisms and wear proper protective 
equipment such as lab coats, gloves and, if necessary , masks to shield themselves and 
others from spills and inadvertent mishaps. Spills will be treated according to Standard 
Operating Procedure ( SOP). All unused reconstituted inoculum and materials containing 
the bacteria will be disposed of properly  in biohazard bags. All exposed materials and all 
disposable materials will be discarded in the biohazard waste for pick up and 
decontamination as per CCHMC policy . At the study  site specific procedures are 
available and site staff will be appropriatel y trained.
7.3.3. Vaccine /placebo dosage and administration
The investigator or designee will be responsible for the oversight of the administration of 
vaccine /placebo to subjects enrolled in the study  according to the procedures stipulated in 
this study  protocol. All vaccines/placebos will
be administered only  by personnel who are 
qualified to perform that function under applicable local laws and regulations for the 
specific stud y site.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b80 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 817.3.4. Challenge agent dosage and administration
The investigator or designee will be responsible for the oversi ght of the administration of 
the challenge agent to subjects enrolled in the study  according to the procedures 
stipulated at the study  site. The challenge agent will be administered only  by personnel 
who are qualified to perform that function under applicable local laws and regulations for 
the specific stud y site.
Table 14 Dosage and administration
Type of contact 
and timepointStudy 
groupTreatment nameVolume to be 
administeredRoute1Site
Location Directionality2Laterality3
Visit 1 (Day 1)S.sonneiGVGH 1790GAHB 
S. sonnei vaccine
(1:4 diluted)0.5 mL IM Deltoid UpperNon-
dominant
Placebo GAHB -Placebo 0.5 mL IM Deltoid UpperNon-
dominant
Visit 3 (Day 29)S.sonneiGVGH 1790GAHB 
S. sonnei vaccine
(1:4 diluted)0.5 mL IM Deltoid UpperNon-
dominant
Placebo GAHB -Placebo 0.5 mL IM Deltoid UpperNon-
dominant
Visit 5 (Day 57)S.sonnei S. sonnei 53G 1500 CFU O NA NA NA
Placebo S. sonnei 53G 1500 CFU O NA NA NA
1IM: intramuscular / O: oral
2Directionality is a qualifier for further detailing the location of the vaccine/placebo administration
3The non- dominant arm is the preferred arm of injection. In case it is not possible to administer the vaccine /placebo in 
the non -dominant arm, an inject ion in the dominant arm may be performed.
Precautions to be observed in administering study vaccine/placebo or challenge 
agent:
Prior to administration of the vaccine/placebo or challenge agent, subjects must be 
determined to be eligible and it must be clinically  appropriate in the judgment of the 
investigator to vaccinate/challenge. Eligibility  for vaccination/challenge is determined by  
evaluating the entry  criteria outlined in p rotocol Sections 5.2, 5.3, 6.6.11 and 6.6.12.
Study  vaccine/placebo or challenge agent should not be administered to individuals with 
known hy persensitivity  to any  component of the vaccine/placebo or challenge agent. 
Standard immunization practices are to be observed and care should be taken to 
administer the vaccine/p lacebo intramuscularl y. Before administering vaccine/p lacebo , 
the vaccination 
site is to be disinfected with a skin disinfectant (e.g., 70% alcohol). Allow 
the skin to dry . DO NOT inject intravascularly.
As with all injectable vaccines/products , trained medical personnel and appropriate 
medical treatment should be readil y available in case of anaphy lactic reactions following 
vaccine /placebo administration. For example, epinephrine 1:1000, diphenhy dramine, 
and/or other medications for treating anaph ylaxis should be available.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b81 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 827.4. Replacement of unusable vaccine /placebo doses and 
challenge agent
In addition to the vaccine /placebo doses provided for the planned number of subjects
(including over -randomization when applicable) , at least 5% additional vaccine/placebo
doses will be supplied to replace those that are unusable. For the challenge agent, at least 
one back -up via
lwill be required.
The investigator will use SBI R to obtain the replacement vial number. The replacement 
numbers will be allocated by  dose . The sy stem will ensure, in a blinded manner that the 
replacement vial matches the formulation the subject was assigned to by  randomization .
7.5. Contraindications to subsequent vaccination or challenge
Eligibility  to administration of a second dose of the vaccine and challenge agent should 
be reconfirmed. The following events constitute absolute contraindications to further 
administration of 1790GAHB vaccine or the placebo and the challenge agent. If an yof 
these events occur during the study , the subject must not receive additional doses of 
vaccine/placebo and challenge agent but may  continue other study  procedures at the 
discretion of the investigator (see Section 9.5).
ÔÇ∑Anaph ylaxis following the administration of vaccine /placebo .
ÔÇ∑Pregnancy  (see Section 9.2.1).
ÔÇ∑Hepatomegal y, right upper quadrant abdominal pain or tenderness.
ÔÇ∑Any confirmed or suspected immunosuppressive or immunodeficient condition, 
including, HIV infection.
ÔÇ∑Any condition that in the judgment of the investigator would make intra muscular 
injection unsafe.
The following event sconstitute contraindications to administration of 1790GAHB 
vaccine or the challenge agent at that point in time; if any of these event soccur at the 
time scheduled for vaccination, the subject may  be vaccinated at a later date, within the 
time window specified in the protocol (see Section 6.5), or the subject may  be withdrawn 
at the discretion of the investigator (see Section 9.5
):
ÔÇ∑Neutropenia below 1800 cell/¬µL (LLN ) based on most recent available laboratory  
results. Subjects with previous neutropenia or unresolved neutropenia may be re -
evaluated prior to vaccination or prior to challenge at the discretion of the 
investigator .
ÔÇ∑Acute disease and/or fever at the time of vaccina tion.
ÔÄ≠Fever is defined as temperature ÔÇ≥38.0¬∞C / 100.4¬∞F. 
The preferred location for 
measuring temperature in this study  will be the oral cavity .
ÔÄ≠Subjects with a minor illness (such as mild diarrhea, mild upper respiratory 
infection) without fever can be administered vaccine/placebo and challenge 
agent.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b82 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 837.6. Concomitant medication s/product sand concomitant 
vaccinations
At each stud y visit/contact, the investigator or delegate should question the subject about 
any medication s/product staken and vaccination sreceived by  the subject.
7.6.1. Recording of concomitant medications/products and 
concomitant vaccination s
The following concomitant medication(s) /product (s)/vaccine (s)must be recorded in the 
eCRF :
ÔÇ∑All concomitant medications/products, except vitamins and dietary  supplements, 
administered during the period starting at vaccination day  to 28 day s following each 
dose of study  vaccine /placebo (1 day  to 28 day s after each vaccination) and 
administration of challenge agent.
ÔÇ∑Relevant medications/products like vaccines, immunoglobulin, blood products, 
immunosuppressors, immunomodulators administered during the period starting 
from the administration of the first dose of the study vaccine /placebo and ending 28 
days after challenge.
ÔÇ∑Any concomitant vaccination administered in the period starting 28 day s before the 
first dose of study  vaccine/p lacebo and ending at 28 day s after challenge with the 
exception of seasonal Flu vaccination .
ÔÇ∑Prophy lactic medication (i.e. medication administered in the absence of ANY 
symptom and in a nticipation of a reaction to the vaccination).
E.g.,an anti -pyretic is considered to be prophy lactic when it is given in the absence 
of fever and an y other s ymptom, to prevent fever from occurring (fever is defined as 
temperature ÔÇ≥38.0¬∞C/100.4¬∞F ).The preferred 
location for measuring temperature in 
this study  will be the oral cavity .
ÔÇ∑Any concomitant medications/products/vaccines relevant to a SAE to be reported as 
per-protocol or administered during the study period for the treatment of a SAE. I n 
addition, concomitant medications relevant to SAEs need to be recorded on the 
expedited Adverse Event report.
7.6.2. Concomitant medications/products/vaccines that may  lead to the 
elimination of a subject from per- protocol analy ses
The use of the following concomitant medications/products/vaccines will not require 
withdrawal of the subject from the study  but may  determine a s ubject‚Äôs evaluability  in the 
per-protocol analysis. See Section 11.5 for analyses sets to be anal yzed.
ÔÇ∑Any investigational or non- registered product (drug or vaccine) other than the study  
vaccine /products used during the study  period.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b83 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 84ÔÇ∑Immunosuppressants or other immune -modify ing drugs administered chronically  
(i.e. more than 14 day s in total) during the study  period. For corticosteroids, this will 
mean prednisone ÔÇ≥20 mg/day  or equivalent. Inhaled, except for doses >800 ÔÅ≠g/day , 
and topical steroids are allowed.
ÔÇ∑Long -acting immune -modify ing drugs administered at any  time during the study  
period (e.g. infliximab).
ÔÇ∑A vaccine not foreseen by the stud y protocol administered during the period starting 
from the first dose and ending at the blood sample at Visit 8 or 28 day s after t he last 
dose of vaccine /placebo administration, with the exception of emergency  mass 
vaccination and influenza vaccination.
In case an emergency  mass vaccination for an unforeseen public health threat (e.g.: a 
pandemic) is organized by the public health authorities, outside the routine 
immunization program, the time period described above can be reduced if necessary  
for that vaccine provided it is licensed and used according to its Summary  of Product 
Characteristics or Prescribing Information and according to the local governmental 
recommendations and provided a written approval of the Sponsor is obtained.
ÔÇ∑Immunoglobulins and/or any  blood products administered during the study period.
ÔÇ∑Drug and/or alcohol abuse during the study  period.
7.7. Intercurrent medical conditions that may  lead to elimination 
of a subject from per-protocol analy ses
At each stud y visit subsequent to the first vaccination visit, it must be verified if the 
subject has experienced or is experiencing an y intercurrent medical condition. If it is the 
case, the condition(s) must be recorded in the eCRF.
Subjects may  be eliminated from the per -protocol cohort for immunogenicity  if, during 
the study :
ÔÇ∑They  incur a condition that has the capability  of altering their immune response (i.e.,
varicella) or are confirmed to have an alteration of their initial immune status.
ÔÇ∑They  have serious chronic or progressive disease according to judgment of the 
investigator (e.g., neoplasm, insulin dependent diabetes, cardiac, renal or hepatic 
disease).
ÔÇ∑They  have any  malignancy  or ly mphoproliferative disorder. 
ÔÇ∑They  have any  confirmed or suspected immunosuppressive or immunodeficient 
condition, based on phy sical examination.
8. HEA LTH ECONOMICS
Not applicable .
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b84 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 859. SAFETY
The investigator or site staff is/are responsible for the detection, documentation and 
reporting of events meeting the criteria and definition of an adverse event (AE) or serious 
adverse event (SAE ) as provided in this protocol.
Each subject will be instructed to contact the investigator immediatel y should they /the 
subject manifest an y signs or sy mptoms they  perceive as serious.
9.1. Safet y definitions
9.1.1. Definition of an adverse event
An AE is an y untoward medical occurrence in a clinical investigation subject, temporall y 
associated with the use of a medicinal product, whether or not considered related to the 
medicinal product.
An AE can therefore be any  unfavorable and unintended sign (including an abnormal 
laboratory  finding), s ymptom, or disease (new or exacerbated) temporall y associated with 
the use of a medicinal pr oduct. For marketed medicinal products, this also includes 
failure to produce expected benefits (i.e. ,lack of efficacy ), abuse or misuse.
Examples of an AE include:
ÔÇ∑Exacerbation of a chronic or intermittent pre-existing condition including either an 
incre ase in frequency  and/or intensity  of the condition.
ÔÇ∑New conditions detected or diagnosed after study vaccine/p
lacebo administration 
even though they  may  have been present prior to the start of the study .
ÔÇ∑Signs, sy mptoms, or the clinical sequelae of a suspe cted interaction.
ÔÇ∑Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study
vaccine/placebo or a concurrent medication (overdose per se should not be reported 
as an AE/SAE).
ÔÇ∑Signs, sy mptoms temporally  associated with study vaccine/placebo.
ÔÇ∑Pre-or post -treatment events that occur as a result of protocol- mandated procedures 
(i.e. invasive procedures, modification of subject‚Äôs previous therapeutic regimen).
AEs to be recorded as endpoints (solicited AEs) are described in Secti on 9.1.3 . All other 
AEs will be recorded as UNSOLI CITED AEs.
Examples of an AE DO NOT include:
ÔÇ∑Medical or surgical procedures (e.g. ,endoscop y, appendectomy); the condition that 
leads to the procedure is an AE/SAE.
ÔÇ∑Situations where an untoward medical occurrence did not occur (e.g. ,social and/or 
convenience admission to a hospital, admission for routine examination).
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b85 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 86ÔÇ∑Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen. 
ÔÇ∑Pre-existing conditions or signs and/or s ymptoms present in a subject prior to the 
firststudy  vaccination. These events will b e recorded in the medical history  section 
of the eCRF.
9.1.2. Definition of a serious adverse event 
A SAE is any  untoward medical occurrence that:
a.Results in death,
b.Is life -threatening,
Note: The term ‚Äòlife
-threatening‚Äô in the definition of ‚Äòserious‚Äô refers to an event in 
which the subject was at risk of death at the time of the event. It does not refer to an 
event, which h ypothetically  might have caused death, had it been more severe.
c.Requires hospitalization or prolongation of existing hospitalization ,
Note: I n general, hospitalization signifies that the subject has been admitted at the 
hospital or emergency  ward for observation and/or treatment that would not have 
been appropriate in the phy sician‚Äôs office or in an out patient setting. Complications 
that occur during hospitalization are also considered AEs. If a complication prolongs 
hospitalization or fulfils any other serious criteria, the event will also be considered 
serious. When in doubt as to whether ‚Äò hospitalization ‚Äô occurred or was necessary , the 
AE should be considered serious.
Hospitalization for elective treatment of a pre -existing condition (known or 
diagnosed prior to informed consent signature) that did not worsen from baseline is 
NOT considered an AE.
d.Results in disability /incapacity , OR
Note: The term disability means a substantial disruption of a person‚Äôs ability  to 
conduct normal life functions. This definition is not intended to include experiences 
of relativel y minor medical significance such as uncomplicated headache, nausea, 
vomiting, diarrh ea, influenza like illness, and accidental trauma (e.g., sprained ankle) 
which may  interfere or prevent every day life functions but do not constitute a 
substantial disruption.
e.Is a congenital anomal y/birth defect in the offspring of a study  subject .
Medica l or scientific judgment should be exercised in deciding whether reporting is 
appropriate in other situations, such as important medical events that may  not be 
immediately  life-threatening or result in death or hospitalization but may jeopardize the 
subjec t or may  require medical or surgical intervention to prevent one of the other 
outcomes listed in the above definition. These should also be considered serious. 
Examples of such events are invasive or malignant cancers, intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dyscrasias or convulsions 
that do not result in hospitalization.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b86 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 879.1.3. Solicited adverse events
The term ‚Äúreactogenicit y‚Äù refers to solicited signs and symptoms (‚Äúsolicited AEs‚Äù) 
occurring in the hours and day s following a vaccination, to be collected b y the subjects
for 7consecutive day s, using a pre defined Subject Diary .
The study  staff must review the data entered into the Subject Diary  as described in 
Section 12.2.
Note: Any  solicited AEthat meets an y of the following criteria must be entered into 
subjects‚Äô source document (see Section 12.2) and also as an AEon the Adverse Event 
CRF:
ÔÇ∑Solicited local or sy stemic AEthat continues bey ond day  7 after vaccination .
ÔÇ∑Solicited local or sy stemic AEthat leads to a visit to a healthcare provider (medically  
attended AE, see Section 9.3.3.4).
ÔÇ∑Solicited local or sy stemic AEleading to the subject withdrawing from the study  or 
the subject being withdrawn from the stud y by the investigator ( AEleading to 
withdrawal).
ÔÇ∑Solicited local or sy stemic AEthat otherwise meets the definition of a SAE (see 
Section 9.1.2).
Solicited AEs after vaccination are included in the Subject Diary . Each AE is to be 
assessed using the scoring s ystemreported in Section 9.3.3.2.1 .
9.1.3.1. Solicited local A dverse events
The following local (injection site) AEs will be solicited:
Table 15 Solicited local adverse events
Both study arms
Pain at injection site
Erythema at injection site
Induration at injection site
9.1.3.2. Solicited systemic A dverse events
The following s ystemic AEs will be solicited:
Table 16 Solicited sy stemic adverse events
Both study arms
Arthralgia
Chills
Fatigue
Malaise
Myalgia
Fever
Headache
Note: Subjects will be instructed to measure and record oral body temperature in the evening 6 hours after vaccination 
and daily during the following 6 days. Subjects will be instructed to record the highest temperature in the diary card.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b87 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 889.1.3.3. Solicited events after challenge phase
During the challenge phase after the subjects have received the challenge agent, events 
associated with the administration of the challenge agent will be collected and recorded 
by the investigator in the CRF .These events include diarrhea , abdominal pain, abdominal 
cramps, gas, anorexia, nausea, headache, my algia, malaise, arthralgia, fever, and 
vomiting beginning the day  of administration of study  challenge agent until 7days after 
chall enge (i.e., Day 64). Any  unresolved events will be followed to resolution or 
stabilization. Oral rehydration will be initiated and recorded for subjects with a Grade 2 
or higher AE of diarrhea, vomiting, dy sentery  or dehy dration. The hy dration of subjects 
developing diarrhea will be maintained with oral electroly te solutions by offering at least 
1.5 mL  for each gram of diarrheal stool lost, as tolerated. Subjects who develop vomiting 
will be offered at least 1.0 mL  for each gram of emesis lost, as tolerated. Subjects will be 
evaluated b y a physician who will consider intravenous hy dration for subjects who:
ÔÇ∑Cannot tolerate oral fluids,
ÔÇ∑Experience fluids loss that exceeds their ability  to drink replacement fluids,
ÔÇ∑Have > 1000 mL deficit in intake in a 24 hour period,
ÔÇ∑Experience weight loss of more than 5%,
ÔÇ∑Have urine specific gravity  >1.030 for 12 hours,
ÔÇ∑Have s yncope or near -syncope,
ÔÇ∑Grade 3 tach ycardia, or
ÔÇ∑Grade 3 h ypotension.
If the subject is unable to tolerate fluids b y mouth and intravenous fluids are dee med 
necessary  by the assessing ph ysician, a 0.9% sterile saline solution 1 -liter bolus will be 
administered intravenously . This bolus will be repeated as needed to resolve Grade 2 and 
above s ymptoms at the discretion of assessing ph ysician. Fluid maintenan ce will be 
continued using 0.45% NaCl, 5% dextrose, and 20 mEq KCL
 per liter at a rate of 
100mL/hour until subject is able to resume oral rehy dration. If the subject develops 
grade 4 h ypotension despite the aggressive fluid management, the subject will be
transferred from the inpatient unit to a hospital setting.
9.1.4. Unsolicited A dverse Events
An unsolicited AEis an AE that was not solicited using a Subject Diary  and that was 
spontaneously  communicated by  a subject who has signed the informed consent or a 
solicited local or sy stemic AE that continues bey ond the solicited period at day  7after 
vaccination .
Potential unsolicited AEs may  be medicall y attended (defined as s ymptoms or illnesses 
requiring hospitalization, or emergency  room visit, or visit t o/by a health care provider), 
or were of concern to the subjects. In case of such events, subjects will be instructed to 
contact the site as soon as possible to report the event(s). The detailed information about 
the reported unsolicited AEs will be collec ted b y the qualified site personnel during the 
interview and will be documented in the subject‚Äôs records.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b88 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 89Unsolicited AEs that are not medically  attended nor perceived as a concern by  subjects
will be collected during interview with the subjects and by  review of available me dical 
records at the next visit.
Unsolicited AEs will be collected until 28 day s after each vaccination and until 28 day s 
after challenge .
9.1.5. Clinical laboratory  parameters and other abnormal assessments 
qualify ing as adverse events or seri ous adverse events
In absence of diagnosis, abnormal laboratory  findings (e.g., clinical chemistry , 
hematology , urinaly sis) or other abnormal assessments that are judged by the investigator 
to be clinically  significant will be recorded as AE or SAE if they meet the definition of an 
AE or SAE (refer to Sections 9.1.1 and 9.1.2). Clinically  significant abnormal laboratory  
findings or other abnormal assessments that are present at baseline and significantly  
worsen following the start of the study  will a lso be reported as AEs or SAEs.
The investigat or will exercise his or her medical and scientific judgment in deciding 
whether an abnormal laboratory finding or other abnormal assessment is clinically  
significant. Clinicall y significant modifications in hematology will be assessed by  
medical judgment b ased on interpretation of deviations from institution‚Äôs normal values 
and recommendations from CBER FDA GUIDANCE FOR INDUSTRY: Toxicity  
Grading Scale for Healthy Adults and Adolescent Volunteers Enrolled in Preventive 
Vaccine Clinical Trials and predefined list of sign and sy mptoms related to neutropenia.
9.1.6. Adverse events of special interest
Adverse eve nts of special interest (AESIs) are predefined (serious or non -serious) AEs of 
scientific and medical concern specific to the product or program, for which ongoing 
monitoring and rapid communication by  the investigator to t
he sponsor can be 
appropriate, because s uch an event might warrant further investigation in order to 
characterize and understand it.
During the two Phase I studies with the study vaccine, n o SAE were reported. Two 
subjects of African descent experienced a transient and clinically  asymptomatic Grade 3 
neutropenia (the two episodes were graded as SAEs ) that was finall y classified as 
‚Äúbenign ethnic neutropenia ‚Äù. In addition to these two Grade 3 cases (one in each stud y), a 
total of 6 cases of transient and clinically  asymptomatic Grade 2 neutropenia ( onecase in 
H03_01TP and 5 cases in H03_02TP) has been reported. GVGH has defined neutropenia 
as AESI. In the phase 2 study  in endemic population, 
there have been 10 cases of 
neutropenia from 6 subjects of which one was severe, three moderate and 6 mild. All of 
these events were clinically  asymptomatic.
During the course of this study , symptomatic neutropenia will be considered as AESI s.
Table 17 List of potential A ESI to be followed during the study
Blood disorders
Symptomatic neutropenia (all Grades)
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b89 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 90Neutropenia is defined as a decrease of neutrophil count asy mptomatically  or 
symptomaticall y. This is completely diagnosed b ylaboratory  testing for complete blood 
count. However , only symptomatic neutropenia cases will be considered as AESI  and 
reported as such.
The following grading will be used to classify  neutropenia :
ÔÇ∑Grade 1: 1800 -1500 cells/ ¬µL.
ÔÇ∑Grade 2: 1499- 1000 cells/ ¬µL.
ÔÇ∑Grade 3: 999- 500 cells/ ¬µL.
ÔÇ∑Grade 4: < 500 cells/ ¬µL.
In performing their assessment of sy mptomatic neutropenia cases, investigators are 
strongl y advised to use the table below.
Table 18 Evaluation of sy mptomatic neutropenia
Comm on presenting symptoms of neutropeniaPhysical findings on examination of a patient with 
neutropenia
Low-grade fever Fever
Sore mouth Stomatitis
Odynophagia Periodontal infection
Gingival pain and swelling Cervical lymphadenopathy
Skin abscessesSkin infection: The skin examination focuses on rashes, 
ulcers, or abscesses
Recurrent sinusitis and otitis Splenomegaly
Symptoms of pneumonia ( e.g., cough, dyspnea ) Associated petechial bleeding
Perirectal pain and irritation Perirectal infection
Neutropenic sepsis Other according to Investigator‚Äôs opinion
Neutropenic infection
Neutropenic colitis
Other according to Investigator‚Äôs opinion
In order to facilitate the documentation of AESI in the eCRF, a list of MedDRA preferred 
terms (PTs) andPT codes corresponding to the above diagnoses will be available to 
investigators at stud y start.
When there is enough evidence to make any of the above diagnoses, the AE must be 
reported as AESI. Sy mptoms, signs or conditions which might (or might not) re present 
the above diagnoses, should be recorded and reported as AEs but not as AESI  until the 
final or definitive diagnosis has been determined, and alternative diagnoses have been 
eliminated or shown to be less likely .
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b90 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 919.2. Events or outcomes not qualify ing as adverse events or 
serious adverse events
9.2.1. Pregnancy
Female subjects who become pregnant before the 2ndvaccination and before the 
challenge must not receive additional doses of study  vaccine/placebo, nor the challenge 
agent, but may  continue other study  procedures at the discretion of the investigator.
While pregnancy  itself is not considered an AE or SAE, any  adverse pregnancy  outcome 
or complication or elective termination of a pregnancy  for medical reasons will be 
recorded and reported as an AE or a SAE.
Note: The pregnancy  itself should alway s be recorded on an electronic pregnancy  report.
The following should alway s be considered as SAE and will be reported as described in 
Sections 
9.4.1 and 9.4.3:
ÔÇ∑Spontaneous pregnancy  loss, including:
ÔÄ≠Spontaneous abortion, (spontaneous pregnancy  loss before/at 22 weeks of 
gestation)
ÔÄ≠Ectopic and molar pregnancy
ÔÄ≠Stillbirth (intrauterine death of fetus after 22 weeks of gestation).
Note: the 22 weeks cut -off in gestational age is based on WHO -ICD 10 noted in the 
EMA Guideline on pregnancy  exposure [ EMA , 2006 ].It is recognized that national 
regulations might be different.
ÔÇ∑Any early neonatal death (i.e. death of a live born infant occurring within the first 7 
days of life). 
ÔÇ∑Any congenital anomal y or birth defect (as per [ CDC MACDP ] guidelines) 
identified in the offspring of a study  subject (either during pregnancy , at birth or 
later) regardless of whether the fetus is delivered dead or alive. This includes 
anomalies ide ntified b y prenatal ultrasound, amniocentesis or examination of the 
products of conception after elective or spontaneous abortion.
Furthermore, an y SAE occurring as a result of a post -study  pregnancy  AND considered 
by the investigator to be reasonabl y rela ted to the study vaccine/placebo or challenge 
agent will be reported to GSK Biologicals as described in Section 9.4.3. While the 
investigator is no t obligated to activel y seek this information from former study  
participants, he/she may  learn of a pregnancy  through spontaneous reporting.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b91 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 929.3. Detecting and recording adverse events, serious adverse 
events and pregnancies
9.3.1. Time period for detecting and recording adverse events, serious 
adverse events and pregnancies
All AEs starting within 28days following administration of each dose of study  
vaccine/ placebo (day of vaccine/p lacebo administration to 28 day s after administration )
and c hallenge agent administration must be recorded into the appropriate section of the 
eCRF, irrespective of intensity  or whether or not they  are considered vaccination -related.
The time period for collecting and recording SAEs will begin at the first receipt of study  
vaccine/placebo and will end at the conclusion of the study  for each subject. See Section 
9.4for instructions on reporting of SAEs.
In add ition to the above -mentioned reporting requirements and in order to fulfil 
international reporting obligations, SAEs that are related to study  participation (i.e. 
protocol -mandated procedures, invasive tests, a change from existing therapy ) or are 
related to a concurrent GSK medication/vaccine will be collected and recorded from the 
time the subject consents to participate in the study until she/he is discharged from the 
study .
The time period for collecting and recording pregnancies will begin at the first receipt of 
study  vaccine/placebo and will end at the conclusion of the study . See Section 9.4for 
instructions on reporting of pregnancies.
The time period for collecting and recording of AESI s will begin at the first receipt of 
study  vaccine/placebo and will end at the conclusion of the study . See Section 9.4for 
instructions on reporting of AESI s.
An overview of the protocol -required reporting periods for AEs, SAEs, and pregnan cies 
is given in Table 19.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b92 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL -2019 93Table 19 Reporting periods for collecting safety  information
Timepoints Scr D1 D8 D29 D36 D57 D57-D64 D85 D237(M8)
Solicited local and systemic AEs
Unsolicited AEs
AEs/SAEs leading to withdrawal from the 
study
AESI
SAEs
Pregnancies
SAEs related to study participation or 
concurrent GSK medication/vaccine
Scr: Screening
D: Day
M: Month
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b93 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 949.3.2. Post -study adverse events and serious adverse events
A post -study  AE/SAE is defined as any  event that occurs outside of the AE/SAE 
reporting period defined in Table 19. Investigators are not obligated to actively seek AEs 
or SAEs in former stud y participants. However, if the investigator learns of any SAE at 
any time after a subject has been discharged from the study , and he/she considers the 
event reasonabl y related to t he study vaccine/placebo or challenge agent , the investigator 
will promptly  notify  the Study  Contact for Reporting SAEs.
9.3.3. Evaluation of adverse events and serious adverse events
9.3.3.1. Active questioning to detect adverse events and serious adverse 
events
As a con sistent method of collecting AEs, the subject should be asked a non -leading 
question such as:
‚ÄòHave you felt different in any way since receiving the vaccine/placebo or since the 
previous visit? ‚Äô
When an AE/SAE occurs, it is the responsibility  of the inves tigator to review all 
documentation (e.g. hospital progress notes, laboratory  and diagnostics reports) relative 
to the event. The investigator will then record all relevant information regarding an 
AE/SAE in the eCRF. T he investigator is not allowed to send photocopies of the 
subject‚Äôs medical records to GSK Biologicals instead of appropriatel y completing the
eCRF . However, there may  be instances when copies of medical records for certain cases 
are requested b y GSK Biologicals. In this instance, all subject identifiers will be blinded 
on the copies of the medical records prior to submission to GSK Biologicals.
The investigator will attempt to establish a diagnosis pertaining to the event based on 
signs, s ymptoms, and/or other clinical information. I n such ca ses, the diagnosis should be 
documented as the AE/SAE and not the individual signs/sy mptoms.
9.3.3.2. Assessment of adverse events
9.3.3.2.1. Assessment of intensity
The intensity  of the following solicited AEs will be assessed as described:
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b94 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 95Table 20 Intensity  scales for solicited sy mptoms
Adverse EventIntensity 
gradeParameter
After vaccine/placebo administration
Pain at injection site 0 Absent
1 Easily tolerated
2 Interferes with normal activity
3 Prevents normal activity
Erythema at injection site Record greatest surface diameter in mm
Induration at injection site Record greatest surface diameter in mm
Fever#* Record temperature in ¬∞C/¬∞F
Headache# 0 Absent 
1 Easily tolerated
2 Interferes with normal activity
3 Prevents normal activity
Fatigue# 0 Absent 
1 Easily tolerated
2 Interferes with normal activity
3 Prevents normal activity
Arthralgia# 0 Absent 
1 Easily tolerated
2 Interferes with normal activity
3 Prevents normal activity
Malaise# 0 Absent 
1 Easily tolerated
2 Interferes with normal activity
3 Prevents normal activity
Myalgia# 0 Absent 
1 Easily tolerated
2 Interferes with normal activity
3 Prevents normal activity
Chills 0 Absent 
1 Easily tolerated
2 Interferes with normal activity
3 Prevents normal activity
After challenge agent administration
Nausea 0 Absent 
1 Mild or transient; maintains reasonable intake
2 Moderate discomfort; intake decreased significantly; some activity limited
3 No significant intake and requires medical intervention
4 Hospitalization required
Abdominal cramping 0 Absent 
1 No interference with daily activities
2 Some interference with daily activities not requiring medical intervention
3 Prevents daily activities and requires medical intervention
4 ER visit or hospitalization
Abdominal pain 0 Absent
1 Easily tolerated
2 Interferes with normal activity
3 Prevents normal activity
Gas 0 Absent
1 Easily tolerated
2 Interferes with normal activity
3 Prevents normal activity
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b95 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 96Adverse EventIntensity 
gradeParameter
Anorexia 0 Absent
1 Easily tolerated
2 Interferes with normal activity
3 Prevents normal activity
Vomiting 0 Absent 
1 One episode within a 24 -hour period Vomiting
2 2 episodes within a 24 -hour period
3 >2 episodes within a 24 -hour period and requires medical intervention
4 ER visit or hospitalization for hypotensive shock
Diarrhea** 0 Absent 
12-3 Grade 3 -5 stools (loose or watery) or <400 g/Grade 3 -5 (loose or watery) 
stools per 24 hours
24-5 Grade 3 -5 stools (loose or watery) or 400 -800 g/ (loose or watery) Grade 3 -5 
stools per 24 hours
36 or more Grade 3 -5 stools (loose or watery) or >800 g/Grade 3 -5 (loose or 
watery) stools per 24 hours or requires medical intervention
4ÔÇ≥10 loose stools (Grade 3 to 5) or ÔÇ≥1000 grams of Grade 3 to 5 stools within 
24 hours
#Same grading is used for events present both post -vaccination and post -challenge.
*Fever is defined as temperature ÔÇ≥38.0¬∞C / 100.4¬∞F. The preferred location for measuring temperature in this study 
will be the oral cavity.
**The end of a diarrheal episode occurs when a volunteer does not pass any Grade 3 -5 stool within 24 hours.
ER: emergency room .
The maximum intensity of local injection -site erythema /induration/fever will be scored at 
GSK Biologicals as follows:
Erythema/Induration
0: < 25 mm
1: ÔÇ≥25 -ÔÇ£50 mm
2: > 50 -ÔÇ£100 mm
3: > 100 mm
Fever
Grade 0
AbsentGrade 1
MildGrade 2
ModerateGrade 3
Severe
ÔÇ£37.9¬∞C ÔÇ≥38.0¬∞C ‚Äì 38.9¬∞C ÔÇ≥39.0¬∞C ‚Äì 39.9¬∞C ÔÇ≥40.0¬∞C
The investigator will assess the maximum intensity that occurred over the duration of the 
event for all unsolicited AEs (including SAEs) recorded during the stud y. The assessment 
will be based on the in vestigator‚Äôs clinical judgment.
Every  effort should be made by  the investigator to evaluate safet y information reported 
by a subject for an underly ing diagnosis and to capture this diagnosis as the event in the 
AE page. In other words, the practice of reporting only  symptoms (e.g., ‚Äúcough‚Äù or ‚Äúear 
pain‚Äù) are better reported according to the underl ying cause (e.g., ‚Äúasthma exacerbation‚Äù 
or ‚Äúotitis media‚Äù).
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b96 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 97The severit y of events reported on the Adverse Events eCRF will be determined by  the 
investigator a s:
Mild: Transient with no limitation in normal daily  activity
Moderate: Some limitation in normal daily  activity
Severe: Unable to perform normal daily  activity
9.3.3.2.2. Assessment of causality
Alternative plausible causes, such as natural history of the underl ying diseases, 
concomitant therap y, other risk factors, and the temporal relationship of the event to the 
study  vaccine/placebo or challenge agent will be considered and investigated. The 
invest igator will also consult the IB to determine his/her assessment.
There may  be situations when a SAE has occurred, and the investigator has minimal 
information to include in the initial report to GSK Biologicals. However, it is very  
important that the investigator always makes an assessment of causality  for every  event 
prior to submission of the Expedited Adverse Events Report to GSK Biologicals. The 
investigator may  change his/her opinion of causality  in light of follow -up information and 
update the SA E information accordingl y. The causality assessment is one of the criteria 
used when determining regulatory  reporting requirements.
All solicited reactions will be considered causall y related to vaccination or challenge. 
Causality  of all other AEs should be assessed b y the investigator using the following 
question:
Is there a reasonable possibility that the AE may have been caused by the study
vaccine/placebo or challenge agent ?
YES: There is a reasonable possibility  that the study  vaccine/placebo or challenge 
agent contributed to the AE. 
NO: There is no reasonable possibility that the AE is causally  related to the 
administration of the study  vaccine/placebo or challenge agent. There are 
other, more likel y causes and administration of the study vaccine/placebo or 
challenge agent is not suspected to have contributed to the AE.
If an event meets the criteria to be determined as ‚Äòserious‚Äô (see Section 9.1.2 ), additional 
examinations/tests will be performed b y the investigator in order to determine ALL 
possible contributing factors for each SAE.
Possible contributing factors include:
ÔÇ∑Medical history .
ÔÇ∑Other medication.
ÔÇ∑Protocol -required procedure.
ÔÇ∑Other procedure not required by  the protocol.
ÔÇ∑Lack of efficacy  of the vaccine , if applicable.
ÔÇ∑Erroneous administration.
ÔÇ∑Other cause (specify ).
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b97 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 989.3.3.3. Assessment of outcomes
The investigator will as sess the outcome of all unsolicited AEs (including SAEs) 
recorded during the study  as:
ÔÇ∑Recovered/resolved.
ÔÇ∑Recovering/resolving.
ÔÇ∑Not recovered/not resolved.
ÔÇ∑Recovered with sequelae/resolved with sequelae.
ÔÇ∑Fatal (SAEs onl y).
9.3.3.4. Medically  attended visits
For each solicited and unsolicited sy mptom the subject experiences, the subject will be 
asked if he/she received medical attention defined as hospitalization , or an otherwise 
unscheduled visit to or from medical personnel for any  reason, including emergency  
room visits. This information will be recorded in the eCRF .
9.4. Reporting of serious adverse events, pregnancies, and 
other events
9.4.1. Prompt reporting of serious adverse events, pregnancies, and 
other events to GSK Biologicals
SAEs that occur in the time period d efined in Section 9.3will be reported promptly  to 
GSK within the timeframes described in Table 21, once the investigator determines that 
the event meets the protocol definition of a SAE. Time of onset of SAE will allow 
distinguishing whether the SAE happened before or after challenge including an y 
possible exacerbat ion of events following challenge.
Pregnancies that occur in the time period defined in Section 9.3will be reported promptly  
to GSK within the tim eframes described in Table 21, once the investigator becomes 
aware of the pregnancy . 
AESI sthat occur in the time period defined in Section 9.3will be reported promptly  to 
GSK within the timeframes described in Table 21, once the investigator determines that 
the event meets the protocol definition of a nAESI .
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b98 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL-2019 99Table 21 Timeframes for submitting serious adverse event, pregnancy and 
other events reports to GSK Biologicals
Type of EventInitial ReportsFollow-up of Relevant Information on a 
Previous Report
Timeframe Documents Timeframe Documents
SAEs 24 hours*‚Ä°electronic Expedited 
Adverse Events Report24 hours*electronic Expedited Adverse 
Events Report
Pregnancies 2 weeks* electronic pregnancy report 2 weeks* electronic pregnancy report
AESIs 24 hours**‚Ä°electronic Expedited 
Adverse Events Report24 hours*electronic Expedited Adverse 
Events Report
*Timeframe allowed after receipt or awareness of the information.**Timeframe allowed once the investigator determines that the event meets the protocol definition of a AESI.
‚Ä° The investigator will be required to confirm review of the SAE/AESI causality by ticking the ‚Äòreviewed‚Äô box in the 
electronic Expedited Adverse Events Report within 72 hours of submission of the SAE/AESI.
9.4.2. Contact information for reporting serious adverse events,
pregnancies and AESIs
Study Contact for Reporting SAEs, AESIs and pregnancies 
Refer to the local study contact information document.
Back-up Study Contact for Reporting SAEs, AESIs and pregnancies 
24/24 hour and 7/7 day availability:
GSK Biologicals Clinical Safety & Pharmacovigilance
US sites only:
Email address: Fax: 
9.4.3. Completion and transmission of SAE reports to GSK Biologicals
Once an investigator becomes aware that a SAE has occurred in a study subject, the 
investigator (or designate) must complete the information in the electronic Expedited Adverse Events Report WITHIN 24 HOURS. The report will always be completed as thoroughly as possible with all available details of the event. Even if the investigator does not have all information regarding a SAE, the report should still be completed within 24 hours. Once additional relevant information is received, the report should be updated WITHIN 24 HOURS.
The investigator will always provide an assessment of causality at the time of the initial 
report. The investigator will be required to confirm the review of the SAE causality by ticking the ‚Äòreviewed‚Äô box in the electronic Expedited Adverse Events Report within 72 hours of submission of the SAE.
9.4.3.1. Back-up system in case the electronic reporting system does not work
If the electronic reporting system does not work, the investigator (or designate) must complete, then date and sign a paper Expedited Adverse Events Report and fax it to the 

CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b99 23-JUL-2019PPD
PPD_5HGDFWHG3URWRFRO$PHQGPHQW$SU_70) _
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 100Study  Contact for Reporting SAEs (refer to the Sponsor Information) or to GSK 
Biologicals Clinical Safety  and Pharmacovigilance department within 24 hours.
This back-up s ystem should only  be used if the electronic reporting s ystem is not working 
and NOT if the s ystem is slow. As soon as the electronic reporting s ystem is working 
again, the investigator (or designate) must complete the electronic Expedited Adverse 
Events Report within 24 hours. The final valid information for regulatory  reporting will 
be the information reported through the e lectronic SAE reporting sy stem.
9.4.4. Completion and transmission of pregnancy  reports to GSK 
Biologicals
Once the investigator becomes aware that a subject is pregnant, the investigator (or 
designate) must complete the requ ired information onto the electronic pregnancy  report 
WITHIN 2 WEEKS.
Note: Conventionally , the estimated gestational age (EGA) of a pregnancy is dated from 
the first day  of the last menstrual period (LMP) of the cy cle in which a woman conceives. 
If the LM P is uncertain or unknown, dating of EGA and the estimated date of delivery  
(EDD) should be estimated by  ultrasound examination and recorded in the pregnancy  
report.
9.4.5. Reporting of AESIsto GSK Biologicals
Once a nAESI is diagnosed (serious or non -serious) i n a study  subject, the investigator 
(or designate) must complete the information in the electronic Expedited Adverse Events 
Report WITHIN 24 HOURS after he/she becomes aware of the diagnosis. The report 
allows to specify  that the event is a nAESI and wheth er it is serious or n on-serious. The 
report will alway s be completed as thoroughly  as possible with all available details of the 
event . Even if the investigator does not have all information regarding a nAESI , the 
report should still be completed within 24 hours. Once additional relevant information is 
received, the report should be updated WITHIN 24 HOURS.
The investigator will alway s provide an assessment of causalit y at the time of the initial 
report. The investigator will be required to confirm the review of the 
AESI causalit y by 
ticking the ‚Äòreviewed‚Äô box in the electronic Expedited Adverse Events Report within 
72 hours of submission of the AESI .
Refer to Section 9.4.3.1 for back-
up system in case the electronic reporting sy stem does 
not work.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b100 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 1019.4.6. Updating of SA E, pregnancy , and AESI information after removal 
of write access to the subject‚Äôs eCRF
When additional SAE, pregnancy , or AESI information is r eceived after removal of the 
write access to the subject‚Äôs eCRF, new or updated inf ormation should be recorded on the 
appropriate paper report , with all changes signed and dated by  the investigator. The 
updated report should be faxed to the Study  Contact for Reporting SAEs (refer to the 
Sponsor I nformation ) or to GSK Biologicals Clinical Safet y and Pharmacovigilance 
department wi thin the designated reporting time frames specified in Table 21.
9.4.7. Regulatory  reporting requirements for serious adverse events
The investigator will promptly  report all SAEs to GSK in accordance with the procedures 
detailed in Section 9.4.1. GSK Biologicals has a legal responsibility  to promptly  notify , 
as appropriate, both the local regulatory  authorit y and other regulatory  agencies about the 
safet y of a product under clinical investigation. Prompt notification of SAEs by  the 
investigator to the Stud y Contact for Report ing SAEs is essential so that legal obligations 
and ethical responsibilities towards the safet y of other subjects are met.
Investigator safety  reports are prepared according to the current GSK policy  and are 
forwarded to investigators as necessary . An investigator safet y report is prepared for a 
SAE(s) that is both attributable to the study vaccine/placebo or challenge agent and 
unexpected. The purpose of the report is to fulfil specific regulatory  and GCP 
requirements, regarding the product under investiga tion.
9.5. Follow -up of adverse events, serious adverse events, and 
pregnancies
9.5.1. Follow -up of adverse events and serious adverse events
9.5.1.1. Follo w
-up during the study
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
subject and provide additional relevant information on the subject‚Äôs condition to GSK 
Biologicals (within 24 hours for SAEs; refer to Table 21).
All SAEs and AESI s (serious or non- serious) documented at a previous visit/contact and 
designated as not recovered/not resolved or recovering/resolving will be reviewed at 
subsequent visits/contacts until the last visit of the subject
.
All AEs documented at a previous visit/contact and desi gnated as not recovered/not 
resolved or recovering/resolving will be reviewed at subsequent visits/contacts until 30 
days after the last vaccination .
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b101 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 1029.5.1.2. Follo w-up after the subject is discharged from the study
The investigator will follow subjects:
ÔÇ∑With SAEs, AESI s (serious or non- serious), or subjects withdrawn from the study  as 
a result of an AE, until the event has resolved, subsided, stabilized , disappeared, or 
until the event is otherwise explained, or the subject is lost to follow-up.
ÔÇ∑With other non- serious neutropenia cases, until the event is otherwise explained or 
they are lost to follow -up.
If the investigator receives additional relevant information on a previousl y reported SAE, 
he/she will provide this information to GSK Biologicals u sing a paper/ electronic 
Expedited Adverse Events Report and/or pregnancy  report as applicable.
GSK Biologicals may  request that the investigator performs or arranges the conduct of 
additional clinical examinations/tests and/or evaluations to elucidate as f ully as possible 
the nature and/or causality of the AE or SAE. The investigator is obliged to assist. I f a 
subject dies during participation in the study  or during a recognized follow -up period, 
GSK Biologicals will be provided with an y available post -mortem findings, including 
histopathology .
9.5.2. Follow -up of pregnancies
Pregnant subjects will be followed to determine the outcome of the pregnancy . At the end 
of the pregnancy , whether full -term or premature, information on the status of the mother 
and child wil l be forwarded to GSK Biologicals using the electronic pregnancy  report and 
the Expedited Adverse Events Report if applicable. Generall y, the follow -up period 
doesn‚Äôt need to be longer than six to eight weeks after the estimated date of delivery .
Regardles s of the reporting period for SAEs for this study , if the pregnancy outcome is a 
SAE, it should alway s be reported as SAE.
9.6. Treatment of adverse events
Treatment of an y AE is at the sole discretion of the investigator and according to current 
good medical p ractice. A ny medication admi nistered for the treatment of a SAE /AESI s 
should be recorded in Expedited Adverse Event Report of the subject‚Äôs eCRF (refer to 
Section 7.6).
9.7. Unblinding
GSK Biologicals‚Äô policy  (which incorporates ICH E2A guidance, EU Clinical Trial 
Directive and US Federal Regulations) is to unblind the report of an y SAE which is 
unexpected and at tributable/suspected to be attributable to the study  vaccine/p lacebo or 
challenge agent , prior to regulatory  reporting. The GSK Biologicals‚Äô Central Safet y 
Physician is responsible for unblinding the treatment assignment in accordance with the 
specified ti meframes for expedited reporting of SAEs (refer to Section 9.4.1 ).
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b102 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL-2019 1039.8. Emergency unblinding
Unblinding of a subject‚Äôs individual treatment code should occur only in the case of a 
medical emergency, or in the event of a serious medical condition, when knowledge of the treatment is essential for the clinical management or welfare of the subject, as judged by the investigator.
The emergency unblinding process consists of an automated system SBIR that allows the 
investigator to have unrestricted, immediate and direct access to the subject‚Äôs individual study treatment.
The investigator has the option of contacting a GSK Biologicals‚Äô On-call Central Safety 
Physician (or Backup) if he/she needs medical advice or needs the support of GSK to perform the unblinding (i.e. he/she cannot access the automated Internet-based system).
Any emergency unblinding must be fully documented by using the Emergency 
Unblinding Documentation Form, which must be appropriately completed by the investigator and sent within 24 hours to GSK Biologicals.
GSK Biologicals‚Äô Contact information for Emergency Unblinding
24/24 hour and 7/7 day availability
GSK Biologicals‚Äô Central Safety Physician:
For US/Canada only:
 (GSK Biologicals Central Safety Physician on-call)
GSK Biologicals‚Äô Central Safety Physician Back-up:
US/Canada only:
Emergency Unblinding Documentation Form transmission:
US/Canada only:
Fax: 
9.9. Subject card
Study subjects must be provided with the address and telephone number of the main contact for information about the clinical study.
The investigator (or designate) must therefore provide a ‚Äúsubject card‚Äù to each subject. In 
an emergency situation this card serves to inform the responsible attending physician that the subject is in a clinical study and that relevant information may be obtained by contacting the investigator.
Subjects must be instructed to keep subject cards in their possession at all times during 
the study duration.

CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b103 23-JUL-2019PPD
PPD
PPD_5HGDFWHG3URWRFRO$PHQGPHQW$SU_70) _
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 1049.10. Holding rule and safety  monitoring
9.10.1. Holding rule
The following holding rule has been defined for the study :
ÔÇ∑At least one subject developing a ÔÇ≥Grade 3 s ymptomatic neutropenia considered 
possibly ,probabl y or definitely  related to vaccination.
The Investigator must notify  GVGH/GSK immediately  if the holding rule is met and 
should halt any  further vaccination until further notice. Vaccination can only  be resumed 
after formal review of unblinded dat a by the IDMC and formal greenlight to proceed with 
further vaccination (please refer to the IDMC charter).
9.10.2. Safety  monitoring
The SRT will monitor the safet y of subjects throughout the stud y. The SRT will review 
blinded data, assess safety  signals and make recommendations to the IDMC and to the 
Sponsor concerning continuation, termination, or other modifications of the study  based 
on the observed adverse effects.
An IDMC will be established by  GSK Biologicals for the purpose of monitoring the 
study  and to provide independent, non -binding advice on safety  and ethics. The IDMC 
will provide recommendations about stopping, holding, continuing or modify ing the trial.
The frequency  of IDMC sessions and other operational details are described in the IDMC 
charter. In case of a serious safet y issue during the study, GSK Biologicals will inform 
the IDMC as well as fulfil its regulatory  obligation expeditiously .
10. SUBJECT COM PLETION A ND WITH DRA WAL
10.1. Subject completion
A subject who returns for the concluding visit foreseen in the protocol is considered to 
have completed the study.
10.2. Subject w ithdrawal
Withdrawals will not be replaced.
10.2.1. Subject w ithdrawal from the study
From an anal ysis perspective, a ‚Äòwithdrawal‚Äô from the study  refers to any  subject who did 
not come back for the concluding visit foreseen in the protocol.
All data collected until the date of withdrawal/last contact of the subject will be used for 
the anal ysis.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b104 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 105A subject is considered a ‚Äòwithdrawal‚Äô from the study  when no study  procedure has 
occurred, no follow -up has been performed and no further information has been collected 
for this subject from the date of withdrawal/last contact.
Investigators will make an attempt to contact those subjects who do not return for
scheduled visits or follow -up.
Information rela tive to the withdrawal will be documented in the eCRF. The investigator 
will document whether the decision to withdraw a subject from the stud y was made b y 
the subject himself/herself, or b y the investigator, as well as which of the following 
possible reas ons was responsible for withdrawal:
ÔÇ∑Serious adverse event.
ÔÇ∑Unsolicited non- serious adverse event.
ÔÇ∑Solicited adverse event
.
ÔÇ∑Protocol violation (specify ).
ÔÇ∑Consent withdrawal, not due to an adverse event*.
ÔÇ∑Moved from the stud y area.
ÔÇ∑Lost to follow -up.
ÔÇ∑Other (specify ).
*In case a subject is withdrawn from the study  because he/she has withdrawn consent, the 
investigator will document the reason for withdrawal of consent, if specified by  the 
subject, in the eCRF .
Subjects who are withdrawn from the study  because of SAEs/AEs must be clearl y 
distinguished from subjects who are withdrawn for other reasons. Investigators will 
follow subjects who are withdrawn from the study  as result of a SAE/AE until resolution 
of the event (see Section 9.5.1.2
).
10.2.2. Subject w ithdrawal from study vaccine/placebo or challenge 
agent
A ‚Äòwithdrawal‚Äô from the study vaccine/placebo or challenge agent refers to any  subject 
who does not re ceive the complete treatment, i.e. when no further planned dose or 
challenge is administered from the date of withdrawal. A subject withdrawn from the 
study vaccine/placebo or challenge agent may not necessarily  be withdrawn from the 
study  as further study procedures or follow
-up may  be performed (safet y or 
immunogenicit y) if planned in the study  protocol.
Information relative to premature discontinuation of the study vaccine/placebo or 
challenge agent will be documented on the Vaccine Administration page/s creen of the 
eCRF. The investigator will document whether the decision to discontinue further 
vaccination/ challenge administration was made by the subject himself/herself , or b ythe 
investigator, as well as which of the following possible reasons was respo nsible for 
withdrawal:
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b105 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 106ÔÇ∑Serious adverse event.
ÔÇ∑Unsolicited non- serious adverse event.
ÔÇ∑Solicited adverse event.
ÔÇ∑Not willing to be vaccinated or to receive the challenge agent.
ÔÇ∑Other (specify ).
11. STATISTICA LMETHODS
11.1. Primary  endpoint
Efficacy
VE will be evaluated with:
ÔÇ∑Rate of shigellosis ( fulfilling the protocol primary case definition) occurring within a 
period starting with the challenge visit and lasting up to the end of the inpatient stay , 
in all subjects.
11.2. Secondary  endpoint s
Efficacy
VE, in 
subjects receiving the 1790GAHB vaccine vs. placebo, will be also measured
during inpatient stay  (Day  57 to Day  64)against:
ÔÇ∑Rate of shigellosis as defined by the CHIM working group case definition for 
shigellosis occurring within a period starting with challenge visit and lasting until the 
end of the inpatient stay , in all subjects. (Amended: 23July 2019)
ÔÇ∑Rate of shigellosis, as defined by : severe diarrhea OR moderate diarrhea with fever 
or with one or more moderate constitutional/enteric sy mptom OR d ysentery [[ ‚â•2 
loose stools with gross blood (hemoccult positive) in 24 hours] AND [ ‚â•1 reportable 
constitutional/enteric symptom]].
ÔÇ∑Rate of more severe shigellosis as defined b y: severe or moderate diarrhea with fever 
or with one or more severe constitutional/enteric sy mptom OR dy sentery  [[‚â•2 loose 
stools with gross blood (hemoccult positive) in 24 hours] AND [ oral temperature 
‚â•38.0oC OR ‚â•1 severe constitutional/enteric sy mptom]]. (Amended: 23July 2019)
ÔÇ∑Shedding of S. sonnei strain 53G.
Shedding of S. sonnei strain 53G is defined as positivity  of at least one stool sample 
either b y culture or qPCR or both.
ÔÇ∑Severe diarrhea .
ÔÇ∑More severe diarrhea .
ÔÇ∑Dysentery .
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b106 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 107ÔÇ∑Weight of all grade 3 -5 stools .
ÔÇ∑Total n umber of all grade 3-
5 stools.
ÔÇ∑Confirmed S. sonnei 53G shedding AND moderate or severe diarrhea OR dy sentery  
ORpresence of oral temperature ÔÇ≥38.5¬∞C OR presence of one or more severe 
intestinal sy mptoms (abdominal pain, cramping, nausea, vomiting , gas, anorexia ).
ÔÇ∑Disease not fulfilling the protocol primary  case definition for shigellosis associated 
or not with mild to moderate s ymptoms including: passing loose stool (not meeting 
the protocol definition of moderate or severe diarrhea), abdominal pain, abdominal 
cramps, gas , anorexia, nausea, headache, my algia, malaise, arthralgia, fever ,
vomiting and IV fluid administration .
ÔÇ∑Time to onset of shigellosis after challenge, according to the protocol primary  case 
definition.
Safety
Solicited adverse events
ÔÇ∑Occurrence of eac h solicited local and s ystemic adverse event within 7 day s after 
each vaccination.
Unsolicited adverse events
ÔÇ∑Occurrence of unsolicited AEs within 28 day s after vaccination and after challenge , 
according to Medical Dictionary  for Regulatory  Activities (MedDRA) classification.
Serious adverse events
ÔÇ∑Occurrence of all SAEs and related SAEs from Day  1 to study  end.
Adverse events of special interest
ÔÇ∑Occurrence of AESI (i.e., sy mptomatic neutropenia) from Day  1 to study  end.
Laboratory  parameters
ÔÇ∑Out of laboratory  reference range and/or clinically significant value (according to 
local ranges) for hematology at 7 day s after first and second vaccination and at last 
study  visit (Visit 8).
Immunogenicity
The measures of immunogenicity , against the L PS of S. sonnei , will include:
ÔÇ∑IgG geometric mean concentrations (GMCs) pre -vaccination (Day  1), 7 and 28 day s 
after first and second vaccination by antibody  concentration at baseline (i.e., above 
vs. below the assay  detection limit), as determined by  anti-S. sonnei LPS IgG 
ELISA.
ÔÇ∑IgG GMC pre -challenge (Day  57), 7 and 28 day s after challenge (Day  64 and Day  
85) as determined b y anti-S. sonnei LPS IgG ELISA.
ÔÇ∑Number and percentage of subjects achieving a post vaccination anti- S. Sonnei L PS 
concentration ‚â• 121 EU/ml at 28 day s after first and second vaccination.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b107 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 108ÔÇ∑Number and percentage of seroresponders* for anti- S. sonnei LPS at 28 day s after 
first and second vaccination.
*Seroresponse is aimed to define a significant increase in anti S.sonnei LPS IgG 
concentration in post- vaccination samples and relies on the definition already  used in 
a previous phase II study in Keny an population . For the purpose of this st
udy 
serorespon se is defined as:
ÔÄ≠If the baseline value is greater than 50 EU /mL then an increase of at least 50% 
in the post -vaccination sample as compared to baseline.
ÔÄ≠If the baseline value is less or equal to 50 EU /mL then an increase of at least 
25EU/mL in the post -vaccination sample as compared to baseline.
Note: Threshold values/increases given in the definition of seroresponse might be 
subject to change during the course of the study  (e.g., in case of 
optimization /qualification/validation of the anti S. sonnei LPSIgGELISA).
11.3. Tertiary  endpoints
ÔÇ∑Specific anti -S. sonnei LPS sIgA antibod y concentration in stool samples at Day 1, 7
days after first and second vaccination and 7 day s after challenge (Day  64).
ÔÇ∑Frequency  of S. sonnei LPS specific IgG Œ±4Œ≤7+ /-antibod y secreting cells per 10^6 
PBMC plasmablast at Day  1and 7 day s after first and second vaccination and 7 day s 
after challenge (Day  8, Day  36 and Day  64). (Amended: 23July 2019)
ÔÇ∑Glycosylation profiles of IgG antibodies at Day  1 and 28 day s after second 
vaccination (Visit 5; Day 57) .
ÔÇ∑Number and percentage of subjects that show correlation between serum anti -S. 
sonnei LPS IgG concentration, SBA titer, 
shigellosis , shedding, MSD, dy sentery  and
mild diarrhea after challenge
.
ÔÇ∑Concentration of stool markers of intestinal inflammation (e.g. calprotectin and 
myeloperoxidase) before oral challenge with S. sonnei , 53G at Visit 5 (Day 57) and 
daily  during the post -challenge inpatient stay  (Day  57 to Day  64).
ÔÇ∑The number of differential expressed genes 7 days after first and second vaccination 
and 7 day s after challenge by  comparing the relative abundance of mRNA sequences 
compared to Day  1 (pre -vaccination baseline).
ÔÇ∑Diversity  and frequency  of microbiome components (taxa a nd/or genes according to 
technology ) at Day  1 prior to vaccination and 28 day s after second vaccination (Visit 
5;Day 57).
Exploratory  anal ysis for hy potheses generation will include the evaluation of the 
association of the microbiome components with efficacy  and immunogenicity  
described above.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b108 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 10911.4. Determination of sample size
Primary objective -Efficacy
In comparing the protective efficacy  of 1790GAHB vaccine against the placebo group the 
following assumptions will be made:
Assuming a true VE of 70%, a t otal number of 21 confirmed cases will be needed to 
demonstrate that the LL of the two -sided 90% CI for the VE is above 0% with 80% 
power (by Pass 2013, One Proportion Power Analysis, one -sided test, one -sided alpha =
5%).
Based on the results obtained by  the Cincinnati Children‚Äôs Hospital Medical Center , 
where the challenge model was developed, in subjects receiving a challenge with 1500 
CFU of S. sonnei 53G, the attack rate for the primary  case definition of this study  is 58%.
Thus considering an AR of 58% in the placebo group and a percentage of non -evaluable 
subjects of 22%, approximately  72 subjects (36 per group) will be recruited to reach these 
21 cases.
The assumption on the value of true VE is based on the percentage of subjects with 
seroresponse observed in previous studies where the 1.5/25 ¬µg OAg/protein dose of 
1790GAHB vaccine was evaluated. In the phase I study  in Europe, the observed 
percentage of subjects with seroresponse was 63% and 88% after 1stand 2ndvaccination 
respectivel y. In the P hase IIa stud y, conducted in endemic region, the observed 
percentage of subjects with seroresponse was 68% and 90% after 1stand 2ndvaccination ,
respectivel y.
11.5. Analysis sets
11.5.1. All Enrolled Set
All screened subjects who provide informed consent ,and provide d
emographic and/or 
baseline screening assessments, regardless of the subject‚Äôs randomization and treatment 
status in the study and received a Subject ID.
11.5.2. All Exposed Set
All subjects in the enrolled set who receive a study vaccination.
11.5.3. Safety  set
11.5.3.1. Solicited Safety Set (solicited local and sy stemic adverse events and 
other solicited adverse events)
All subjects in the Exposed Set with any solicited AE data and/or indicators of solicited 
AEs.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b109 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 11011.5.3.2. Unsolicited Safety  Set (unsolicited adverse events)
All subjects in t he Exposed Set with unsolicited AE data.
11.5.3.3. Overall safety  set
All subjects who are in the Solicited Safety  Set and/or Unsolicited Safet y Set.
Subjects will be analyzed as ‚Äútreated‚Äù (i.e., according to the vaccine *a subject received, 
rather than the vaccine *to which the subject may  have been randomized ).
*Vaccine refers to stud y vaccine or placebo.
11.5.4. Full analysis set (FAS) efficacy /Immunogenicity  set
11.5.4.1. Full analysis set efficacy  
All subjects in the All Enrolled Set who are randomized , receive a study vaccinati on and 
provide efficacy  data.
11.5.4.2. Full analysis set Immunogenicity
All subjects in the All Enrolled Set who are randomized , receive at least one study 
vaccination and provide immunogenicit y data at the relevant timepoints.
In case of vaccination error, subject
s in the FAS sets will be analyzed ‚Äúas randomized ‚Äù 
(i.e., according to the vaccine *a subject was designated to receive, which may  be 
different from the vaccine *the subject actually  received).
*Vaccine refers to stud y vaccine or placebo.
11.5.5. Per-protocol (PP) set for efficacy /Immunogenicity  set
All subjects in the FAS Efficacy  / Immunogenicity who:
ÔÇ∑Correctl y receive the vaccine * (i.e., receive the vaccine* to which the subjects is 
randomized
and at the scheduled time points).
*Vaccine refers to stud y vaccine or placebo.
ÔÇ∑Have no protocol deviations leading to exclusion as defined prior to unblinding / 
analysis.
ÔÇ∑Are not excluded due to other reasons defined prior to unblinding or analysis .
PPS are subsets of FAS and should be alway s defined even if the objectives do not 
require it.
Examples for subjects excluded due to other reasons than protocol deviations are:
ÔÇ∑Subjects who withdrew informed consent.
The primary  anal ysis will be based on the PP cohort for efficacy  and immunogenicity . 
However efficacy  and immunogenicit y anal yses will be performed on both FAS and PP 
sets.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b110 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 11111.5.6. Other analysis sets
There are no additiona l analy sis sets for anal ysis in this study .
All subjects who are screened, i.e., consented but not y et randomized/enrolled.
11.5.7. Sub-groups
The analysis for the primary  efficacy  endpoint will be repeated for the two subgroups of 
subjects who were responders or non- responders at the immunogenicit y assessment of the 
pre-challenge visit .
11.6. Derived and transformed data
ÔÇ∑Screening (anti S. sonnei LPS IgG Screening -ELISA)
ÔÄ≠The cut -off value for the anti S. sonnei LPS IgG Screening- ELISA is defined by  
the laboratory .
ÔÄ≠A seronegative subject is a subject whose titeris below the cut -off value.
ÔÄ≠A seropositive subject is a subject whose titeris greater than or equal to the cut -
off value.
ÔÇ∑Immunogenicit y (anti S. sonnei LPS IgG -ELISA) :
ÔÄ≠The cut -off value for the anti S. sonnei LPS IgG-ELISA is defined by  the 
laboratory .
Seroresponse is aimed to define a significant increase in anti S.sonnei LPSIgG 
concentration in post- vaccination samples and relies on the definition already  used in 
a previous phase II study in Keny an population . For the purpose of this study  
seroresponse is defined as:
ÔÄ≠If the baseline value is greater than 50 EU/mL  then an increase of at least 50% 
in the post -vaccination sample as compared to baseline.
ÔÄ≠If the baseline value is less or equal to 50 EU/mL  then an increase of at least 
25EU/mL  in the post -vaccination sample as compared to baseline.
Note: Threshold values/increas es given in the definition of seroresponse might be 
subject to change during the course of the study  (e.g., in case of 
optimization /qualification/validation of the anti S. sonnei LPSIgGELISA).
ÔÄ≠The GMC calculations are performed by  taking the anti -log of the mean of the 
log concentration transformations. Values to be used for the antibody  
concentrations below the assay  cut-off will be described in the S tatistical 
Analy sis Plan (SAP).
ÔÄ≠Handling of missing data: for a given subject and a given immunogenicity  
measurement, missing or non -evaluable measurements will not be replaced.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b111 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 112ÔÇ∑Reactogenicit y and safety :
ÔÄ≠Handling of missing data: subjects who missed reporting s ymptoms 
(solicited/unsolicited or concomitant medications) will be treated as subjects 
without symptoms (solicited/unsolicited or concomitant medications, 
respectivel y). In case of significant non -compliance of study  procedures for 
reporting s ymptoms, the anal ysis plan will be reassessed to ensure more accurate 
reporting of stud y data by further ana lysis.
ÔÄ≠For the anal ysis of solicited sy mptom, missing or non -evaluable measurements 
will not be replaced. Therefore, the analy sis of the solicited sy mptoms based on 
theAll Enrolled Set will include only  subjects/doses with documented safety  
data (i.e., symptom screen completed).
11.7. Analysis of demographics
Descriptive statistics (mean, standard deviation, median, minimum and maximum) for 
age, height and weight at enrolment will be calculated overall and by  vaccine /placebo 
group.
Distributions of subjects b y gender and geographic ancestry  will be summarized .
11.8. Analysis of efficacy
VE will be evaluated at the end of stud y period. VE will be estimated as 1 -RR where RR 
is the risk ratio (proportion of subjects reporting the disease in the vaccinated group over 
the proportion in the placebo group) together with 90% CI s.
11.9. Analysis of immunogenicity
Analysis of binary variables:
The number and percentages of subjects will be summarized . Two -sided 95% CI s for the 
percentages will be computed.
Antibody  titers
/concentrat ion below the limit of detection in the respective assay  will be 
set to half the limit for the purposes of anal ysis. Missing values of immunogenicity  will 
be excluded from analy ses (i.e. complete -case analy sis) since they  are considered missing 
completely  at random, i.e. not informative an d with no impact on inferences.
Analysis of continuous variables:
The antibody  concentrations/titers will be logarithmically  transformed (base10) (to fulfil 
the normal distribution assumption). GMCs will be calculated, wit h their associated two -
sided 95% CI s, by  exponentiating the corresponding log -transformed means and their 
95% CI .
Additionally , within -subject geometric mean ratios (GMRs) will be computed for 
geometric mean titers/GMCs at each time point after vaccination versus baseline (Day  1). 
The GMRs and 95% CIs will be constructed b
y exponentiating the mean within -subject 
differences in log -transformed titers and the corresponding 95% CIs.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b112 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 11311.10. Analysis of safety
The primary  anal ysis will be performed on the All Exposed Set .
Analysis of solicited local and systemic adverse events and other reactions :
Solicited AEs will be summarized according to d efined severity  grading scales.
Frequencies and percentages of subjects experiencing each AE will be presented for each 
symptom severit y. Summary tables showing the occurrence of an y local or sy stemic AE 
overall and at each time point will also be presented.
Post-vaccination /challenge solicited AE reported from Day  1 to 7 day s post-
vaccinat ion/challenge will be summarized by maximal severity  and by  vaccine /placebo
group. The severity  of solicited local AE will be summarized according to categories 
based on linear measurement.
Injection -site pain and s ystemic reactions occurring up to 7 days after each vaccination 
will be summarized according to ‚Äú mild‚Äù, ‚Äúmoderate‚Äù or ‚Äúsevere‚Äù.
Each solicited local and systemic AE will also be further summarized as ‚Äúnone‚Äù versus 
‚Äúany‚Äù.
Analysis of unsolicited AEs :
All the AEs occurring during the stud y, judged either as probabl y related, possibly  
related, or not related to vaccination /challenge by the investigator, will be recorded.
The original verbatim terms used by  investigators to identify  AEs in the eCRFs will be 
mapped to preferred terms using the MedDRA d ictionary . The AEs will then be grouped 
by MedDRA preferred terms into frequency  tables according to s ystem organ class. All 
reported AEs, as well as AEs judged by the investigator as at least possibly related to 
study  vaccine/placebo or challenge agent, w ill be summarized according to sy stem organ 
class and preferred term within sy stem organ class. These summaries will be presented by  
vaccination group. When an AE occurs more than once for a subject, the maximal 
severit y and strongest relationship to the v accine /placebo group will be counted.
Separate summaries will be produced for the following categories:
ÔÇ∑SAEs .
ÔÇ∑AEs that are possibl y or probably related to vaccine/placebo or challenge agent .
ÔÇ∑AEs leading to withdrawal from the study .
Data listings of all AE s will be provided by  subject. I n addition, AEs in the categories 
above will be provided as listed data.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b113 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 11411.11. Interpretation of analy ses
Except for anal yses on objectives with a pre defined success criterion and an appropr iate 
type I error control (see S ection 2), comparative analy ses will be descriptive with the aim 
to characterize the difference in reactogenicity  and immunogenicit y efficacy between 
groups. These descriptive anal yses should not be i nterpreted.
11.12. Conduct of analy ses
Any deviation(s) or change(s) from the original statistical plan outlined in this protocol 
will be described and justified in the final study  report.
11.12.1. Sequence of analy ses
The total of 72 subjects will be divided in 4 cohorts of 18 subjects each (for bed 
availability  at the stud y site). The vaccination and challenge will be done per cohort.
However, if for an y reason, a cohort does not reach the planned 18 subjects, additional 
subjects can be added in the next cohorts. The maximum number of subjects must not be 
more than 20 (maximum number of beds in the clinic) in each cohort.
The following 2 interim analyses are planned:
1.After completion of the 
Visit 5 (Day 64):post-challenge efficacy data of all 
subjects (all 4 cohorts) 
2.After Visit 6 (Day 85): secondary immunogenicity data and tertiary SBA 
immunogenicity data of all subjects (all 4 cohorts).
(Amended: 23July 2019)
All analy ses will be conducted before unblinding on clean and final data. (Amended: 23 
July 2019)
An integrated Clinical Study 
Report containing all data will be written after the End of 
Study and made available to the investigators. (Amended: 23 July 2019)
If the data for tertiary  endpoints become available at a later s tage, (an) additional 
analysis/analyses will be performed. These data will be documented in annex(es) to the 
study  report and will be made available to the investigators at that time.
11.12.2. Statistical considerations for interim analyses
No statistical adjustment will be made for the interim analy ses, which are intended to 
provide final outputs related to the different endpoints and timepoints in a phased 
manner.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b114 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 11512. ADM INISTRA TIVE MATTERS
To comply  with ICH GCP administrative obligations relating to data collection, 
monitoring, archiving data, au dits, confidentiality ,public disclosure requirements and 
publications must be fulfilled.
12.1. Electronic case report form instructions
A validated GSK defined electronic data collection tool will be used as the method for 
data colle ction.
In all cases, subject initials will not be collected nor transmitted to GSK. Subject data 
necessary  for anal ysis and reporting will be entered/transmitted into a validated database 
or data s ystem. Clinical data management will be performed in accordance with 
applicable GSK sta ndards and data cleaning procedures.
While completed eCRFs are reviewed b y a GSK Biologicals‚Äô Site Monitor at the study 
site, omissions or inconsistencies detected b y subsequent eCRF review may necessitate 
clarification or correction by  the investigator or appropriatel y qualified designee. In all 
cases, the investigator remains accountable for the study  data. 
The investigator will be provided with a n electronic format in read only  mode of the final 
version of the data generated at the investigational site once the database is archived and 
the study  report is complete and approved b y all parties.
12.2. Subject Diary
Paper Diaries (pDiaries), hereafter referred to as Subject Diaries will be the only source 
document allowed for solicited local and s ystemic adverse events (including body  
temperature measurements), starting after the initial 30 minute post -vaccination period at 
the clinic. The following additional rules appl y to documentation of sa fety information 
collected in the Subject Diary .
The Investigator or delegated staff should monitor the Subject‚Äôs Diary  status throughout 
the study  for compliance and an y solicited local and systemic adverse events that were of 
concern to the subject.
ÔÇ∑No c orrections or additions to the information recorded by  the subject within the 
Subject Diary  will be allowed after it is delivered to the site.
ÔÇ∑Any blank or illegible fields on the Subject Diary  must be described as missing in the 
eCRF.
The following additi
onal rules appl y to documentation of Subject Diary information 
collected in the eCRFs:
ÔÇ∑The site must enter all readable entries in the Subject Diary  into the eCRF, including 
those values that may  be biologicall y implausible (e.g. bod y temperature: 400¬∞C).
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b115 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 116ÔÇ∑Any illegible or implausible data should be reviewed with the Subject . If an 
underly ing solicited or unsolicited AE is described on review with the subject, this 
should be described in the source document and reported as an unsolicited AE in the 
Adverse Event e CRF (e.g., if the subject above confirms body  temperature of 40¬∞C 
on the day  in which bod y temperature: 400¬∞C was written into his/her Subject Diary , 
this fever of 40¬∞C should be recorded in the Adverse Event e CRF).
ÔÇ∑Any newl y described safety information (including a solicited AE) must not be 
written into the Subject Diary  and must be described in the study  file as a verball y 
reported AE. Any  AE reported in this fashion must be described as an unsolicited AE 
and there fore ent ered on the Adverse Event eCRF.
12.3. Stud y monitoring by  GSK biologicals
GSK will monitor the stud y to verify  that, 
among other items, the:
ÔÇ∑Data are authentic, accurate, and complete.
ÔÇ∑Safety  and rights of subjects are being protected.
ÔÇ∑Study  is conducted in accordance with the currently  approved protocol, any other 
study  agreements, GCP and all appl icable regulatory  requirements.
The investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor direct access to all re levant documents.
The investigator must ensure provision of reasonable time, space and qualified personnel 
for monitoring visits.
Direct access to all stud y-site related and source data is mandatory  for the purpose of 
monitoring review. The monitor will pe rform a neCRF review and a Source Document 
Verification (SDV). By  SDV we understand verifying 
eCRF entries b y comparing them 
with the source data that will be made available by the investigator for this purpose.
The Source Documentation Agreement Form describes the source data for the different 
data in the eCRF . This document should be completed and signed by  the site monitor and 
investigator and should be filed in the investigator‚Äôs study  file. Any data item for which 
the eCRF will serve as the source must be identified, agreed and documented in the 
source documentation agreement form. 
Upon completion or premature discontinuation of the study , the monitor will conduct site 
closure activities with the investigator
or site staff, as appropriate, in accordance with 
applicable regulations, GCP, and GSK procedures.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b116 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 11712.4. Record retention
Following closure of the study , the investigator must maintain all site study  records 
(except for those required by  local regulations to be maintained elsewhere) in a safe and 
secure location. The records must be easily  accessible, when needed (e.g. audit or 
inspection), and must be available for review in conjunction with assessment of the 
facility , supporting s ystems, and staff. Where permi tted by  applicable laws/regulations or 
institutional policy , some or all of these records can be maintained in a validated format 
other than hard copy (e.g. microfiche, scanned, electronic); however, caution needs to be 
exercised before such action is take n. The investigator must ensure that all reproductions 
are legible and are a true and accurate cop y of the original and meet accessibility  and 
retrieval standards, including re -generating a hard copy, if required. Furthermore, the 
investigator must ensure that an acceptable back -up of the reproductions exists and that 
there is an acceptable quality  control procedure in place for making these reproductions.
GSK will inform the investigator/institution of the time period for retaining these records 
to comply  with all applicable regulatory  requirements. The minimum retention time will 
meet the strictest standard applicable to a particular site, as dictated b y ICH GCP, any  
institutional requirements, applicable laws or regulations, or GSK standards/procedures , 
otherwise, the minimum retention period will default to 25 y ears after completion of the 
study  report.
The investigator/institution must notify  GSK of any  changes in the archival 
arrangements, including, but not limited to archival at an off -site facility , transfer of 
ownership of the records in the event the investigator leaves the site. 
12.5. Qualit y assurance
To ensure compliance with GCP and all applicable regulatory  requirements, GSK may  
conduct a qualit y assurance audit. Regulatory agencies may also conduct a regulatory  
inspection of this study . Such audits/inspections can occur at any  time during or after 
completion of the study. If an audit or inspection occurs, the investigator and institution 
agree to allow the auditor/inspector direct access to all rele vant documents and to allocate 
his/her time and the time of his/her staff to the auditor/inspector to discuss findings and 
any relevant issues.
12.6. Posting of information on publicly  available clinical trial 
registers and publication policy
GSK assures that th
e key design elements of this protocol will be posted on the GSK 
website and in publicly  accessible database(s) such as clinicaltrials.gov, in compliance 
with the current regulations.
GSK also assures that results of this study  will be posted on the GSK we bsite and in 
publicly  accessible regulatory  registry (ies) within the required time frame , in compliance 
with the current regulations. The minimal requirement is to have primary  endpoint 
summary  results disclosed at latest 12 months post PCD and to have seco ndary  endpoint 
disclosed at latest 12 months after the Last Subject L ast Visit as described in the protocol.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b117 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 118GSK also aims to publish the results of these studies in searchable, peer reviewed 
scientific literature and follows the guidance from the I nternational Committee of 
Medical Journal Editors.
12.7. Provision of study  results to investigators
Where required b y applicable regulatory  requirements, an investigator signatory  will be 
identified for the approval of the study  report. The investigator will be provided 
reasonable access to statistical tables, figures, and relevant reports and will have the 
opportunity  to review the complete study  results at a GSK site or other mutually -
agreeable location.
GSK Biologicals will also provide the investigator with t he full summary  of the study  
results. The investigator is encouraged to share the summary  results with the study  
subjects, as appropriate.
12.8. Data sharing
Under the framework of the SHARE initiative, results of GSK studies may  be combined 
with non- GSK studie s, to investigate further about the study  product(s) and other 
product(s), and /or the disease/condition under investigation and related diseases and 
conditions.
12.9. Pharmacogenomics
As part of the sequencin gfor the microbiome, human genome will be sequenced as 
bypass product but the intent is not to analy zethe data which will be stored securel y.
Analy ses of the transcriptomics signals evaluating the number of differential expressed 
genes b y comparing the relative abundance of mRNA sequences are also conside red a 
pharmacogenomics experiment.
By United States federal regulation, annual reports must include relevant 
pharmacogenomics results experiment. Refer to the US Guidance for industry  
‚ÄúPharmacogenomic data submissions‚Äù for more information on the process a nd format 
for submission of such data.
13. COUNTRY SPECIFIC REQUIREMEN TS
Not applicable .
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b118 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 11914. REFERENCES
Bodhidatta L, Pitisuttithum P, Chamnanchanant S, Chang K, Islam D, Bussaratid V, 
Venkatesan M, Hale T. Establishment of a S. sonnei human challenge model in Thailand. 
Vaccine. 2012 Nov; 30(49): 7040-5.
Cent ersfor Disease Control and Prevention Metropolitan Atlanta Congenital Defects 
Program (CDC MACDP) guidelines. Birth defects and genetic diseases branch 6 -digit 
code for reportable congenital anomalies; 
http://www.cdc.gov/ncbddd/birthdefects/documents/MACDPcode0807.pdf
Cohen D, Block C, Green MS, L owell G, Ofek I. Immunoglobulin M, A, and G antibody  
response to lipopoly saccharide O antigen in s ymptomatic and as ymptomatic Shigella 
infections. J Clin Microbiol . 1989 Jan; 27 (1):162
‚Äì167.
Cohen D, Green M, Block C, Slepon R, Ambar R, Wasserman SS, L evine MM. 
Reduction of transmission of shigellosis b y control of houseflies ( Musca domestica). 
Lancet . 1991 Apr 27; 337 (8748): 993-7.
EMA G uideline on the exposure to medicinal products during pregnancy : need for post
-
authorization data ( Doc. Ref. EMEA/CHMP/313666/2005 ) ‚Äòadopted at Community  level 
in May  2006);
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_g
uideline/2009/11/W C500011303.pdf
Ferreccio C, Prado V, Ojeda A, Cayy azo M, Abrego P, Guers L, Levine MM. 
Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a 
poor periurban setting in Santiago, Chile. Am J Epidemiol . 1991 Sep 15; 134 (6):614-27.
GBD 2015 Mortality  and Causes of Death Collaborators. Global, regional, and national 
life expectancy , all-cause mortality , and cause
-specific mortality  for 249 causes of death, 
1980‚Äì2015: a sy stematic anal ysis for the Global Burde n of Disease Study  20. Lancet. 
2016; 388: 1459
-544
Gerke C, Colucci AM, Giannelli C, Sanzone S, Vitali CG, Sollai L , Rossi O, Martin LB, 
Auerbach J, Di Cioccio V, Saul A. Production of a Shigella sonnei Vaccine Based on 
Generalized Modules for Membrane Antigens (GMMA), 1790GAHB. PLoS One . 2015; 
10(8): e013
4478.
Pitisuttithum P, I slam D, Chamnanchanunt S, Ruamsap N, Khantapura P, Kaewkungwal 
J, Kittitrakul C, Luvira V, Dhitavat J, Venkatesan MM, Mason CJ , Bodhidatta L . Clinical 
trial of an oral live Shigella sonnei vaccine candidate, WRSS1, in Thai adults. Clin 
Vaccine Immunol . 2016; 23: 564-575.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b119 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 120Appendix A LABORA TORY ASSAYS
Hematology , Virology , Blood chemistry , HLA -B27, anti S.sonnei LPS IgG -Screening, 
urinaly sis:
Hematology , Virology , Blood chemistry , HLA -B27, urinaly sis and antiS. sonnei LPS 
IgG Screening -ELISA will be done at the local site according to the methods available 
there. The anti S. Sonnei LPS IgG Screening -ELISA will be done locall y for the anti -S. 
sonnei LPSIgG antibod y determination at screening.
HEMATOLOGY
White Blood Cells (WBC)
Red Blood Cells (RBC)
Hemoglobin
Hematocrit
Platelets
Eosinophils
Basophils
Neutrophils
Monocytes
Lymphocytes
CLINICAL CHEMISTRY
Total bilirubin
Aspartic Aminotransferase (ASAT/GOT)
Alanine Aminotransferase (ALAT/GPT)
Œ≥-Glutamyl Transferase ( Œ≥-GT)
Lactic Dehydrogenase (LDH)
Alkaline Phosphatase (AP)
Total Proteins
Glucose (random glucose)
Blood Urea Nitrogen (BUN)
Creatinine
Sodium
Potassium
Prothrombin time (only at screening)
SEROLOGY for VIROLOGY
HBsAg
HCV antibodies
HIV antibodies
PREGNANCY TEST
Human chorionic gonadotropin (hCG) in urine
HLA-B27
HLA-B27
URINE DIPSTICK
Glucose
Proteins
pH
Ketones
Nitrites
Blood
URINALYSIS: Microscopic test on urine
(performed if urine dipstick shows deviations from normal values)
Leucocytes (WBC)
Erythrocytes (RBC)
Epithelial Cells
Casts
Bacteria
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b120 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 121Anti S. sonnei LPS antibody  determination from serum:
Anti- S. sonnei LPSIgG antibodies in serum (for all timepoints except screening) will be 
measured b y ELISA in the GVGH -Laboratories ( Siena , Italy). The ELISA is performed 
using S. sonnei LPS as coating antigen. A standard curve is run in duplicate on each 
plate. Results are expressed in ELI SA units (EU) /mL  of serum. 1 unit equals the 
reciprocal of the dilutio n to give an OD of 1.
Serum Bactericidal Activity  in serum:
Serum bactericidal activity  against S. sonnei will be measured by serum bactericidal 
assay .This assay  is currently  in development in a GVGH laboratory . 
S. sonnei determination from stool:
ÔÇ∑Culture: The presence of S. sonnei in stool samples will be assessed using a 
qualitative procedure and following the SOPs of the local or designated laboratory  
for culture, isolation and identification of S. sonnei from stool specimens.
ÔÇ∑qPCR :S. sonnei qPCR determination will be done following the SOPs of the local or 
designated laboratory  for identification of S. sonnei by a qPCR f rom stool 
specimens.
ÔÇ∑S. sonnei s IgAand total sIgAdetermination from stool :S. Sonnei ELISA will be 
performed following the SOPs of the local or designated laboratory  for ELISA assay  
from stool specimens. The S. sonnei s IgA result will be normalized to the total sIgA.
Stool inflammatory  markers assay
Inflammatory  markers including c alprotectin and my eloperoxidase levels in stools 
(ng/mL) will be measured using commerciall y available (Epitope Diagnostics, I nc.) 
quantitative ELI SA kits according to the manufacturer‚Äôs instructions.
Œ±4Œ≤7 plasmablast ELISA (Amended: 23July 2019)
Anti-S. sonnei LPS -specific IgG titers will be determined in plasmablasts, in both Œ±4Œ≤7
positive and Œ±4Œ≤7 negative populations. The titers provided will be measured by ELISA 
assay in the culture supernatant of 5x10^6 cells, by using an in -house method 
developed in WRAIR. ( Amended: 23July 2019)
Transcriptomics
The transcriptomics signals anal ysis will be performed evaluating the number of 
differential expressed genes by  comparing the relative abundance of mRNA sequences .
Gut Microbiome profile:
Gut microbiome anal ysis in stool using 16s ribosomal DNA amplicon sequencing and/or 
shotgun whole genome sequencing (refer to Section 6.7.3).
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b121 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 122Glycosylation profiles of IgG antibodies:
The activity  of IgG antibody  is mediated through two functional domains, the Fab and the 
Fc. The Fc domain mediates effector functions though specific interactions with FcŒ≥Rs 
expressed on the surface of leukocy tes, and activation of diverse immunomodulatory  
pathway s impacting both innate and adaptive immunity  [1]. The mechanisms of Fc 
domain diversification that determine Fc -FcŒ≥R interaction include IgG subclass and Fc -
associated gl ycan structure [ 2]. Distinct profiles are enriched following vaccination or 
during inflammatory  diseases or infection. Vaccination with 1790GAHB is hy pothesized 
to enrich certain IgG subclasses and Fc gl ycan structures and specific profiles of elicited 
IgG will contribute to clinical protection observed in controlled human infection models.
References for Appendix A:
1. Bournazos S and Ravetch JV. FcŒ≥ receptor pathways during active and passive 
immunization. I mmunol Rev. 2015; 
268:88 -103.
2.Pincetic A et al. Ty pe I and ty pe II Fc receptors regulate innate and adaptive 
immunity .Nat I mmunol. 2014; 15:707 -716.
Appendix B CLINICA L LA BORATORIES
Table 22 GSK Biologicals‚Äô laboratories
Laboratory Address
GSK Biological‚Äôs Clinical Laboratory Sciences, 
Rixensart Biospecimen Reception -B7/44
Rue de l'Institut, 89 - B-1330 Rixensart ‚ÄìBelgium
GVGH LaboratoryVia Fiorentina 1
53100 Siena
Italy
Table 23 Outsourced laboratories
Laboratory Address
Cincinnati Children's Hospital Medical Center
Core Laboratories3333 Burnet Avenue, 
Building B, MLC 1010
Cincinnati, O hio4522 9-3039, USA
Cincinnati Children's Hospital Medical Center
Clinical site Laboratories619 O akstreet, Room 2803
Cincinnati, Ohio, 45206, USA
Rockefeller University1230 York Avenue
New York, NY 10065, USA
WRAIR503 Robert Grant Avenue
Silver Spring, MD 20910
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b122 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL-2019 123Appendix C AMENDMENTS  AND ADMINISTRATIVE 
CHANGES TO THE PROTOCOL
GlaxoSmithKline Biologicals SA
Vaccines R&D
Protocol Amendment 1
eTrack study number 
and Abbreviated Title205626 (S SONNEI MONO GMMA SBVGH-003 
[H03_03TP])
Amendment number: Amendment 1
Amendment date: 08 February 2018
Coordinating author: (XPE Pharma for GSK Biologicals)
Rationale/background for changes:
!To increase the yield of the peripheral blood mononuclear cell (PBMC) analysis, 
volume of the blood collected for PBMC analysis has been changed from 40 mL to 50 mL.
!To make the definition of the primary objective more conclusive, the wording of 
the primary objective definition has been updated.
!The case definition of shigellosis has been also reworded to make it complete and 
more conclusive.
Amended text has been included in bold italics and deleted text in strikethrough in 
the following sections:
Section 2.1 Primary objective (+ in synopsis)
!To demonstrate the efficacy of two vaccinations with 25 Œºg of 1790GAHB vaccine 
in healthy adults compared to placebo in preventing (reduction of shigellosis, 
fulfilling according to the protocol primary case definition, i.e. moderate or severe 
diarrhea, OR oral temperature of ‚àÄ38¬∞C after challenge with S. sonnei strain 53G).
Section 2.2 Secondary objective (+ in synopsis)
Efficacy
!To determine the efficacy of the 1790GAHB vaccine compared to placebo against:
#[‚Ä¶]
#Confirmed S. sonnei 53G shedding AND moderate or severe diarrhea OR 
dysentery AND ORpresence of fever ‚àÄ38¬∞C OR presence of one or more 
severe intestinal symptoms (abdominal pain, cramping, tenesmus, nausea, 
vomiting ‚Ä¶).

CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b123 23-JUL-2019PPD_5HGDFWHG3URWRFRO$PHQGPHQW$SU_70) _
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 124Section 3 Study design overview (+ in synopsis)
ÔÇ∑Sampling schedule:
ÔÄ≠[‚Ä¶]
ÔÄ≠4050mL of peripheral venous blood for Œ±4Œ≤7 plasmablast flow -cytometry  and 
RNA extraction from PBMCs for gene expression profiling : Visit 1, Visit 2, 
Visit 4 and 7 day s after Visit 5 (Day  64).
Section 3.2 Challenge phase
Four weeks after completion of the two -dose vaccination schedule (approximately  28 
days after Visit 43) subjects will be admitted the day before the challenge date [‚Ä¶]
Section 4 Case definitions (+ in synopsis)
Shigellosis
For the challenge phase of the study , the protocol primary  case definition for shigellosis 
is:
ÔÇ∑Moderate or severe diarrhea OR fever (oral temperature ÔÇ≥38¬∞C).
Section 5.6 Outline of study procedures
Table 4 List of study procedures
Blood sampling for PBMC isolation (Œ±4Œ≤7 plasmablasts response and transcriptomics) (~ 4050mL)
Section 6.6.10.1 Blood sampling for safety or immune response assessments
ÔÇ∑An overall volume of 360 400 mL  will be collected per subject during the entire 
study  period (8 months).
Section 6.7.2 Biological samples
Table 6 Biological samples
Sample ty pe (analysis) (All subjects) Quantity Unit Timepoint
Blood (PBMC for Œ±4Œ≤7 plasmablasts response and transcriptomics) ~ 4050 mL scheduled
[‚Ä¶]
**Includes anti S. sonnei LPS IgG -ELISA (Clinical Laboratory Sciences)
Section 6.7.3 Laboratory assays
Table 10 Hematology, Serum Chemistry, Virology, HLA -B27 test, Urine and 
Stool tests
System Component Method Laboratory
EDTA Blood HLA-B27 Flow Cytometry PCR Study site
[‚Ä¶],PCR: Polymerase Chain Reaction
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b124 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 125Section 6.7.4.1 Immunological read -outs
Table 11 Immunological read -outs
Note: Anti -S. sonnei LPS IgG will be determined by local Screening -ELISA at screening and by Clinical Laboratory 
Sciences GVGH ELISA for the rest of the timepoints.
Section 11.2 Secondary endpoints (+ in synopsis)
Efficacy
VE, in subjects receiving the 1790GAHB vaccine vs. placebo, will be also measured 
against:
ÔÇ∑[‚Ä¶]
ÔÇ∑Confirmed S. sonnei 53G shedding AND moderate or severe diarrhea OR dy sentery  
AND ORpresence of fever ÔÇ≥ 38¬∞C OR presence of one or more severe intestinal 
symptoms (abd ominal pain, cramping, tenesmus, nausea, vomiting ‚Ä¶).
Section 12.9 Pharmacogenomics
As part of the sequencin g for the microbiome , human genome will be sequence
sequenced as bypass product but the intent is not to anal yze the data which will be store 
securel y.
Analyses of the transcriptomics signals evaluating the number of differential expressed 
genes by comparing the relative abundance of mRNA sequences are also consider eda 
pharmacogenomics experiment.
Appendix A Laboratory assays
Anti S. sonnei LPS antibody  determination from serum:
Anti- S. sonnei LPSIgG antibodies in serum (for all timepoints except screening) will be 
measured b y ELISA in the Clinical L aboratory  Sciences laboratories of GSK Biologicals
GVGH-Laboratories, Siena. The ELISA is performed using S. sonnei LPS [‚Ä¶]
Appendix B Clinical laboratories
Table 22 GSK Biologicals‚Äô laboratories
Laboratory Address
GSK Vaccines GmbH
Clinical Laboratory Sciences, Marburg, GermanyEmil-von-Behring -Str. 76
35041 Marburg
Germany
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b125 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL-2019 126GlaxoSmithKline Biologicals SA
Vaccines R&D
Protocol Amendment 2
eTrack study number 
and Abbreviated Title205626 (S SONNEI MONO GMMA SBVGH-003 
[H03_03TP])
Amendment number: Amendment 2
Amendment date: 22 June 2018
Coordinating author:
Rationale/background for changes:
!To address FDA comment that the case definition as stated in Protocol 
Amendment 1 did not appear to be sufficiently specific for shigellosis versus 
other causes of fever: therefore shedding has been added to address the deficiency in the primary case definition.
!The definition of fever in the previous case definition (Temperature ‚â•38¬∞C) has 
been changed to (Temperature ‚â•38.5¬∞C) to be in line with the definition of fever 
used for the challenge model set up at Cincinnati.
!To address FDA comment on performing screening safety laboratories but not 
proposing eligibility criteria based on them.
!To address the FDA request to provide a sample size calculation based on human 
challenge data relevant to the primary endpoint case definition in this study.
!To incorporate FDA recommendation on definition of holding rule for the study.
Amended text has been included in bold italics and deleted text in strikethrough in 
the following sections:
Section 2.1 Primary objective (+ in synopsis)
!To demonstrate the efficacy of two vaccinations with 25 Œºg of 1790GAHB vaccine 
in healthy adults compared to placebo (Reduction of shigellosis according to the 
protocol primary case definition , i.e. Shedding of S. sonnei 53G accompanied by 
moderate or severe diarrhea, OR shedding with an oral temperature of ‚àÄ38.5¬∞C
after challenge with S. sonnei strain 53G ).
Section 2.2 Secondary objective (+ in synopsis)
Efficacy
!To determine the efficacy of the 1790GAHB vaccine compared to placebo against:
#[‚Ä¶]

CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b126 23-JUL-2019PPD_5HGDFWHG3URWRFRO$PHQGPHQW$SU_70) _
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 127ÔÄ≠Confirmed S. sonnei 53G shedding AND moderate or severe diarrhea OR 
dysentery  OR presence of fever ÔÇ≥ 38.5¬∞ C OR presence of one or more severe 
intestinal symptoms (abdominal pain, cramping, tenesmus, nausea, vomiting 
‚Ä¶).
Section 4 Case definitions (+ in synopsis)
Shigellosis
For the challenge phase of the study , the protocol primary  case definition for shigellosis 
is:
ÔÇ∑Shedding of S. sonnei 53G accompanied by m Moderate or severe diarrhea OR 
shedding with fever ( an oral temperature of ÔÇ≥38.5¬∞C ).
Section 5.3 Exclusion criteria
Subjects with a baseline neutrophil count below 1800 cells/¬µL  LLN ORwith clinically 
significant abnormalities in other laboratory values (CBC, CMP, UA ), according to 
local reference ranges and investigator judgment)
Section 9.10.1 Holding rule
The following holding rule has been defined for the study : at least one subject developing 
a ‚â•Grade 3 s ymptomatic neutropenia considered possibly, probably or definitely  related 
within 7 day s after tovaccination
Section 11.2 Secondary endpoints
Confirmed S. sonnei 53G shedding AND moderate or severe diarrhea OR dy sentery  OR 
presence of fever ‚â•38.5¬∞C OR presence of one or more severe intestinal symptoms 
(abdominal pain, cramping, tenesmus, nausea, vomiting ‚Ä¶).
Section 11.4 
Determination of sample siz e
Based on the results obtained by the Cincinnati Ch ildren‚Äôs Hospital Medical Center , 
where the challenge model was developed, in subjects receivi ng a challenge with 1500 
CFU of S. sonnei 53G, the attack rate for the primary case definition of this study is 
58%. Thus considering an AR of 6058% in the placebo group and a percentage of non-
evaluable subjects of 22%, approximately  72 subjects (36 per group) will be recruited to 
reach these 21 cases.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b127 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL-2019 128GlaxoSmithKline Biologicals SA
Vaccines R&D
Protocol Amendment 3
eTrack study number 
and Abbreviated Title205626 (S SONNEI MONO GMMA SBVGH-003 
[H03_03TP])
Amendment number: Amendment 3
Amendment date: 07 September 2018
Coordinating author:
Rationale/background for changes:
!To address a comment made by the FDA asking if listings of unblinded unsolicited 
adverse events after challenge are made available to the IDMC.
!To add a secondary objective for evaluating efficacy of the vaccine also against a 
consensus definition of shigellosis by the Controlled Human Infection Model 
(CHIM) expert working group that was convened by the Gates Foundation, the 
funder of the study, on 06 February 2018.
!To clarify that regarding weight and number of stools, the interest is in total 
number and weight of all grade 3-5 stools, and not only in grade 3-5 stools concurring in diarrhea episodes.
!To further harmonize the protocol with the challenge model established at the 
Cincinnati Children‚Äôs Hospital Medical Center with previous GVGH studies in terms of grading of events and immunological parameters evaluated, and with GSK standards.
!To introduce a mitigation strategy in case the site is not able to include the 
required number of subjects in a given cohort.
!To add a tertiary objective to evaluate inflammatory response in stools as 
discussed with the funder of the study and other partners.
Amended text has been included in bold italics and deleted text in strikethrough in 
the following sections:
Cover Page:
Investigational New Drug IND18163
(IND) number
Contributing authors , , GVGH 
Serology Representatives (Scientific Technical Leaders)

CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b128 23-JUL-2019PPD
PPD PPD_5HGDFWHG3URWRFRO$PHQGPHQW$SU_70) _
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 129List of Abbreviations
CHIM:
ICH:Controlled Human Infection Model
International Council for Harmonisation Conference on 
Harmonization
Section 1.3.1 Risk Assessment
The most common sy mptoms that happen after taking Bactrim TMP- SMX are nausea, 
vomiting, loss of appetite, skin rash and itching.
Section 1.3.3 Overall Benefit: Risk Conclusion
However the S. sonnei 53G challenge strain used in the challenge phase is known to be 
susceptible to multiple antimicrobial agents including TMP -SMX and quinolones which 
will be used in this study  and will be given to all challenged subjects at Day  5 of the 
challenge phase (4thday after administration of the challenge agent) 5 days after 
administration of the challenge agent (day 62) or earlier if medicall y needed.
Section 2.2 Secondary objectives (+in synopsis)
Efficacy
ÔÇ∑To determine the efficacy of the 1790GAHB vaccine com pared to placebo against:
ÔÄ≠Shigel losis as defined by the CHIM expert working group on case definition .*
ÔÄ≠[‚Ä¶]
ÔÄ≠Weight of all grade 3 -5 diarrhea episodes stools.
ÔÄ≠Total number of allgrade 3-5 diarrhea episodes stools.
ÔÄ≠Confirmed S. sonnei 53G shedding AND moderate or severe diarrhea OR 
dysentery  OR presence of oral temperature fever ‚â• 38.5¬∞C OR presence of one 
or more severe intestinal sy mptoms (abdominal pain, cramping, tenesmus,
nausea, vomiting‚Ä¶, gas, and anorexia).
ÔÄ≠[‚Ä¶]
ÔÄ≠Time to onset of shigellosis after challenge, according to the primary case 
definition .
*According to the working group, the participant must fulfil any one of the three 
following possible endpoints to qualify as having reached the CHIM case definition for
this objective:
1.Severe diarrhea defined as [ ÔÇ≥6 loose stools in 24 hours] OR [ ÀÉ800 grams loose 
stools in 24 hours] 
2.Moderate diarrhea defined as [4 -5 loose stools in 24 hours OR 400 -800 grams 
loose stools in 24 hours] AND [oral temperature ÔÇ≥38.0oC OR ÔÇ≥1 moderate 
constitutional/enteric symptom OR ÔÇ≥2 episodes of vomiting in 24 hours] 
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b129 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 1303.Dysentery defined as [ ÔÇ≥2 loose stools with gross blood (hemoccult positive) in 24 
hours] AND [oral temperature ÔÇ≥38.0oC OR ÔÇ≥1 moderate constitutional/enteric 
symptom OR ÔÇ≥2 episodes of vomiting in 24 hours].
Safety
ÔÇ∑To assess the safet y and reactogenicity of the 1790GAHB vaccine in terms of 
solicited symptoms adverse events , unsolicited sy mptoms adverse events , serious 
adverse events (SAEs), adverse events of special interest (AESI) and laboratory  
parameters.
ÔÇ∑To assess safety  after challenge in terms of SAEs, unsolicited adverse events , AESI , 
and laboratory  parameters.
Immunogenicity
ÔÇ∑To evaluate the IgG ELISA immunogenicity profile of the 1790GAHB vaccine at 7 
days and 28 day s after the first and second vaccination (IgG ELISA coated with 
OAg containing L PS).
ÔÇ∑[‚Ä¶]
ÔÇ∑To assess anti -S.sonnei LPS concentration ‚â• 121 EU/ml at 28 days after first and 
second vaccination.
Section 2.3 Tertiary objectives (+ in synopsis)
ÔÇ∑[‚Ä¶]
ÔÇ∑Evaluate inflammatory response from stools collected before challenge at Visit 5 
(Day 57) and daily, post challenge, during inpatient stay (Day 57 to Day 64)
ÔÇ∑[‚Ä¶]
Section 3 Study Design Overview
The total of 72 subjects will be divided in 4 cohorts of 18 subjects e ach (for logistical 
reasons due to bed capacity  at the stud y site). The vaccination and challenge will be done 
in overlapping cohorts and randomization will ensure there is the same number of 
vaccinees and controls in each cohort. However, if for any reaso n, a cohort does not 
reach the planned 18 subjects, additional subjects can be added in the next cohorts. 
The maximum number of subjects must not be more than 20 (maximum number of 
beds in the clinic) in each cohort.
Section 3.2 Challenge Phase
ÔÇ∑Sampling schedule:
ÔÄ≠[‚Ä¶]
ÔÄ≠Stool sample for inflammatory response before challenge at Visit 5 (Day 57) 
and daily, post challenge, during inpatient stay (Day 57 to Day 64)
ÔÄ≠[‚Ä¶]
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b130 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 131ÔÇ∑Safety monitoring:
ÔÇ∑[‚Ä¶]
The safet y review team (SRT) will monitor the safety  of subjects throughout the study . 
The SRT will review blinded data, assess safet y signals and make recommendations to 
the IDMC and Sponsor concerning continuation, termination, or other modifications of 
the study  based on the observed adverse effects.
Section 4.1 Diarrhea (+ in synopsis)
For the purpose of this study , diarrhea is defined as :
ÔÇ∑[‚Ä¶]
ÔÇ∑Severe diarrhea: 6 or more loose or watery  (Grade 3 to 5) stools or > 800 grams of 
Grades 3 to 5 stools within 24 hours or required medical intervention. In case of 
severe diarrhea, medical intervention is defined as intravenous (IV) fluids 
administration or anticipation of antibiotic treatment before the 5thday after 
challenge.
ÔÇ∑More severe diarrhea: ÔÇ≥10 loose 10 or more loose or watery (Grade 3 to 5) stools or 
ÔÇ≥1000 grams of Grade 3 to 5 stools within 24 hours or required medical 
intervention. In case of more severe diarrhea, medical intervention is defined as 
ER visit or hospitalization for hypotensive shock.
Section 4.3 Shigellosis (+ in synopsis)
For the primary and secondary objectives in the challenge phase of the study , the 
protocol primary case definition for shigellosis is:
ÔÇ∑Shedding of S. sonnei 53G accompanied by  moderate or severe diarrhea OR 
shedding with an oral temperature of ÔÇ≥38.5¬∞C).
For the secondary objectives in the challenge phase of the study, the CHIM working 
group case definition will require the participant to fulfil any one of the three following 
possible endpoints: 
1.Severe diarr hea defined as [ ÔÇ≥6 loose stools in 24 hours] OR [ ÀÉ800 grams loose 
stools in 24 hours] 
2.Moderate diarrhea defined as [4 -5 loose stools in 24 hours OR 400 -800 grams 
loose stools in 24 hours] AND [oral temperature ÔÇ≥38.0oC OR ÔÇ≥1 moderate 
constitutional/enteric symptom OR ÔÇ≥2 episodes of vomiting in 24 hours]  
3.Dysentery defined as [ ÔÇ≥2 loose stools with gross blood (hemoccult positive) in 24 
hours] AND [oral temperature ÔÇ≥38.0oC0 ¬∞C OR ÔÇ≥1 moderate constitutional/enteric 
symptom OR ÔÇ≥2 episodes of vomiting in 24 hours].
Section 5.1 Number of subjects/center
Enrolment will take place in 4 overlapping cohorts of 18 subjects each to accommodate 
for the availability of beds required for the challenge phase of the study at the clinical 
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b131 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 132site (see also Section 11.12.1). However, if for any reason, a cohort does not reach the
planned 18 subjects, additional subjects can be added in the next cohorts. The 
maximum number of subjects must not be more than 20 (maximum number of beds in 
the clinic) in each cohort. The vaccination and challenge will be done per cohort.
Section 6.2.2.2.1 Study group and treatment allocation
Subjects will be enrolled in 4 overlapping cohorts of 18 subjects each, for logistical 
reasons at the clinical site, therefore a 1:1 ratio should be maintained at the cohort level.
However, if for any reason, a cohort does notreach the planned 18 subjects, additional 
subjects can be added in the next cohorts. The maximum number of subjects must not 
be more than 20 (maximum number of beds in the clinic) in each cohort. 
Table 4 List of Study Procedures
Record any concomitant medications/vaccinations ‚óèVisit 8
Stool sample for inflammatory response ‚óè Visit 5, ‚óè Inpatient Stay 
Recording of solicited adverse events within 7 days post -vaccination
Recording of non-serious unsolicited adverse events within 28 days post -vaccination
Recording of solicited adverse events within 7 days post -challenge ‚óèInpatient Stay
Recording of unsolicited adverse events within 28 days post -challenge ‚óèInpatient Stay  ‚óèVisit 6
Recording of AESI, SAEs and pregnancies ‚óèPhone call (Day 3 and Day 7) ‚óèPhone call (Day 31 and 
Day 35) 
Recording of SAEs related to study participation, ‚óèPhone call (Day 3 and 
or to a concurrent GSK medication/vaccine Day 7) ‚óè Phone call (Day
                                                                                                                                 31 and Day 35) 
7Before vaccination/challenge (Day 1/Day 57 sample can be collected by the subject at most a week before and stored 
as described in the Investigator Manual and SPM.
Table 5 Intervals between study visits
Interval Optimal length of interval Allowed interval
Visit 5 ÔÇÆVisit 7 56days 5649 days -7063 days
Visit 5 ÔÇÆVisit 8 180days 180166 days -194days
Section 6.6.8 Assess pre -vaccination body temperature
The oral bod y temperature of each subject needs to be measured prior to any stud y 
vaccine/placebo or challenge agent administration. If the subject has fever (fever is 
defined as temperature ÔÇ≥38.0¬∞C/100.4¬∞F regardless the location of measurement )on the 
day of vaccination, the visit will be rescheduled within the allowed interval (see Table 5).
Section 6.6.10.3 Stool sampling
Aliquots of stool will be collected for fecal sIgA, inflammatory  response, culture and 
qPCR, at each pre defined timepoint (see Table 4). If, during the inpatient stay , no stools 
are passed on a given day , up to two rectal swabs can be collected for culture and qPCR
(see also Section 3.2). The aliquots for fecal sIgA and inflammatory  markers should be 
frozen at -80¬∞C as soon as possible at the clinical site.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b132 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 133Section 6.6.12 Challenge administration and inpatient stay
Refer to Section 3.2and SPM for more details related to challenge administration and the 
preparation and administration of the challenge agent and the collection of samples 
during the inpatient stay .
Section 6.6.14.1 Subject Diary
Subject Diary  training should be directed at the individual(s) who will perform the 
measurements of adverse events and who will enter the information into the Subject 
Diary . This individual may  not be the subject, but if a person other than the subject enters 
information into the Subject Diary , this person‚Äôs identity  must be documented in the
Subject Diary Subject‚Äôs source records . Any individual that makes entries into the 
Subject Diary  must receive training on completion of the Subject Diary  at the time of the 
visit when Subject Diary  is dispensed. This training must be documented in the subject‚Äôs 
source record.
Section 6.7 Biological sample handling and analysis
Please refer to the SPM and Investigator Manual for details on biospecimen 
management (handling, storage and shipment).
Table 6 Biological samples
Stool *** (sIgA, microbiome, inflammatory markers, weight, 
consistency and blood assessment, culture and qP CR)scheduled
Table 10   Hematology, Serum Chemistry, Virology, HLA -B27 test, Urine and 
Stool tests
Stool Inflammatory markers ELISA WRAIR or GVGH 
designated lab
ELISA: Enzyme- Linked Immunosorbent Assay, WRAIR: Walter Reed Army Institute of Research (US)
Section 6.7.3 Laboratory assays
ÔÇ∑[‚Ä¶]
Fecal markers of intestinal inflammation will be meas ured as a sensitive predictor for 
inflammatory activities in the gastrointestinal tract. This analysis will assess if 
concentrations of inflammatory markers such as calprotectin and myeloperoxidase will 
increase after oral challenge with S. sonnei 53G and will additionally investigate if the 
S. sonnei 1790GAHB vaccine can reduce or abrogate the inflammatory response in the 
intestine after oral challenge.
Table 12 Hematology/Blood Chemistry read -outs
Visit 8 (Day 240 237) Post-challenge 72 Hematology
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b133 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 134Section 7.6.1 Recording of concomitant medications/products and concomitant 
vaccinations
ÔÇ∑Prophy lactic medication (i.e. medication administered in the absence of ANY 
symptom and in anticipation of a reaction to the vaccination).
E.g.,an anti -pyretic is considered to be prophy lactic when it is given in the absence of 
fever and an y other s ymptom, to prevent fever from occurring (fever is defined as 
temper ature ÔÇ≥38.0¬∞C/100.4¬∞F regardless the location of measurement ).The preferred 
location for measuring temperature in this study will be the oral cavit y.
Section 9.1.3 Solicited adverse events
The following solicited AEs Solicited AEs after vaccination are included in the Subject 
Diary . Each AE is to be assessed using the scoring sy stem reported in parentheses 
below Section 9.3.3.2.1.
Section 9.1.3.3 Solicited events after challenge phase
The hy dration of subjects developing diarrhea will be maintained wi th oral electrol yte 
solutions (i.e., Pedialy te, Gatorade) by offering at least 1.5 mL  for each gram of diarrheal 
stool lost, as tolerated.
Section 9.1.4 Unsolicited adverse events
Unsolicited AEs will be collected until 28 days after each vaccination and u ntil 28 
days after challenge .
Table 19 Reporting periods for collecting safety information
TimepointsScrD1 D8 D29 D36 D57D57-
D64D85D237
(M8)
Solicited local and systemic 
AEs
Unsolicited AEs
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b134 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 135Table 20 Intensity scales for solicited symptoms
Pain at injection site 0 None Absent
1Mild: Any pain neither interfering with nor preventing normal every day activities.
Easily tolerated.
2Moderate: Painful when limb is moved and interferes with every day activities
Interferes with normal activity
3Severe: Significant pain at rest. Prevents normal every day activities. Prevents 
normal activity.
Headache# 0 Normal Absent
1 Easily tolerated
2 Interferes with normal activity
3 That Prevents normal activity
Fatigue# 0 Absent
1 Easily tolerated
2 Interferes with normal activity
3 That Prevents normal activity
Arthralgia# 0 Absent
1 Easily tolerated
2 Interferes with normal activity
3 That Prevents normal activity
Malaise# 0 Absent
1 Easily tolerated
2 Interferes with normal activity
3 That Prevents normal activity
Myalgia# 0 Absent
1 Easily tolerated
2 Interferes with normal activity
3 That Prevents normal activity
Chills 0 Absent
1 Easily tolerated
2 Interferes with normal activity
3 That Prevents normal activity
After challenge agent administration
Nausea 0 Normal Absent
1 Mild or transient; maintains reasonable intake
2 Moderate discomfort; intake decreased significantly; some activity limited
3 No significant intake and requires medical intervention
4 Hospitalization required
Abdominal cramping 0 Normal Absent
1 No interference with daily activities
2 Some interference with daily activities not requiring medical intervention
3 Prevents daily activities and requires medical intervention
4 ER visit or hospitalization
Abdominal pain 0 Absent
1 Easily tolerated
2 Interferes with normal activity
3 Prevents normal activity
Gas 0 Normal Absent
1 Easily tolerated
2 Interferes with normal activity
3 Prevents normal activity
Anorexia 0 Normal Absent
1 Easily tolerated
2 Interferes with normal activity
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b135 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 1363 Prevents normal activity
Vomiting 0 Normal Absent
1 One episode within a 24 -hour period Vomiting
2 2 episodes within a 24 -hour period
3 >2 episodes within a 24 -hour period and requires medical intervention
4 ER visit or hospitalization for hypotensive shock
Diarrhea** 0 Normal Absent
12-3 Grade 3 -5 stools (loose or watery) or <400 g/Grade 3 -5 (loose or watery) 
stools per 24 hours
24-5 Grade 3 -5 stools (loose or watery) or 400 -800 g/ (loose or watery) Grade 3 -5 
stools per 24 hours
36 or more Grade 3 -5 stools (loose or watery) or >800 g/Grade 3 -5 (loose or 
watery) stools per 24 hours and or requires medical intervention
4ÔÇ≥10 loose stools (Grade 3 to 5) or ÔÇ≥1000 grams of Grade 3 to 5 stools within 
24 hours or ER visit or hospitalization for hypotensive shock
Section 9.3.3.2.1 Assessment of intensity
Erythema/Induration
0: ÔÇ£20 <25 mm 
1: > 20 ÔÇ≥25-ÔÇ£50 mm 
2: > 50 -ÔÇ£100 mm
3: > 100 mm
Section 9.10.2 Safety monitoring
The SRT will monitor the safet y of subjects throughout the study . The SRT will review 
blinded data, assess safety  signals and make recommendations to the IDMC and to the 
Sponsor concerning continuation, termination, or other modifications of the study  based 
on the observed adverse effects.
Section 11.1 Primary endpoint (plus Synopsis)
ÔÇ∑Rate of shigellosis (fulfilling the protocol primary case definition) occurring within a 
period starting with the challenge visit and lasting up to the end of the inpatient stay , 
in all subjects.
Section 11.2 Secondary endpoints (plus Synopsis)
VE, in subjects receiving the 1790GAHB vaccine vs. placebo, will be also measured
during inpatient stay (Day 57 to Day 64) against:
ÔÇ∑Rate of shigellosis (fulfilling the CHIM working group case definition for 
shigellosis) occurring within a period starting with challenge visit and lasting until 
the end of the inpatient stay, in all subjects. 
ÔÇ∑[‚Ä¶]
ÔÇ∑Weight of all grade 3 -5 diarrhea episodesstools.
ÔÇ∑Total number of allgrade 3-5 diarrhea episodesstools.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b136 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 137ÔÇ∑Confirmed S. sonnei 53G shedding AND moderate or severe diarrhea OR dy sentery  
OR presence of oral temperature fever ÔÇ≥ 38.5¬∞C OR presence of one or more severe 
intestinal symptoms (abdominal pa in, cramping, tenesmus, nausea, vomiting, ‚Ä¶gas, 
anorexia). 
ÔÇ∑Disease not fulfilling the protocol primary  case definition for shigellosis associated 
or not with mild to moderate s ymptoms including: passing loose stool (not meeting 
the protocol definition of moderate or severe diarrhea), abdominal pain, abdominal 
cramps, gas, anorexia, nausea, headache, my algia, malaise, arthralgia, fever, 
vomiting and IV fluid administration.
ÔÇ∑Time to onset of shigellosis after challenge, according to the protocol primary case
definition. 
Safety
Solicited adverse events
ÔÇ∑Occurrence of each solicited local and s ystemic adverse event within 7 day s after 
each vaccination.
Unsolicited adverse events
ÔÇ∑Occurrence of unsolicited AEs within 28 day s after any vaccination and after 
challenge , according to Medical Dictionary  for Regulatory  Activities (MedDRA) 
classification. 
ÔÇ∑[‚Ä¶]
Immunogenicity
The measures of immunogenicity , against the L PS of S. sonnei , will include:
ÔÇ∑IgG geometric mean concentrations (GMCs) pre -vaccination (Day  1), 7 and 28 day s
after first and28 day s after second vaccination by antibody  concentration at baseline 
(i.e., above vs. below the assay  detection limit), as determined by  anti-S. sonnei LPS 
IgG ELISA.
ÔÇ∑[‚Ä¶]
ÔÇ∑Number and percentage of subjects achieving a post vaccination anti -S. Sonnei 
LPS concentration ‚â• 121 EU/ml at 28 days after first and second vaccination. 
ÔÇ∑Number and percentage of seroresponders* for anti- S. sonnei LPS at 28 day s after 
first and second vaccination. 
*Seroresponse is aimed to define a significant increase in anti S. sonnei LPS IgG 
concentration in post- vaccination samples and relies on the definition already  used in a 
previous phase II study  in Keny an population. [‚Ä¶]
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b137 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 138Section 11.3 Tertiary endpoints (plus Synopsis)
ÔÇ∑[‚Ä¶]
ÔÇ∑Glycosylation profiles of IgG antibodies at Day  1 and 28 day s after second 
vaccination (Visit 5; Day 57).
ÔÇ∑[‚Ä¶]
ÔÇ∑Concentration of stool markers of intestinal inflammation (e.g. calprotectin and 
myeloperoxi dase) before oral challenge with S. sonnei, 53G at Visit 5 (Day 57) and 
daily during the post -challenge inpatient stay (Day 57 to Day 64)
ÔÇ∑[‚Ä¶]
ÔÇ∑Diversity  and frequency  of microbiome components (taxa and/or genes according to 
technology ) at Day  1 prior to vac cination and 28 day s after second vaccination (Visit 
5; Day 57).
Section 11.5.7 Sub-groups
There are no intended sub- groups for anal ysis in this study .The analysis for the primary 
efficacy endpoint will be repeated for the two subgroups of subjects who we re 
responders or non -responders at the immunogenicity assessment of the pre-challenge 
visit. 
Section 11.12.1 Sequence of analyses
The total of 72 subjects will be divided in 4 cohorts of 18 subjects each (for bed 
availability  at the stud y site). The vaccination and challenge will be done per cohort.
However, if for any reason, a cohort does not reach the planned 18 subjects, additional 
subjects can be added in the next cohorts. The maximum number of subjects must not 
be more than 20 (maximum number of beds in the clinic) in each cohort. 
One interim anal ysis is intended and will include post -challenge efficacy  data of all 
subjects (all 4 cohorts) and immunogenicit y data up to 28 days after second vaccination 
for the first 3 vaccinated cohorts. Further serological results will follow after the 
conclusion of the study ..
Appendix A Laboratory Assays
[‚Ä¶]
Stool inflammatory markers assay
Inflammatory markers including c alprotectin and myeloperoxidase levels in stools 
(ng/mL) will be measured using commerci ally available (Epitope Diagnostics, Inc.) 
quantitative ELISA kits according to the manufacturer‚Äôs instructions. 
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b138 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL-2019 139GlaxoSmithKline Biologicals SA
Vaccines R&D
Protocol Amendment 4
eTrack study number 
and Abbreviated Title205626 (S SONNEI MONO GMMA SBVGH-003 
[H03_03TP])
Amendment number: Amendment 4
Amendment date: 19 February 2019
Coordinating author: (XPE Pharma for GSK Biologicals)
Rationale/background for changes:
!Subjects of African descent are known to have a lower Absolute Neutrophil Count 
(ANC) than subjects of European descent. African Americans represent about 75% 
of all included subjects in the study so far, which is more than was initially anticipated. Furthermore, all cases of neutropenia recorded so far in the study occurred in African-American subjects. The threshold and grading scale, appropriate for this population, in line with the recommended criteria of the Division of AIDS (DAIDS), have been added to the protocol. This change will provide a more appropriate definition of neutropenia for African-American subjects as a basis to decide on eligibility for participation in the study and for vaccination and administration of the challenge agent, and will mitigate the risk that African-American subjects are excluded from the study due to episodes of neutropenia that are not clinically relevant.
!The current definition of ‚Äúmore severe diarrhea‚Äù was inconsistent with the 
definition of ‚ÄúShigellosis‚Äù. A change has been introduced to the definition of ‚Äúmore severe diarrhea‚Äù for a clear classification of cases.
!Minor editorial mistakes are corrected.
Amended text has been included in bold italics and deleted text in strikethrough in 
the following sections:
Contributing Authors
! , Safety Scientist, Safety Evaluation and Risk Management team
List of Abbreviations
DAIDS: Division of Acquired Immunodeficiency Syndrome

CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b139 23-JUL-2019PPD
PPD_5HGDFWHG3URWRFRO$PHQGPHQW$SU_70) _
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 140Section 1.3.1 Risk Assessment
Important 
Potential/Identified RiskData/Rationale for Risk Mitigation Strategy
Investigational vaccine: 1790GAHB vaccine
Symptomatic Neutropenia Eight cases of Grade 2 or Grade 3 
neutropenia were reported from 
Phase 1 clinical trials 
(asymptomatic).
All cases occurred in the first 20 days 
after administration of first vaccine 
dose, and reversed after 
discontinuation.
Literature review of reports of 
neutropenia in association with 
vaccination indicates factors noted to 
be associated with neutropenia 
(including ethnicity, and low baseline 
counts) with the majority of cases 
detected within 2 weeks of the 
vaccination. None of the reported 
cases was clinically symptomatic.
Five cases of asymptomatic 
neutropenia (Grade 1 and 2) have 
been reported at Day 7 after receipt 
of the first dose in 5 subjects.
One of the 5 subjects had an 
additional Grade1 neutropenia 
episode at Day 28, and another one 
had two additional episodes, one of 
which was Grade 3 (940 cells/mL) at 
7 days after the second dose and the 
second was Grade 2 (1,410 cells/mL) 
at 28 days after second vaccination . 
All cases were resolved before last 
study visit.Exclusion criteria for this clinical 
studies study include:
ÔÇ∑ Subjects with a low baseline 
neutrophil (below 1800 cells/ ¬µl 
LLN 1000 cells/¬µL for African -
American subjects or other 
subjects of African descent 
and 1800 cells/¬µL for subjects 
of other ethnicity) . As guidance ,
the WHO criteria should be 
followed Division of Acquired 
Immunodeficiency Syndrome 
(DAIDS) criteria [DAIDS, 2017] 
should be followed for African -
American subjects or other 
subjects of African descent, 
whereas WHO criteria should 
be followed for all other 
subjects.
ÔÇ∑ Previous history of Benign Ethnic 
Neutropenia, or drug related 
Neutropenia.
ÔÇ∑ Concomitant treatment with 
neutropenic agents.
Monitoring for this clinical study to include:
ÔÇ∑ Baseline neu trophil counts.
ÔÇ∑ Full blood counts with differential 
measured at 7 days post each 
scheduled vaccination.
ÔÇ∑ Assessment of clinical impact of 
neutropenia.
Subjects will be closely monitored during 
the entire study and have hematology 
repeated every 7 days when neutropenia is 
identified until resolution. If a case of 
neutropenia does not resolve based on 
most recent available laboratory results,
before the second vaccination, or 
challenge agent administration, the 
subject will not be re -vaccinated or 
administered the challenge agent.
Section 4.1 (+Synopsis) Diarrhea
For the purpose of this study , diarrhea is defined as:
ÔÇ∑[‚Ä¶]
ÔÇ∑More severe diarrhea: 10 or more loose or watery  (Grade 3 to 5) stools or ÔÇ≥1000 
grams of Grade 3 to 5 stools within 24 hours or required medical intervention. I n 
case of more severe diarrhea, medical intervention is defined as ER visit or 
hospitalization for hy potensive shock.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b140 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 141Section 5.3 Exclusion criteria
ÔÇ∑[‚Ä¶]
ÔÇ∑Subjects with a baseline neutrophil below 1800 1000 cells/ÔÅ≠L LLN for African -
American subjects or other subjects of African descent, and 1800 cells/ÔÅ≠Lfor 
subjects of other ethnicity OR with clinically  significant abnormalities in other 
laboratory  values (CBC, CMP, UA), according to local reference ranges and 
investigator judgment).
Section 7.5 Contraindications to subsequent vaccination or challenge
ÔÇ∑[‚Ä¶]
ÔÇ∑Neutropenia below 1800 cells/ ÔÅ≠L LLN.
ÔÇ∑[‚Ä¶]
The following event sconstitute scontraindications to administration of 1790GAHB 
vaccine or the challenge agent at that point in time; if thisany of these event soccur sat 
the time scheduled for vaccination, the subject may be vaccinated at a later date, within 
the time window specified in the protocol (see Section 6.5), or the subject may  be 
withdrawn at the discretion of the investigator (see Section 9.5):
ÔÇ∑Neutropenia (for threshold values refer to Section 9.1.6 )based on most recent 
available laboratory results. Subjects with previous neutropenia or unresolved 
neutropenia may be re -evaluated prior to vaccination or prior to challenge at the 
discretion of the investigator.
ÔÇ∑[‚Ä¶]
Section 9.1.6 Adverse events of speci al interest
ÔÇ∑[‚Ä¶]
Neutropenia is defined as a decrease of neutrophil count asy mptomatically  or 
symptomaticall y. Available local laboratory  ranges will be used to define neutropenia. 
This is completely  diagnosed by  laboratory  testing for complete blood count. However ,
only symptomatic neutropenia cases will be considered as AESI and reported as such.
The following grading will be used to classify  neutropenia in African- American subjects 
or other subjects of African descent :
ÔÇ∑Grade 1: 1000 -800 cells/¬µL.
ÔÇ∑Grade 2: 799-600 cells/¬µL.
ÔÇ∑Grade 3: 599- 400 cells/¬µL .
ÔÇ∑Grade 4: < 400 cells/¬µL.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b141 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 142The following grading will be used to classify neutropenia for subjects of other 
ethnicity:
ÔÇ∑Grade 1: 1800- 1500 cells/¬µL .
ÔÇ∑Grade 2: 1499- 1000 cells/¬µL .
ÔÇ∑Grade 3: 999- 500 cells/¬µL.
ÔÇ∑Grade 4: < 500 cells/¬µL .
Section 9.3.3.2.1, Table 20 Intensity scales for solicited symptoms
Diarrhea** 0 Absent 
12-3 Grade 3 -5 stools (loose or watery) or <400 g/Grade 3 -5 (loose or watery) 
stools per 24 hours
24-5 Grade 3 -5 stools (loose or watery) or 400-800 g/ (loose or watery) Grade 3 -5 
stools per 24 hours
36 or more Grade 3 -5 stools (loose or watery) or >800 g/Grade 3 -5 (loose or 
watery) stools per 24 hours orrequires medical intervention
4ÔÇ≥10 loose stools (Grade 3 to 5) or ÔÇ≥1000 grams of Grade 3 to 5 stools within 24 
hours or ER visit or hospitalization for hypotensive shock
References
U.S. Department of Health and Human Services, National Institutes of Health, 
National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of 
AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, 
Corrected V ersion 2.1. (July 2017). 
https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b142 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL-2019 143GlaxoSmithKline Biologicals SA
Vaccines R&D
Protocol Amendment 5
eTrack study number 
and Abbreviated Title205626 (S SONNEI MONO GMMA SBVGH-003 
[H03_03TP])
Amendment number: Amendment 5
Amendment date: 15 April 2019
Coordinating author: (XPE Pharma for GSK 
Biologicals)
Rationale/background for changes:
!To meet a FDA request for removing the DAIDS thresholds and criteria specific 
for African-American subjects that had been added in Amendment 4.
!To add secondary endpoints and case definitions for shigellosis that would 
facilitate comparison of results with other CHIM studies.
!To specify that stool samples will be analyzed for both S. sonnei secretory IgA 
(sIgA) and total sIgA ( S. sonnei sIgA to be normalized for total sIgA). 
!Minor editorial mistakes are corrected.
Amended text has been included in bold italics and deleted text in strikethrough in 
the following sections:
List of Abbreviations
DAIDS: Division of Acquired Immunodeficiency Syndrome
Section 1.3.1. Risk Assessment (in the column ‚ÄúMitigation Strategy)
Exclusion criteria for this clinical study include :
!Subjects with a lowbaseline neutrophil count below 1000 1800 cells/ŒºL (LLN) for 
African-American subjects or other subjects of African descent and 1800 cells/ ŒºL 
for subjects of other ethnicity). As guidance, the Division of Acquired 
Immunodeficiency Syndrome (DAIDS) criteria [DAIDS, 2017] should be followed 
for African-American subjects or other subjects of African descent, whereas WHO 
criteria should be followed for all other subjects .
Section 2.2 Secondary objectives (+ in synopsis) 
!To determine the efficacy of the 1790GAHB vaccine compared to placebo against:
#Shigellosis as defined by the CHIM expert working group on case definition.* 

CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b143 23-JUL-2019PPD_5HGDFWHG3URWRFRO$PHQGPHQW$SU_70) _
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 144ÔÄ≠Shigellosis, as defined by: severe diarrhea OR moderate diarrhea with fever or 
with one or more moderate constitu tional/enteric symptoms OR dysentery [[ 
‚â•2 loose stools with gross blood (hemoccult positive) in 24 hours] AND [‚â•1 
reportable constitutional/enteric symptom ]].
ÔÄ≠More severe shigellosis , asdefined by: severe ormoderate diarrhea with fever 
or with one or more severe constitutional/enteric symptoms OR dysentery [ [‚â•2 
loose stools with gross blood (hemoccult positive) in 24 hours] AND [ ‚â•1 severe 
constitutional/enteric symptom]]
.
ÔÄ≠Shedding of S. sonnei strain 53G.
ÔÄ≠[‚Ä¶]
Section 2.3 Tertiary objective (+ in synopsis)
The following tertiary  objectives which are part of the study  exploratory  objectives may  
be evaluated in addition to the primary  and secondary  objectives and will complement 
assessment of the vaccine immunog enicit y profile:
ÔÇ∑Evaluate S. sonnei specific secretory immunoglobulin A ( sIgA )in stool at Day  1 
and 7 day s after first and second vaccination and 7 day s after challenge (Day  64).
ÔÇ∑[‚Ä¶]
Section 3 Study design overview (+ in synopsis)
ÔÇ∑Sampling schedule:
ÔÄ≠[‚Ä¶]
ÔÄ≠Stool sample: for microbiome testing at Visit 1 and Visit 5, for S. sonnei 
specific sIgA at Visit 1, Visit 2, Visit 4 and 7 days after challenge (Day  64) and 
stool analy sis, culture and qPCR daily  during inpatient stay  (from Visit 5 to 7 
days after challen ge [Day  57 to Day  64] or prolonged until 2 consecutive 
negative stool samples if subject still shedding ).
Section 4.2 Dystentery (+ in synopsis)
For the purpose of this study , dysentery  is defined as:
ÔÇ∑A Grade 3, 4, or 5 stool with gross blood on at least 2 occasions within 24 hours and 
presence of constitutional /enteric symptoms (e.g., fever, vomiting, chills, fatigue‚Ä¶, 
refer to Table 23
).
Section 4.3 Shigellosis (+ in synopsis)
For the primary  and secondary  objectives in the challenge phase of the study , the protocol 
primary case definition for shigellosis is:
ÔÇ∑Shedding of S. sonnei 53G accompanied by  moderate or severe diarrhea OR 
shedding with an oral temperature of ÔÇ≥38.5¬∞C) .
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b144 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 145For the secondary  objectives in the challenge pha se of the study ,2 definitions of 
shigellosis are used:
1.CHIM working group case definition for shigellosis as defined by any oneof the 
three following possible endpoints:
ÔÇ∑Severe diarrhea defined as [ ÔÇ≥6 loose stools in 24 hours] OR [ ÀÉ800 grams loose 
stools in 24 hours]
ÔÇ∑Moderate diarrhea defined as [4 -5 loose stools in 24 hours OR 400 -800 grams 
loose stools in 24 hours] AND [oral temperature ÔÇ≥38.0oC OR ÔÇ≥1 moderate 
constitutional/enteric symptom OR ÔÇ≥2 episodes of vomiting in 24 hours]  
ÔÇ∑Dysentery defined as [ ÔÇ≥2 loose stools with gross blood (hemoccult positive) in 
24 hours] AND [oral temperature ÔÇ≥38.0¬∞C OR ÔÇ≥1 moderate 
constitutional/enteric symptom OR ÔÇ≥2 episodes of vomiting in 24 hours].
2.Shigellosis as defined by any one of the three following possible endpoi nts:
ÔÇ∑Severe diarrhea defined as [ ‚â•6 loose stools in 24 hours OR ÀÉ800 grams loose 
stools in 24 hours]
ÔÇ∑Moderate diarrhea defined as [4 -5 loose stools in 24 hours OR 400 -800 grams 
loose stools in 24 hours] AND [oral temperature ‚â•38.0oC OR ‚â•1 moderate 
constitu tional/enteric symptom].
ÔÇ∑Dysentery defined as [ ‚â•2 loose stools with gross blood (hemoccult positive) in 
24 hours] AND [ ‚â•1 reportable constitutional/enteric symptom].
For the secondary objectives in the challenge phase of the study, more severe 
shigellosis is defined by any one of the two following possible endpoints:
ÔÇ∑Moderate OR severe diarrhea [‚â•4 loose stools in 24 hours OR ‚â•400 grams 
loose stools in 24 hours] AND [oral temperature ‚â•38.0oC OR ‚â•1 severe 
constitutional/enteric symptom].
ÔÇ∑Dysentery defined as [‚â•2 loose stools with gross blood (hemoccult positive) in 
24 hours] AND [ ‚â•1 severe constitutional/enteric symptom].
the CHI M working group case definition will require the participant to fulfil any  one of 
the three following possible endpoints: 
Severe di arrhea defined as [ ÔÇ≥6 loose stools in 24 hours] OR [ ÀÉ800 grams loose stools in 
24 hours] 
Moderate diarrhea defined as [4 -5 loose stools in 24 hours OR 400 -800 grams loose 
stools in 24 hours] AND [oral temperature ÔÇ≥38.0oC OR ÔÇ≥1 moderate 
constitutional/ente ric symptom OR ÔÇ≥ 2 episodes of vomiting in 24 hours] 
Dysentery  defined as [ ÔÇ≥2 loose stools with gross blood (hemoccult positive) in 24 hours] 
AND [oral temperature ÔÇ≥38.0oC0 ¬∞C OR ÔÇ≥1 moderate constitutional/enteric sy mptom OR 
ÔÇ≥2 episodes of vomiting in 24 hours]. 
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b145 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 146Section 5.3 Exclusion criteria
ÔÇ∑[‚Ä¶]
ÔÇ∑Subjects with a baseline neutrophil count below 1000 cells/ ÔÅ≠L for African- American 
subjects or other subjects of African descent, and 1800 cells/ ÔÅ≠L(LLN) for subjects 
of other ethnicit yOR with clinically  significant abnormalities in other laboratory  
values (CBC, CMP, UA), according to local reference ranges and investigator 
judgment ).
ÔÇ∑[‚Ä¶]
Section 6.7.3 , Table 7  Immunity (Antibody determination)
System Component MethodKit/
ManufacturerUnit2 Cut-off2 Laboratory3
Serum
(screening)Anti-S. sonnei
LPS IgGELISA1 WRAIREndpoint 
titerplate 
dependentCCHMC
Serum
(except 
screening)Anti-S. sonnei
LPS IgGELISA In-house EU/mLplate 
dependentGVGH4or GVGH 
designated lab
SerumBactericidal 
antibodiesSBA In-houseDilution 
Factor 
(titer)NAGVGH4or GVGH 
designated lab
StoolAnti-S. sonnei
LPS sIgAELISA WRAIRTiter
EU/mL100.200 
ODCCHMC or 
GVGH 
designated lab
Stool Anti-total sIgA ELISA WRAIR mg/mL 0.001 CCHMC
1 Local Screening -ELISA will be used for this testing.
2Assay cut -off and unit might be subject to change during the course of the study (e.g. in case of requalification, 
revalidation or standardization). In this case, this will be documented in the clinical report.
3Refer to Appendix B for the laboratory addresses.
4GVGH laboratory refers to the GVGH -laboratories in Siena, Italy.
ELISA : enzyme- linked immunosorbent assay, NA: not applicable, EU: ELISA unit, LPS: lipopolysaccharide, IgA/G : 
immunoglobulin A/G, SBA : serum bactericidal Assay, WRAIR : Walter Reed Army Institute of Research (US), GVGH : 
GSK Vaccines Institute for Global Health, CCHMC : Cincinnati Children‚Äôs Hospital Medical Cent er; sIgA: secretory 
Immunnoglobulin A
Section 7.5 Contraindications to subsequent vaccination or challenge
[‚Ä¶]
The following event sconstitute contraindications to administration of 1790GAHB 
vaccine or the challenge agent at that point in time; if an y of these events occur at the 
time scheduled for vaccination, the subject may  be vaccinated at a later date, within the 
time window specified in the protocol (see Section 6.5), or the subject may  be withdrawn 
at the discretion of the investigator (see Section 9.5):
ÔÇ∑Neutropenia (for threshold values refer to Section 9.1.6) below 1800 cell/¬µL based on 
most recent available laboratory  results. Subjects with previous neutropenia or 
unresolved neutropenia may  be re -evaluated prior to vaccination or prior to challenge 
at the discretion of the investigator.
ÔÇ∑[‚Ä¶]
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b146 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 147Section 9.1.6 Adverse events of special interest
[‚Ä¶]
The following g rading will be used to classify  neutropenia :in African- American subjects 
or other subjects of African descent:
Grade 1: 1000- 800 cells/¬µL . 
Grade 2: 799- 600 cells/¬µL.
Grade 3: 599- 400 cells/¬µL.
Grade 4: < 400 cells/¬µL . 
The following grading will be used to classify  neutropenia for subjects of other ethnicity :
ÔÇ∑Grade 1: 1800 -1500 cells/ ¬µL.
ÔÇ∑Grade 2: 1499- 1000 cells/ ¬µL. 
ÔÇ∑Grade 3: 999- 500 cells/ ¬µL.
ÔÇ∑Grade 4: < 500 cells/ ¬µL.
[‚Ä¶]
Section 11.2 Secondary endpoints (+ in Synopsis)
VE, in subjects receiving the 1790GAHB vaccine vs. placebo, will be also measured
during inpatient stay  (Day  57 to Day  64)against:
ÔÇ∑Rate of shigellosis (fulfilling the CHIM working group case definition for 
shigellosis) occurring within a period starting with challenge visit and lastin g until 
the end of the inpatient stay , in all subjects.
ÔÇ∑Rate of shigellosis, as defined by severe diarrhea OR moderate diarrhea with fever 
or with one or more moderate constitutional/enteric symptom OR dysentery [[‚â•2 
loose stools with gross blood (hemoccul t positive) in 24 hours] AND [ ‚â•1 reportable 
constitutional/enteric symptom]].
ÔÇ∑Rate of more severe shigellosis as defined by: severe or moderate diarrhea with 
fever or with one or more severe constitutional/enteric symptom OR dysentery [[‚â•2 
loose stools with gross blood (hemoccult positive) in 24 hours] AND [ ‚â•1 severe 
constitutional/enteric symptom] ].
ÔÇ∑[‚Ä¶]
Section 11.3 Tertiary endpoints (+ in Synopsis)
ÔÇ∑Specific anti -S. sonnei LPS sIgA antibod y concentration in stool samples at Day 1, 7 
days after first and second vaccination and 7 day s after challenge (Day  64).
ÔÇ∑[‚Ä¶]
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b147 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 148Section 14 References
U.S. Department of Health and Human Services, National Institutes of Health, National 
Institute of Allergy  and Infectious Diseases, Division of AIDS. Division of AIDS 
(DAIDS) Table for Grading the Severity  of Adult and Pediatric Adverse Events, 
Corrected Version 2.1. (July  2017). 
https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf
Appendix A LABORATORY ASSAYS
[‚Ä¶]
S. sonnei determination from stool:
ÔÇ∑Culture: The presence of S. sonnei in stool samples will be assessed using a 
qualitative procedure and following the SOPs of the local or designated laboratory  
for culture, isolation and identification of S. sonnei from stool specimens.
ÔÇ∑qPCR :S. sonnei qPC R determination will be done following the SOPs of the local or 
designated laboratory  for identification of S. sonnei by a qPCR from stool 
specimens.
ÔÇ∑S. sonnei s IgA and total sIgAdetermination from stool :S. Sonnei ELISA will be 
performed following the SO Ps of the local or designated laboratory  for ELISA assay  
from stool specimens. The S. sonnei sIgA result will be normalized to the total 
sIgA.
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b148 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
23-JUL-2019 149GlaxoSmithKline Biologicals SA
Vaccines R&D
Protocol Amendment 6
eTrack study number 
and Abbreviated Title205626 (S SONNEI MONO GMMA SBVGH-003 
[H03_03TP])
Amendment number: Amendment 6
Amendment date: 23 July 2019
Coordinating author: (Modis for GSK Biologicals)
Rationale/background for changes:
!To add an additional interim analysis for immunogenicity data, which will allow a 
faster interpretation of study results and planning of subsequent follow-up studies.
!To correct an error in the definitions of dysentery and more severe shigellosis, and 
align these definitions to other CHIM studies; oral temperature ‚â• 38.0¬∞C (fever) is 
added to the definitions.
!To correct an error in the primary completion date of the study.
!To clarify the different applicable case definitions of dysentery in the study.
!To provide clarification in the study design by showing the inpatient stay in the 
study design figure as per the Schedule of Activities table.
!To specify the allowed time interval window for the blood draw that occurs during 
the inpatient stay.
!To specify the assay used for the Œ±4Œ≤7 plasmablast analysis as measuring both 
positive and negative cells by ELISA, and not using flow cytometry.
!To change the assay used for HLA-B27 testing from PCR to qualitative flow 
cytometry.
Amended text has been included in bold italics and deleted text in strikethrough in 
the following sections:
List of Abbreviations
ELISPOT: Enzyme-linked immunospot assay
Section 2.2 Secondary objectives (+Synopsis)
!To determine the efficacy of the 1790GAHB vaccine compared to placebo against:
#[‚Ä¶]
#More severe shigellosis, as defined by: severe or moderate diarrhea with fever or 
with one or more severe constitutional/enteric symptoms OR dysentery [[ ‚â•2 

CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b149 23-JUL-2019PPD_5HGDFWHG3URWRFRO$PHQGPHQW$SU_70) _
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 150loose stools with gross blood (hemoccult positive) in 24 hours] AND [ oral 
temperature ‚â•38.0oC OR ‚â•1 severe constitutional/enteric s ymptom]].
ÔÄ≠[‚Ä¶]
Section 2.3 Tertiary objectives (+Synopsis)
The following tertiary  objectives which are part of the study  exploratory  objectives may  
be evaluated in addition to the primary  and secondary  objectives and will complement 
assessment of the vaccine immunogenicit y profile:
ÔÇ∑[‚Ä¶]
ÔÇ∑Evaluate S. Sonnei LPS IgG -specific presence and migration of Œ±4Œ≤7+/ -plasmablast 
response at Day  1 and 7 day s after first and second vaccination and 7 day s after 
challenge (Day  64).
ÔÇ∑[‚Ä¶]
Section 3.2, Figure 1 Study design
[‚Ä¶] [‚Ä¶]
Inpatient stay *
Day 57 to Day 65
B & S
*Refer to Section 3.2 for details of procedures during the inpatient stay
Section 3.2 Challenge phase
[‚Ä¶]
Study Design
ÔÇ∑Primary completion date (PCD): Visit 8 End of inpatient stay (Visit 5, 6 months 
after challenge Day 64) .
[‚Ä¶]
ÔÇ∑Sampling schedule:
ÔÄ≠[‚Ä¶]
ÔÄ≠50mL of peripheral venous blood for Œ±4Œ≤7+/ -plasmablast flow-
cytometry analysis by ELISA and RNA extraction from PBMCs for gene 
expression profiling: Visit 1, Visit 2, Visit 4 and 7 day s after Visit 5 (Day  64).
ÔÄ≠[‚Ä¶]
Section 4.2 Dysentery (+Synopsis)
For the purpose of this study , dysentery  is defined :
A Grade 3, 4, or 5 stool with gross blood on at least 2 occasions within 24 hours and 
presence of constitutional /enteric s ymptoms (e.g., fever, vomiting, chills, fatigue‚Ä¶, refer 
to 23).For the purpose of the endpoint ‚ÄúRate of shigellosis as defined by the CHIM 
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b150 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 151expert working group occurring within a period starting with challenge visit and 
lasting unti l the end of the inpatient stay, in all subjects‚Äù, dysentery is defined as 
follows:
ÔÇ∑At least 2 loose stools with gross blood (hemoccult positive) in 24 hours AND [oral 
temperature ‚â•38.0oC OR ‚â•1 moderate constitutional/enteric symptom OR ‚â•2 
episodes of vomiting in 24 hours]. In this case constitutional/enteric symptom are 
the following: nausea, abdominal pain, abdominal cramping, myalgia, arthralgia, 
malaise.
For the purpose of the endpoint ‚ÄúRate of shigellosis, as defined by: severe diarrhea OR 
moderate dia rrhea with fever or with one or more moderate constitutional/enteric 
symptoms OR dysentery‚Äù , dysentery is defined as follows:
ÔÇ∑At least 2 loose stools with gross blood (hemoccult positive) in 24 hours AND [ ‚â•1 
reportable constitutional/enteric symptom]. In this case constitutional/enteric 
symptom are the following: headache, fatigue, arthralgia, malaise, myalgia, chills, 
nausea, abdominal cramping, abdominal pain, gas, anorexia, vomiting.
For the purpose of the endpoint ‚ÄúRate of more severe shigellosis as def ined by: severe 
or moderate diarrhea with fever or with one or more severe constitutional/enteric 
symptom OR dysentery [[ ‚â•2 loose stools with gross blood (hemoccult positive) in 24 
hours] AND [ oral temperature ‚â•38.0oC OR ‚â•1 severe constitutional/enteric 
symptom]]. ‚Äù, dysentery is defined as follows:
ÔÇ∑At least 2 loose stools with gross blood (hemoccult positive) in 24 hours] AND 
[oral temperature ‚â•38.0oC OR ‚â•1 severe constitutional/enteric symptom]. In this 
case constitutional/enteric symptom are the followi ng: headache, fatigue, 
arthralgia, malaise, myalgia, chills, nausea, abdominal cramping, abdominal pain, 
gas, anorexia, vomiting.
For the purpose of the endpoints ‚ÄúDysentery‚Äù and ‚ÄúConfirmed S. sonnei 53G shedding 
AND moderate or severe diarrhea OR dysenter y OR presence of oral temperature ‚â• 
38.5¬∞C OR presence of one or more severe intestinal symptoms (abdominal pain, 
cramping, nausea, vomiting, gas, and anorexia)‚Äù, dysentery is defined as follows:
ÔÇ∑A Grade 3, 4, or 5 stool with gross blood on at least 2 occa sions within 24 hours 
and presence of constitutional/enteric symptoms. In this case, 
constitutional/enteric symptoms consist of headache, fatigue, arthralgia, malaise, 
myalgia, chills, nausea, abdominal cramping, abdominal pain, gas, anorexia, 
vomiting, an d fever.
Section 4.3 Shigellosis (+S ynopsis)
For the secondary  objectives in the challenge phase of the study , more severe shigellosis 
is defined b y any one of the two following possible endpoints: 
ÔÄ≠[‚Ä¶]
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b151 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 152ÔÄ≠Dysentery  defined as [ ‚â•2 loose stools with gross bloo d (hemoccult positive) in 
24 hours] AND [ oral temperature ‚â•38.0oC OR ‚â•1 severe constitutional/enteric 
symptom].
Section 6.5, Table 4 List of study procedures
Blood sampling for PBMC isolation (Œ±4Œ≤7 +/-plasmablasts response and transcriptomics) (~50 mL) 
Section 6.5 Table 5 Intervals be tween study visits
Visit 5 ÔÇÆVisit 5 post -challenge 
blood draw7 days 7 days ‚Äì10 days
Section 6.7.2, Table 6 Biological samples
Blood (PBMC )for Œ±4Œ≤7+/-plasmablasts response and 
transcriptomics)~ 50 ml scheduled
Section 6.7.3, Table 8 Cell-Mediated I mmunity (CMI) using ELISPOT
System Component Method Unit Laboratory
PBMCŒ±4Œ≤7 positive 
plasmablastELISPOT ELISAAnti-S. sonnei 
LPS specific Titer/ 
5x10^6 cells spot-
forming unitsWRAIR or GVGH designated lab
PBMCŒ±4Œ≤7 negative 
plasmablastELISAAnti-S. sonnei 
LPS specific Titer/ 
5x10^6 cellsWRAIR or GVGH designated lab
PBMCGene expression 
(transcriptomics) 
studyNextGen 
sequencing/ 
microarraySequencing or 
fluorescent intensityGVGH* or GVGH designated lab
ELISA: Enzyme- Linked Imunosorbent Assay; PBMC : peripheral blood mononuclear cells ,Elispot : enzyme -linked 
immunospot assay, WRAIR : Walter Reed Army Institute of Research (US) , GVGH : GSK Vaccines Institute for Global 
Health .
*GVGH laboratory refers to the G VGH- laboratories in Siena, Italy.
Section 6.7.3, Table 10 Hematology, Serum Chemistry, HLA -B27 test, Urine 
and Stool tests
EDTA Blood HLA-B27 PCR Qualitative flow cytometry Study site
PCR: Polymerase Chain Reaction,
Section 11.2 Secondary endpoints (+Synopsis)
Efficacy 
VE, in subjects receiving the 1790GAHB vaccine vs. placebo, will be also measured
during inpatient stay  (Day  57 to Day  64)against:
ÔÇ∑Rate of shigellosis (fulfilling as defined by the CHI M working group case definition 
for shigellosis) occurring within a period starting with challenge visit and lasting 
until the end of the inpatient stay , in all subjects.
ÔÇ∑[‚Ä¶]
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b152 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0
CONFIDENTIA L
205626 (S SONNEI MONO GMMA SBVGH -003 [H03_03TP])
Protocol Amendm ent 6 Final
23-JUL -2019 153ÔÇ∑Rate of more severe shigellosis as defined b y: severe or moderate diarrhea with fever 
or with one or more severe constitutional/e nteric sy mptom OR dy sentery  [[‚â•2 loose 
stools with gross blood (hemoccult positive) in 24 hours] AND [ oral temperature 
‚â•38.0oC OR ‚â•1 severe constitutional/enteric sy mptom]].
ÔÇ∑[‚Ä¶]
Section 11.3 Tertiary endpoints (+Synopsis)
ÔÇ∑[‚Ä¶]
ÔÇ∑Frequency  of S. sonnei LPS specific IgG Œ±4Œ≤7+ /-antibody  secreting cells per 10^6 
PBMC plasmablast at Day  1 and 7 day s after first and second vaccination and 7 day s 
after challenge (Day  8, Day  36 and Day  64).
ÔÇ∑[‚Ä¶]
Section 11.12.1 Sequence of analyses
[‚Ä¶]
One interim anal ysis is intended and will include post -challenge efficacy  data of all 
subjects (all 4 cohorts).
The following 2 interim analyses are planned:
1.After completion of the Visit 5 (Day 64): post- challenge efficacy data of all 
subjects (all 4 cohorts) 
2.After Visit 6 (Day 85): secondary immunogenicity data and tertiary SBA 
immunogenicity data of all subjects (all 4 cohorts).
All analy ses will be conducted before unblinding on clean and final data as clean as 
possible .
An integrated Cclinical Sstudy Rreport containing all data will be written after the End 
of Study and made available to the investigators.
[‚Ä¶]
Appendix A Laboratory Assays
Œ±4Œ≤7 plasmablast ELISA
Anti-S. sonnei LPS -specific IgG titers will be determined in plasmablasts, in both Œ±4Œ≤7
positi ve and Œ±4Œ≤7 negative populations. The titer sprovided will be measured by ELISA 
assay in the culture supernatant of 5x10^6 cells, by using an in -house method 
developed in WRAIR. 
 
CONFIDENTIAL
205626 (S SONNEI MONO GMMA SBVGH-003 [H03_03TP])
Protocol Amendment 6 Final
5889c076f178fb77b7f8644dc83edbbe4030715b153 23-JUL-2019205626 | Redacted Protocol Amendment 6 28 Apr 2020 | TMF-831981 | 1.0